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Chapter 1
GENERAL  INTRODUCTION  
AND OUTLINE  OF THE THESIS
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Chapter 1
Deep venous thrombosis is caused by pathological thrombus formation in the deep veins of 
the leg, pelvis or arm. In case a part of the thrombus is dislodged and migrates through the 
venous system to the pulmonary arteries, a pulmonary embolism may arise. Depending on 
the size, these thrombi can be located in central, segmental or subsegmental arteries.
Pulmonary embolism is a common disease with an estimated incidence of 30 per 100.000 
inhabitants per year (< 70 years) increasing to 250 per 100.000 inhabitants per year among 
patients of older age (≥ 70 years) 1. Clinical symptoms are diverse. The most common 
symptoms are dyspnoe, (pleuritic) chest pain that worsens with breathing and (less frequent) 
hemoptysis and cough. On physical examination signs that accompany pulmonary embolism 
are tachycardia, pleuritic rub, an accentuated second heart sound and neck vein distention 2. 
Diagnosing or excluding pulmonary embolism on clinical signs and symptoms is difficult since 
none of these clinical manifestations are specific 3. In less than 30% of patients presenting with 
clinically suspected suggestive of pulmonary embolism the disease can actually be confirmed 
by objective testing 4-6. Therefore, the need for accurate diagnostic tests to exclude or confirm 
pulmonary embolism is obvious. 
Pulmonary embolism if untreated is associated with high morbidity and mortality; even if 
treated adequately it remains it is the third cause of cardiovascular mortality after coronary 
artery disease and stroke 7. In 1966 Barrit and Jordan compared in a randomized study 
anticoagulant treatment with no treatment in patients with clinically suspected pulmonary 
embolism. In this landmark study 26% of the untreated patients had fatal thromboembolic 
events and another 26% developed nonfatal recurrent emboli in the first weeks after the 
diagnosis. There were no fatalities in the group receiving anticoagulants 8. Nowadays 
anticoagulant treatment provides effective prophylaxis of fatal and non-fatal recurrences, 
since the rate of recurrent thromboembolic events has been estimated at 4% during the 
first 3 months of treatment, although the risk of recurrence of pulmonary embolism remains 
present and gradually increases to 30% over the ten year after presentation 9,10. The mortality 
rate due to fatal pulmonary embolism during 3 months of anticoagulant treatment is 1-2.2% 
11,12. However, anticoagulant treatment carries a substantial risk of bleeding. With vitamin-K 
antagonists, the risk of bleeding has been estimated at 16.5 per 100 treatment-years. Of these 
bleedings, approximately 1 per 100 treatment-years is an intracranial bleeding and about 2 
per 100 treatment-years are other major bleedings with a case-fatality rate of 13% 13,14. Given 
the high mortality in the absence of anticoagulant treatment on one hand, and the risk of 
bleeding with anticoagulant treatment on the other hand, it is important to rapidly confirm or 
exclude pulmonary embolism in patients who present with suspicion of pulmonary embolism.
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Development of diagnostic tests
Prior to the development of accurate diagnostic tests, clinical history and physical examination 
have been the main diagnostic tools in patients with suspected pulmonary embolism. Even 
when the clinical evaluation was combined with results from arterial blood gas measurements, 
electrocardiogram and chest x-ray, the overall results were still inaccurate in confirming or 
ruling out pulmonary embolism 15,16.
Pulmonary angiography, which was introduced in the 1960s, has long been considered 
the gold standard for the diagnosis of pulmonary embolism 17,18. Pulmonary angiography is 
sometimes difficult to interpret, with disagreement more often about the absence of pulmonary 
embolism (17% of angiograms) than about its presence (8% of angiograms) 4. Despite these 
difficulties in interpretation, the 3 months thromboembolic risk in patients in whom anticoagulant 
treatment was withheld after a normal pulmonary angiogram was 1.7% (95% CI 1.0-2.7%) in a 
meta-analysis of eight studies based on a total of 1050 patients 19. Three of these recurrences 
were fatal (0.3%; 95% CI 0.02-0.7%). A pulmonary angiogram is an invasive procedure 
and costly. At present with improved technology and with the assistance of experienced 
radiologists the complication rate has been low with a major non-fatal complication rate of 
0.4% and a mortality rate of 0.1% 20. The role of pulmonary angiography in the diagnosis 
of pulmonary embolism nowadays is limited, because of the availability of alternative non-
invasive strategies. As a consequence the practical experience with angiography in hospitals 
has declined. Nevertheless, in patients with inconclusive non-invasive test results pulmonary 
angiography remains an excellent diagnostic method.
Also in the 1960s the lung perfusion scintigraphy was introduced 21. Perfusion lung 
scintigraphy is a noninvasive technique allowing the visualization of pulmonary perfusion 
through intravenous injection of albumin macroaggregates labeled with Technetium 99m. A 
normal perfusion scan can safely rule out pulmonary embolism and anticoagulant treatment 
can be withheld 4,22. Not all perfusion defects are specific for the diagnosis pulmonary 
embolism. A perfusion defect corresponding to a (large part of a) segment is more specific. 
The specificity can be increased by adding ventilation scintigraphy (with Xenon 133, Krypton 
81m, or aerolized Technetium 99m). A high probability scan, defined as at least one segmental 
perfusion defect with locally normal ventilation (a mismatch) confirms pulmonary embolism 
with a specificity of 97% 4. The major disadvantage of lung scanning is that in 50-60% of 
patients pulmonary embolism can be excluded nor confirmed (non-diagnostic scan result), so 
that further testing is needed.
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Since the late 1990s the diagnostic strategy for pulmonary embolism has changed. As stated 
before, pulmonary embolism is present in 20-30% of patients presenting with signs and 
symptoms suggestive of the disease, hence the first goal of the diagnostic work up should be to 
distinguish those individuals who have the disease and should be treated with anticoagulants 
from the majority who do not. For this purpose standardized clinical probability assessments 
have been introduced in combination with D-dimer testing, a marker of coagulation activation 
23-27. Using pre-test clinical probability, either as a probability assessment or as a standardized 
clinical decision rule, patients can be classified into three categories corresponding to the 
prevalence of pulmonary embolism: in patients with a low, intermediate or high probability, 
the prevalence of pulmonary embolism is 6-10%, 27-30%, or 63-68%, respectively 7. More 
recently a dichotomized clinical decision rule has been introduced with the categories 
pulmonary embolism unlikely of likely 28. 
D-dimer is a degradation product of cross-linked fibrin. The finding of a normal plasma 
D-dimer concentration was shown to be able to exclude pulmonary embolism accurately in 
most patients presenting with clinical suspicion. The sensitivity and negative predictive value 
vary depending on the type of D-dimer assay. With the current rapid tests, both sensitivity and 
specificity are usually high (90-100% and 94-100%, respectively) 27,29-31. To safely exclude 
pulmonary embolism the sensitivity should preferably approach 100%. This is important 
because, for every 2% decrease in sensitivity 1 in 1000 patients presenting with symptoms of 
pulmonary embolism will die of recurrent pulmonary embolism as a result of unjustly withholding 
anticoagulant treatment 32. Most D-dimer assays lack a sufficiently high sensitivity to justify 
their use as the sole test. In patients with a low clinical probability and a normal D-dimer 
concentration, present in 20-30% of patients with clinically suspected pulmonary embolism, 
pulmonary embolism seems safely excluded, however this has to be further documented in 
large cohort studies 6,23,33-35. 
In the remaining proportion of patients, who are more likely to have pulmonary embolism, 
diagnostic imaging is necessary. Since 2002 the clinical utility of single slice spiral CT has been 
studied as part of several diagnostic strategies. In these strategies spiral CT was not used as 
the sole diagnostic test, but it was combined with other diagnostic imaging techniques, mostly 
compression ultrasonography 6,36,37. The main drawback of single slice spiral CT has been the 
limitation to detect peripheral emboli, and therefore is not able to safely exclude pulmonary 
embolism without further testing 38,39. Multi slice CT has become available since 2004 and has 
improved the detection rate of peripheral emboli. It is possible that multi slice CT indeed might be 
safely used as the sole imaging test to confirm or exclude pulmonary embolism, however for the 
time being large studies are also lacking that document the validity of this approach 34.
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Outline of the thesis
The aim of this thesis is to investigate diagnostic strategies for patients with suspected 
pulmonary embolism. For this purpose several studies addressing different aspects of the 
diagnostic work up have been performed. In Chapter 2 we reviewed the current status of 
pulmonary embolism diagnosis. Thereafter, the clinical usefulness of D-dimer testing, the 
clinical decision rule, and radiological imaging techniques are studied. In Chapter 3 the 
safety of withholding anticoagulant treatment in patients with a low clinical probability, using 
an extended clinical decision rule, in combination with a normal D-dimer concentration is 
evaluated. In the remaining patients a diagnostic strategy using compression ultrasonography 
and pulmonary angiography was evaluated. The clinical decision rule has been simplified and 
dichotomized. In  a large management study in Chapter 4 this simple clinical decision rule in 
combination with a normal D-dimer concentration is used to exclude pulmonary embolism. In 
this study spiral CT was used as the sole diagnostic imaging technique to exclude or diagnose 
pulmonary embolism. Whether this strategy can also be used in hospitalized patients or other 
subgroups of patients at risk for pulmonary embolism is assessed in Chapter 5 and Chapter 6, 
respectively. 
Clinical decision rules are frequently used in diagnostic strategies. The observer variability 
in the assessment of clinical probability is assessed in Chapter 7 and further simplification of 
the Wells clinical decision rule is studied and validated in Chapter 8. 
D-dimer testing has a central role in excluding pulmonary embolism. Many assays are 
available and in Chapter 9 a fast assay is evaluated. Finally, in Chapter 10, the potential 
clinical utility of C-reactive protein, alone or in combination with a clinical decision rule and 
D-dimer in excluding pulmonary embolism is evaluated for its use as a diagnostic variable in 
patients with suspected pulmonary embolism.
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ABSTRACT
Background: Pulmonary embolism is a common clinical disorder that is associated with high 
morbidity and mortality if untreated. It is important to confirm or rule out the diagnosis in 
patients with clinical suspicion of the disease.
Purpose: To evaluate various diagnostic strategies for excluding pulmonary embolism.
Data Sources: MEDLINE (1966 to February 2003), EMBASE, and DARE; study investigators; 
and reference lists.
Study Selection: Prospective clinical outcome studies.
Data Extraction: The researchers recorded the frequency of symptomatic venous 
thromboembolism over 3 months of follow-up in patients in whom pulmonary embolism had 
been excluded according to various strategies. Strategies were divided into three categories 
according to the number of rounds of diagnostic tests needed to exclude pulmonary embolism.
Data Synthesis: 25 studies involving more than 7000 patients were included. In all referred 
patients, two strategies—normal results on pulmonary angiography or lung scintigraphy and 
normal D-dimer levels combined with low clinical probability—safely excluded pulmonary 
embolism (failure rates 5 3%). In the second round of diagnostic tests, in patients who had 
had a nondiagnostic lung scan, both pulmonary angiography and serial leg testing for venous 
thrombosis were accurate and safe. When D-dimer testing combined with clinical probability 
was inconclusive, a normal perfusion lung scan safely excluded pulmonary embolism. 
Accumulating evidence shows that normal results on spiral computed tomography may also 
safely exclude the disease.
Conclusions:  Many diagnostic strategies to exclude pulmonary embolism have been evaluated 
in consecutive patients. Interest is likely to increase in a simple, fast strategy, starting with a 
normal perfusion lung scan or a combination of normal D-dimer levels and low clinical probability. 
After the initial round of testing, a reliable diagnostic method, such as angiography or lung 
scintigraphy, is warranted.
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INTRODUCTION
Pulmonary embolism is a common clinical disorder that is associated with high morbidity 
and mortality if untreated. In the only randomized study comparing anticoagulant therapy 
with no treatment in patients with pulmonary embolism, 26% of untreated patients had 
a fatal embolic event and another 26% developed nonfatal recurrent emboli1. With a course 
of anticoagulant treatment, the recurrence rate of thromboembolic events decreases to 
approximately 2% to 9% over 3 to 6 months2, 3. However, anticoagulation always carries a risk 
for bleeding (annual rate of major bleeding, 7%)4, 5. To avoid unnecessary anticoagulant 
therapy, it is therefore important to rapidly confirm or exclude pulmonary embolism in 
patients who present with suspicion of the disorder.
Diagnosing or excluding pulmonary embolism on the basis of clinical manifestations alone 
is difficult because such manifestations are nonspecific6. Approximately 25% of patients 
with suspected pulmonary embolism have the disease confirmed by objective testing7-9. 
The goal of the first diagnostic strategies introduced was to confirm rather than exclude the 
presence of pulmonary emboli. The more recently evaluated diagnostic approaches have 
focused on identifying patients who probably do not have pulmonary embolism and therefore 
do not require anticoagulant therapy. Various invasive and noninvasive diagnostic methods 
have been advocated for excluding the disease.
We performed a systematic review of the literature to evaluate diagnostic strategies 
designed to exclude pulmonary embolism. Our objective was to investigate whether clinical 
outcome evaluation properly documented the safety of withholding anticoagulant 
treatment in patients in whom pulmonary embolism was excluded according to a given 
diagnostic strategy. We assessed the accuracy of the various diagnostic strategies by 
examining the number of symptomatic thromboembolic events (deep venous thrombosis or 
pulmonary embolism) that occurred without anticoagulant treatment during a follow-up period 
of at least 3 months. Studies were grouped according to the number of rounds of diagnostic 
testing performed before pulmonary embolism was ruled out.
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METHODS
Study Selection
We attempted to identify all published clinical studies that evaluated the outcome of diagnostic 
strategies for excluding pulmonary embolism in consecutive patients who presented with 
clinical suspicion of the disease. We adhered to the criteria for systematic review outlined by 
McAlister and colleagues10, 11. We conducted a comprehensive search of English-language 
literature on MEDLINE (1966 to February 2003), EMBASE, and DARE using the Medical 
Subject Headings pulmonary embolism and diagnosing, diagnosis, pulmonary angiography, 
ventilation–perfusion lung scan, compression ultrasonography, contrast venography, 
impedance plethysmography, D-dimer, clinical probability, computerized tomography, and 
magnetic resonance angiography. We also included published abstracts that provided enough 
details for analysis. In addition, we contacted investigators and conducted a manual search by 
reviewing the reference lists of original and review articles. Duplicate reports were excluded.
We used predefined methodologic criteria to select studies. To be included, a study had 
to 1) be prospective and involve consecutive patients; 2) define a priori the diagnostic strategy 
used to exclude or confirm the diagnosis of pulmonary embolism; 3) withhold anticoagulant 
treatment when pulmonary embolism was excluded; 4) provide a detailed description of the 
method of follow-up; 5) have a minimum follow-up of 3 months, with fewer than 10% of 
patients lost during follow-up; and 6) provide detailed descriptions of diagnostic management 
in patients with recurrent symptoms of venous thromboembolism.
Data Extraction
One investigator abstracted data on study size, setting, patient sampling and characteristics, 
and prevalence of pulmonary embolism. Three investigators independently extracted data 
on the diagnostic strategy and tests used, the number of patients who had negative test 
results and therefore did not receive anticoagulant treatment, the number of symptomatic 
thromboembolic events confirmed by objective testing in patients without pulmonary 
embolism and without anticoagulant treatment, and duration and method of follow-up. 
Although some studies had a longer follow-up, we limited our analysis to the first 3 months 
after pulmonary embolism was excluded. We used the original study authors’ interpretations 
of the different test outcomes for our analysis. Investigator disagreements were resolved by 
consensus.
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Statistical Analysis
We defined the failure rate as the frequency with which symptomatic venous 
thromboembolic events were confirmed by objective testing during a 3-month follow-up period 
in patients who had had negative results on diagnostic tests for pulmonary embolism. The 
upper 95% confidence limit (CL) of the failure rate was estimated. For studies with similar 
diagnostic strategies, we assessed heterogeneity by using the Fisher exact test (StatXact, 
version 3.0, Cytel Corp., Cambridge, Massachusetts). Pooled and weighted estimates of the 
failure rate and their upper 95% CLs were calculated by using CIA software, version 1.0 
(Confidence Interval Analysis, University of Southampton, Southampton, United Kingdom). 
We considered a diagnostic strategy to be safe if the upper 95% CL of the observed 
rate of confirmed symptomatic episodes of venous thromboembolism did not exceed 
3% during the 3-month follow-up12-17
FIGURE. Study selection.
Numbers in square brackets are reference numbers.
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TABLE 1. Main Characteristics of the Included Studies*
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RESULTS
We identified 77 studies. Of these, 52 were excluded because they did not meet the predefined 
selection criteria 18-69 (Figure). Therefore, 25 studies including more than 7000 patients 
with clinical suspicion of pulmonary embolism in whom the diagnosis was ruled out by a 
particular strategy 7, 9, 12-15, 17, 70-87 met all selection criteria and were available for our analysis. 
We divided the diagnostic strategies into tests done in all referred patients, tests performed 
after a first diagnostic round, and tests performed in patients with nondiagnostic results after 
two diagnostic rounds. Among the similar diagnostic strategies, no heterogeneity in the 
incidence of venous thromboembolism was observed. Table 1 lists the main characteristics 
of each study.
Diagnostic Strategies for Excluding  
Pulmonary Embolism in All Referred Patients
In 19 studies involving 4096 patients, several diagnostic strategies were evaluated in 
consecutive patients presenting with suspected pulmonary embolism (Table 2).
STRATEGIES INVOLVING PULMONARY ANGIOGRAPHY
In one multicenter study7, 755 of 931 inpatients and outpatients (81%) underwent 
pulmonary angiography. Of these, 480 had normal test results and did not receive 
anticoagulant treatment. During follow-up, 4 patients died of pulmonary embolism, all 
within the first week (failure rate, 0.8% [upper 95% CL, 2.1%])7.
(18–69) (Figure). Therefore, 25 studies including more
than 7000 patients with clinical suspicion of pulmonary
embolism in whom the diagnosis was ruled out by a par-
ticular strategy (7, 9, 12–15, 17, 70–87) met all selection
criteria and were available for our analysis. We divided the
diagnostic strategies into tests done in all referred patients,
tests performed after a first diagnostic round, and tests
performed in patients with nondiagnostic results after two
diagnostic rounds. Among the similar diagnostic strategies,
no heterogeneity in th ncidence of venous t romb em-
bolism was observed. Table 1 lists the main characteristics
of each study.
Diagnostic Strategies for Excluding Pulmonary Embolism
in All Referred Patients
In 19 studies involving 4096 patients, several diagnos-
tic strategies were evaluated in consecutive patients pre-
senting with suspected pulmonary embolism (Table 2).
Strategies Involving Pulmonary Angiography
In one multicenter study (7), 755 of 931 inpatients
and outpatients (81%) underwent pulmonary angiogra-
phy. Of these, 480 had normal test results and did not
receive anticoagulant treatment. During follow-up, 4 pa-
tients died of pulmonary e bolism, all within the first
week (failure rate, 0.8% [upper 95% CL, 2.1%]) (7).
Strategies Involving Lung Scintigraphy
Seven studies evaluated the outcome of excluding pul-
monary embolism by using normal results on perfusion
lung scintigraphy in consecutive patients (15, 71, 73, 75,
77, 86, 87). These studies were similar in prevalence of
pulmonary embolism and patient characteristics at study
entry, except for the study by Miron and associates (87),
which included only inpatients. Most observed failure rates
were low during 3-month follow-up, and the combined
failure rate showed that a normal lung scan seemed to
accurately exclude pulmonary embolism (failure rate, 0.9%
[upper 95% CL, 2.3%]).
In three studies, pulmonary embolism was excluded by
a normal perfusion lung scan combined with normal re-
sults of bilateral leg testing (compression ultrasonography
[13] or impedance plethysmography [12, 70]) performed
on the same day. Patient characteristics in these studies
were similar to those in the studies that examined lung
scintigraphy alone. Adding a single leg test to a normal
perfusion lung scan did not materially improve the accu-
racy of a normal perfusion scan alone (12, 13, 70). Another
approach studied involved using a nondiagnostic perfusion
l ng scan in patients with low clinical probabili y or with
normal D-dimer levels and moderate clinical probability.
Perrier and coworkers (15) evaluated these strategies in 48
and 53 patients, respectively, and observed no thromboem-
bolic complications dur ng follow-up (upper 95% CL,
7.4% and 6.7%, respectively).
Strategies Using Only D-Dimer Tests or a Combination of
D-Dimer Tests and Clinical Probability
A normal result on a D-dimer test was used in two
ways. In two studies (14, 85), a normal D-dimer level on a
rapid enzyme-linked immunosorbent assay (ELISA) was
the only indicator used to exclude pulmonary embolism in
201 referred patients (failure rate, 0% [upper 95% CL,
1.8%]). The assay had a sensitivity and negative predictive
value of 98% to 100% (14, 56, 79, 83, 85).
In other studies, a normal D-dimer concentration was
sed to exclude pulmonary embolism in patients with low
(78, 81, 83, 84) or low to moderate (82) clinical probabil-
ity. Three methods of D-dimer testing were used: a whole-
blood agglutination assay (78, 84), a rapid ELISA assay
(83), and a latex-enhanced photometric immunoassay (81,
82). In general, the two latter assays have a sensitivity and
negative predictive value of nearly 100% (14, 56, 79, 81–
83, 85, 88). However, these indices vary for the agglutina-
tion as ays (sensitivity, 85% to 94%; negative predictive
value, 96% to 98%) (89, 90). Most studies used a stan-
dardized clinical model for clinical probability assessment
(78, 82–84). Combining low clinical probability and nor-
mal D-dimer results appeared to safely exclude pulmonary
Table 1—Continued
Study, Year
(Reference)
Setting Patient
Characteristics
Pretest Probability
of Pulmonary
Embolism
Prevalence of
Pulmonary
Embolism, %
Diagnostic Strategy Reference Standard for
Failure Rate
Leclercq et al.,
2003 (82)
Hospital Consecutive in-
patients and out-
patients
Low 29 Clinical probability, DD
(Tinaquant**), lung
scan, CUS, PA
Clinical outcome
Musset et al.,
2002 (17)
Multicenter (14 cen-
ters)
Consecutive in-
patients and out-
patients
Low 35 Spiral CT and CUS, clin-
ical probability, lung
scan, PA
Clinical outcome
* CT � computed tomography; CUS � compression ultrasonography; DD � D-dimer concentration; IPG � impedance plethysmography; PA � pulmonary angiography;
PE � pulmonary embolism; PIOPED � Prospective Investigation of Pulmonary Embolism Diagnosis.
† Performed only in patients with adequate cardiorespiratory reserve.
‡ Diagnostica Stago, Asnie`res, France.
§ bioMe´rieux, Inc., Marcy L’Etoile, France.
� Agen Biochemical, Ltd., Brisbane, Australia.
¶ In patients who underwent PA to test for DVT.
** Roche Diagnostics, Almere, the Netherlands.
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STRATEGIES INVOLVING LUNG SCINTIGRAPHY
Seven studies evaluated the outcome of excluding pulmonary embolism by using normal 
results on perfusion lung scintigraphy in consecutive patients 15, 71, 73, 75, 77, 86, 87. These 
studies were similar in prevalence of pulmonary embolism and patient characteristics at study 
entry, except for the study by Miron and associates 87, which included only inpatients. Most 
observed failure rates were low during 3-month follow-up, and the combined failure rate 
showed that a normal lung scan seemed to accurately exclude pulmonary embolism (failure 
rate, 0.9% [upper 95% CL, 2.3%]).
In three studies, pulmonary embolism was excluded by a normal perfusion lung scan 
combined with normal results of bilateral leg testing (compression ultrasonography 13 or 
impedance plethysmography12, 70) performed on the same day. Patient characteristics 
in these studies were similar to those in the studies that examined lung scintigraphy alone. 
Adding a single leg test to a normal perfusion lung scan did not materially improve the 
accuracy of a normal perfusion scan alone 12, 13, 70. Another approach studied involved using a 
nondiagnostic perfusion lung scan in patients with low clinical probability or with normal D-dimer 
levels and moderate clinical probability. Perrier and coworkers15 evaluated these strategies in 
48 and 53 patients, respectively, and observed no thromboembolic complications during 
follow-up (upper 95% CL, 7.4% and 6.7%, respectively).
STRATEGIES USING ONLY D-DIMER TESTS OR A COMBINATION  
OF D-DIMER TESTS AND CLINICAL PROBABILITY
A normal result on a D-dimer test was used in two ways. In two studies14, 85, a normal D-
dimer level on a rapid enzyme-linked immunosorbent assay (ELISA) was the only indicator 
used to exclude pulmonary embolism in 201 referred patients (failure rate, 0% [upper 95% 
CL, 1.8%]). The assay had a sensitivity and negative predictive value of 98% to 100%14, 56, 79, 
83, 85.
In other studies, a normal D-dimer concentration was used to exclude pulmonary embolism 
in patients with low 78, 81, 83, 84 or low to moderate82 clinical probability. Three methods of 
D-dimer testing were used: a wholeblood agglutination assay 78, 84, a rapid ELISA assay 
83, and a latex-enhanced photometric immunoassay 81, 82. In general, the two later assays 
have a sensitivity and negative predictive value of nearly 100%14, 56, 79, 81-83, 85, 88. However, 
these indices vary for the agglutination assays (sensitivity, 85% to 94%; negative predictive 
value, 96% to 98%)89, 90. Most studies used a standardized clinical model for clinical probability 
assessment78, 82-84. Combining low clinical probability and normal D-dimer results appeared 
to safely exclude pulmonary embolism in the 894 included patients; only two venous 
thromboembolic events occurred during follow-up (failure rate, 0.2% [upper 95% CL, 0.8%])78, 
81, 83, 84. In the single study that excluded pulmonary embolism by using low to moderate 
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clinical probability and normal D-dimer levels, no venous thromboembolic events were noted 
(failure rate, 0% [upper 95% CL, 5.6%])82.
STRATEGIES INVOLVING SPIRAL COMPUTED TOMOGRAPHY  
AND COMPRESSION ULTRASONOGRAPHY
One study excluded pulmonary embolism with normal results on spiral computed 
tomography (CT) and compression ultrasonography in 507 patients with low to moderate 
clinical probability. During follow-up, nine patients had a thromboembolic event (failure rate, 
1.8% [upper 95% CL, 3.3%]). Of these, five died, possibly of pulmonary embolism or related 
causes. Ten patients were lost to follow-up17.
embolism in the 894 included patients; only two venous
thromboembolic events occurred during follow-up (failure
rate, 0.2% [upper 95% CL, 0.8%]) (78, 81, 83, 84). In the
single study that excluded pulmonary embolism by using
low to moderate clinical probability and normal D-dimer
levels, no venous thromboembolic events were noted (fail-
ure rate, 0% [upper 95% CL, 5.6%]) (82).
Strategies Involving Spiral Computed Tomography and
Compression Ultrasonography
One study excluded pulmonary embolism with nor-
mal results on spiral computed tomography (CT) and
compression ultrasonography i 507 pati nt with ow t
moderate clinical probability. During follow-up, nine pa-
tients had a thromboembolic event (failure rate, 1.8% [up-
per 95% CL, 3.3%]). Of these, five died, possibly of pul-
monary embolism or related causes. Ten patients were lost
to follow-up (17).
Diagnostic Strategies after the First Diagnostic Round
Twenty studies involving 3376 patients (Table 3) in-
vestigated different strategies when a first diagnostic test or
tests did not exclude or confirm the diagnosis of pulmo-
nary embolism. The study samples tested in this second round
may have varied with respect to clinical characteristics and
likelihood of disease, depending on the first tests used.
Strategies after an Abnormal or Nondiagnostic Lung Scan
After an abnormal or nondiagnostic lung scan, four
diagnostic strategies were studied: pulmonary angiography,
D-dimer testing and clinical probability assessment, serial
leg testing, and spiral CT. Pulmonary angiography was
used as the sole test in four studies (9, 74, 80, 86). In three
of the four (9, 74, 86), pulmonary angiography was per-
formed in 457 consecutive inpatients and outpatients with
suspected pul onary embolism after an abnormal lung
scan (9, 74, 86). In the remaining study (80), pulmonary
angiography was performed in 105 patients after a nondi-
agnostic lung scan. During follow-up, 6 thromboembolic
events (9, 74, 86) and 0 thromboembolic events (80) were
observed, with respective failure rates of 1.3% (upper 95%
CL, 2.8%) and 0% (upper 95% CL, 3.5%). Another study
(15) used pulmonary angiography in combination with
Table 2. Outcome of Diagnostic Strategies for Excluding Pulmonary Embolism in All Referred Patients*
Exclusion Strategy Study, Year (Reference) Included
Patients
VTE
Complications†
Failure Rate
(95% CL)
n %
Pulmonary angiography
Normal results PIOPED, 1990 (7) 480 4 0.8 (2.1)
Lung scintigraphy
Normal results Kruit et al., 1991 (71) 44 0 0 (8.0)
van Beek et al., 1995 (75) 113 0 0 (3.2)
Perrier et al., 1996 (15) 43 0 0 (8.2)
van Beek et al., 1997 (73) 137 1 0.7 (4.0)
de Groot et al., 1999 (77) 54 3 5.6 (15.4)
Miron et al., 1999 (87) 16 0 0 (20.6)
Miniati et al., 2001 (86) 34 0 0 (10.3)
Total 441 4 0.9 (2.3)
Normal results plus normal results on leg testing‡ Hull et al., 1990 (70) 515 3 0.6 (1.7)
Hull et al., 1994 (12) 576 4 0.7 (1.8)
Wells et al., 1998 (13) 332 2 0.6 (2.2)
Total 1423 9 0.6 (1.2)
Nondiagnostic results in patients with low clinical probability Perrier et al., 1996 (15) 48 0 0 (7.4)
Nondiagnostic results in patients with normal D-dimer levels
and moderate clinical probability
Perrier et al., 1996 (15) 53 0 0 (6.7)
D-Dimer testing alone or combined with clinical probability
Normal D-dimer level Perrier et al., 1999 (14) 159 0 0 (2.3)
Bernier et al., 2001 (85) 42 0 0 (8.4)
Total 201 0 0 (1.8)
Normal D-dimer level in patients with low clinical probability Wells et al., 2001 (78) 437 1 0.2 (1.3)
Anderson et al., 2001 (84) 306 1 0.3 (1.8)
Kruip et al., 2002 (83) 60 0 0 (6.0)
ten Wolde et al., 2001 (81) 91 0 0 (4.0)
Total 894 2 0.2 (0.8)
Normal D-dimer level in patients with low to moderate
clinical probability
Leclercq et al., 2002 (82) 64 0 0 (5.6)
Spiral CT and CUS
Normal results on both in patients with low to moderate
clinical probability
Musset et al., 2002 (17) 507 9 1.8 (3.3)
* CL � confidence limit; CT� computed tomography; CUS� compression ultrasonography; PIOPED� Prospective Investigation of Pulmonary Embolism Diagnosis;
VTE � venous thromboembolic.
† Symptomatic VTE complications during the 3-month follow-up.
‡ Leg testing includes impedance plethysmography or compression ultrasonography.
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Diagnostic Strategies after the First Diagnostic Round
Twenty studies involving 3376 patients (Table 3) investigated different strategies when a first 
diagnostic test or tests did not exclude or confirm the diagnosis of pulmonary embolism. 
The study samples tested in this second round may have varied with respect to clinical 
characteristics and likelihood of disease, depending on the first tests used.
compression ultrasonography in 55 outpatients with ele-
vated D-dimer levels and moderate clinical probability.
One nonfatal venous thromboembolic event occurred dur-
ing follow-up (failure rate, 1.8% [upper 95% CL, 9.7%])
(15). Two studies used clinical probability alone or in com-
bination with normal D-dimer levels to exclude pulmonary
embolism after a nondiagnostic lung scan (77, 87). Of these
studies, one (87) was performed in hospitalized patients;
both studies involved small numbers of patients (77, 87).
Four studies used serial leg testing (impedance pleth-
ysmography [12, 71, 72] or compression ultrasonography
[13]) over approximately 10 days to exclude pulmonary
embolism after a nondiag ostic lung scan. Hull and col-
leagues (9) also performed serial impedance plethysmogra-
phy but only in patients with adequate cardiorespiratory
reserve. The three studies that used serial impedance pleth-
ysmography in 779 referred patients had a failure rate of
1.7% (upper 95% CL, 2.8%) (12, 71, 72). Wells and
associates (13) included only patients with low to moderate
clinical probability as assessed by a standardized clinical
model. Of the 665 inpatients and outpatients with normal
results on serial compression ultrasonography, 3 had a
thromboembolic event during follow-up (failure rate, 0.5%
[upper 95% CL, 1.3%]).
Finally, one study used spiral CT in combination with
normal results on compression ultrasonography to exclude
pulmonary embolism in 109 inpatients and outpatients
with low to moderate clinical probability after a nondiag-
nostic lung scan (76). The failure rate was 5.5% (upper
95% CL, 11.6%).
Strategies after Elevated D-Dimer Level in Combination with
Normal Results on Compression Ultrasonography or Clinical
Probability Assessment
After elevated D-dimer levels were detected, most di-
agnostic strategies continued with lung scintigraphy, some-
Table 3. Outcome of Diagnostic Strategies for Excluding Pulmonary Embolism after the First Inconclusive Diagnostic Round*
Exclusion Strategy Study, Year (Reference) Included
Patients
VTE
Complications†
Failure Rate
(95% CL)
n %
After abnormal lung scan
Normal results on pulmonary angiography Hull et al., 1983 (9) 44 1 2.3 (12.0)
Henry et al., 1995 (74) 380 5 1.3 (3.1)
Miniati et al., 2001 (86) 33 0 0 (10.6)
Total 457 6 1.3 (2.8)
After nondiagnostic lung scan
Normal results on pulmonary angiography van Beek et al., 1996 (80) 105 0 0 (3.5)
Normal results on CUS and pulmonary angiography in patients with
elevated D-dimer levels and moderate clinical probability
Perrier et al., 1996 (15) 55 1 1.8 (9.7)
Low clinical probability Miron et al., 1999 (87) 20 0 0 (16.8)
Normal D-dimer levels in patients with low to moderate clinical probability de Groot et al., 1999 (77) 59 1 1.7 (9.1)
Serial IPG Kruit et al., 1991 (71) 62 0 0 (5.8)
Ginsberg et al., 1993 (72) 90 1 1.1 (6.0)
Hull et al., 1994 (12) 627 12 1.9 (3.3)
Total 779 13 1.7 (2.8)
Serial CUS in patients with low to moderate clinical probability Wells et al., 1998 (13) 665 3 0.5 (1.3)
Normal results on spiral CT and CUS in patients with low to moderate
clinical probability
Ferretti et al., 1997 (76) 109 6 5.5 (11.6)
After elevated D-dimer level and normal results on CUS
Normal or near-normal lung scan Perrier et al., 2001 (79) 44 0 0 (8.0)
Nondiagnostic lung scan in patients with low clinical probability Perrier et al., 2001 (79) 79 0 0 (4.6)
Lung scan normal or near-normal, or nondiagnostic lung scan in patients
with low clinical probability
Perrier et al., 1999 (14) 144 2 1.4 (4.9)
After elevated D-dimer level and low clinical probability or moderate to high
clinical probability
Normal lung scan Wells et al., 2001 (78) 183 0 0 (2.0)
ten Wolde et al., 2001 (81) 160 0 0 (2.3)
Total 343 0 0 (1.1)
Normal results on CUS and pulmonary angiography Kruip et al., 2002 (83) 122 1 0.8 (4.5)
Normal results on spiral CT and CUS Anderson et al., 2001 (84) 287 0 0 (1.3)
After elevated D-dimer level and low to moderate clinical probability or high
clinical probability
Normal lung scan Leclercq et al., 2002 (82) 31 0 0 (11.2)
After CT and CUS
Negative results on both tests in patients with high clinical probability,
normal lung scan, normal results on PA, or both
Musset et al., 2002 (17) 70 0 0 (5.1)
Inconclusive results on both tests in patients with normal lung scan,
normal results on PA, or both‡
Musset et al., 2002 (17) 84 0 0 (4.3)
* CL � confidence limit; CT � computed tomography; CUS � compression ultrasonography; IPG � impedance plethysmography; VTE � venous thromboembolic.
† Symptomatic VTE complications during the 3-month follow-up.
‡ Inconclusive results were nondiagnostic results on CT and normal results on CUS, normal results on CT and nondiagnostic results on CUS, or subsegmental pulmonary
embolism on CT and normal results on CUS.
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STRATEGIES AFTER AN ABNORMAL OR NONDIAGNOSTIC LUNG SCAN
After an abnormal or nondiagnostic lung scan, four diagnostic strategies were studied: 
pulmonary angiography, D-dimer testing and clinical probability assessment, serial leg 
testing, and spiral CT. Pulmonary angiography was used as the sole test in four studies9, 
74, 80, 86. In three of the four9, 74, 86, pulmonary angiography was performed in 457 consecutive 
inpatients and outpatients with suspected pulmonary embolism after an abnormal lung 
scan9, 74, 86. In the remaining study 80, pulmonary angiography was performed in 105 patients 
after a nondiagnostic lung scan. During follow-up, 6 thromboembolic events9, 74, 86 and 0 
thromboembolic events 80 were observed, with respective failure rates of 1.3% (upper 95% 
CL, 2.8%) and 0% (upper 95% CL, 3.5%). Another study 15 used pulmonary angiography in 
combination with compression ultrasonography in 55 outpatients with elevated D-dimer 
levels and moderate clinical probability. One nonfatal venous thromboembolic event 
occurred during follow-up (failure rate, 1.8% [upper 95% CL, 9.7%]) 15. Two studies used 
clinical probability alone or in combination with normal D-dimer levels to exclude pulmonary 
embolism after a nondiagnostic lung scan 77, 87. Of these studies, one 87 was performed in 
hospitalized patients; both studies involved small numbers of patients.
Four studies used serial leg testing (impedance plethysmography 12, 71, 72 or compression 
ultrasonography 13) over approximately 10 days to exclude pulmonary embolism after 
a nondiagnostic lung scan. Hull and colleagues 9 also performed serial impedance 
plethysmography but only in patients with adequate cardiorespiratory reserve. The three 
studies that used serial impedance plethysmography in 779 referred patients had a failure 
rate of 1.7% (upper 95% CL, 2.8%) 12, 71, 72. Wells and associates 13 included only patients with 
low to moderate clinical probability as assessed by a standardized clinical model. Of the 665 
inpatients and outpatients with normal results on serial compression ultrasonography, 3 had a 
thromboembolic event during follow-up (failure rate, 0.5% [upper 95% CL, 1.3%]).
Finally, one study used spiral CT in combination with normal results on compression 
ultrasonography to exclude pulmonary embolism in 109 inpatients and outpatients with 
low to moderate clinical probability after a nondiagnostic lung scan 76. The failure rate was 
5.5% (upper 95% CL, 11.6%).
STRATEGIES AFTER ELEVATED D-DIMER LEVEL IN COMBINATION  
WITH NORMAL RESULTS ON COMPRESSION ULTRASONOGRAPHY  
OR CLINICAL PROBABILITY ASSESSMENT
After elevated D-dimer levels were detected, most diagnostic strategies continued with lung 
scintigraphy, sometimes in combination with clinical probability assessment or compression 
ultrasonography (Table 3) 14, 78, 79, 81-84. The subgroups were mostly moderate in size and 
were tested by using strategies that had been previously examined in only a single study. 
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Consequently, the upper 95% CLs of the failure rates clearly exceeded 3%. In two studies78, 81, 
a normal lung scan excluded pulmonary embolism in 343 patients with moderate to high 
clinical probability or with low clinical probability and elevated D-dimer levels. During follow-up, 
no thromboembolic events were noted (failure rate, 0% [upper 95% CL, 1.1%]).
Kruip and colleagues83 studied the combination of normal results on compression 
ultrasonography and pulmonary angiography in 122 inpatients and outpatients with 
moderate to high clinical probability or with low clinical probability and elevated D-dimer levels. 
This diagnostic strategy resulted in a failure rate of 0.8% (upper 95% CL, 4.5%). Anderson 
and coworkers 84 found that normal results on spiral CT in combination with one instance 
of normal results on compression ultrasonography excluded pulmonary embolism in 287 
consecutive patients with moderate to high clinical probability or with elevated D-dimer levels 
and low clinical probability. No thromboembolic complications were noted during follow-up 
(failure rate, 0% [upper 95% CL, 1.3%]) 84. 
STRATEGIES AFTER SPIRAL CT AND COMPRESSION ULTRASONOGRAPHY
In 95 of 1041 patients, Musset and associates17 could not confirm or exclude the 
diagnosis of pulmonary embolism with spiral CT and compression ultrasonography. Lung 
scintigraphy, pulmonary angiography, or both were therefore performed, and results were 
normal in 84 patients. No thromboembolic events were observed during follow-up (failure rate, 
0% [upper 95% CL, 4.3%]) 17.
Strategies after Two Diagnostic Rounds
After two diagnostic rounds, pulmonary embolism could still not be confirmed or excluded 
in small subgroups of the original referred cohorts (Table 4). We identified seven studies 
that used a third round of diagnostic tests involving six strategies 14, 77-79, 81, 82, 87. Miron and 
associates 87 studied only hospitalized patients. Testing ended when patients were found to 
have normal results on serial compression ultrasonography and a nondiagnostic lung scan 
or normal results on both compression ultrasonography and pulmonary angiography. Three 
studies 14, 79, 87 used the same diagnostic strategy and D-dimer assay. In patients with elevated 
D-dimer levels, nondiagnostic lung scans, and moderate to high clinical probability, pulmonary 
embolism was excluded by normal results on compression ultrasonography and pulmonary 
angiography. Among the 130 studied patients in all three studies, one thromboembolic event 
occurred (failure rate, 0.8% [upper 95% CL, 4.2%])14, 79, 87.
ten Wolde and colleagues 81 performed serial compression ultrasonography in 246 patients 
who had a nondiagnostic lung scan, elevated D-dimer levels, and low or moderate to high 
clinical probability. The observed failure rate, 2.0% (upper 95% CL, 4.7%), appears some 
what higher than those in other studies that used serial leg testing 12, 13, 71, 72, 81. However, 
this may be the result of chance.
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times in combination with clinical probability assessment
or compression ultrasonography (Table 3) (14, 78, 79,
81–84). The subgroups were mostly moderate in size and
were tested by using strategies that had been previously
examined in only a single study. Consequently, the upper
95% CLs of the failure rates clearly exceeded 3%. In two
studies (78, 81), a normal lung scan excluded pulmonary
embolism in 343 patients with moderate to high clinical
probability or with low clinical probability and elevated
D-dimer levels. During follow-up, no thromboembolic events
were noted (failure rate, 0% [upper 95% CL, 1.1%]).
Kruip and colleagues (83) studied the combination of
normal results on compression ultrasonography and pul-
monary angiography in 122 inpatients and outpatients
with moderate to high clinical probability or with low clin-
ical probability and elevated D-dimer levels. This diagnos-
tic strategy resulted in a failure rate of 0.8% (upper 95%
CL, 4.5%) (83). Anderson and coworkers (84) found that
normal results on spiral CT in combination with one in-
stance of normal results on compression ultrasonography
excluded pulmonary embolism in 287 consecutive patients
with moderate to high clinical probability or with elevated
D-dimer levels and low clinical probability. No thrombo-
embolic complications were noted during follow-up (fail-
ure rate, 0% [upper 95% CL, 1.3%]) (84).
Strategies after Spiral CT and Compression Ultrasonography
In 95 of 1041 patients, Musset and associates (17)
could not confirm or exclude the diagnosis of pulmonary
embolism with spiral CT and compression ultrasonogra-
phy. Lung scintigraphy, pulmonary angiography, or both
were therefore performed, and results were normal in 84
patients. No thromboembolic events were observed during
follow-up (failure rate, 0% [upper 95% CL, 4.3%]) (17).
Strategies after Two Diagnostic Rounds
After two diagnostic rounds, pulmonary embolism
could still not be confirmed or excluded in small subgroups
of the original referred cohorts (Table 4). We identified
seven studies that used a third round of diagnostic tests
involving six strategies (14, 77–79, 81, 82, 87). Miron and
associates (87) studied only hospitalized patients. Testing
ended when patients were found to have normal results on
serial compression ultrasonography and a nondiagnostic
lung scan or normal results on both compression ultra-
sonography and pulmonary angiography. Three studies
(14, 79, 87) used the same diagnostic strategy and D-dimer
assay. In patients with elevated D-dimer levels, nondiagnos-
tic lung scans, and moderate to high clinical probability,
pulmonary embolism was excluded by normal results on
compression ultrasonography and pulmonary angiography.
Among the 130 studied patients in all three studies, one
thromboembolic event occurred (failure rate, 0.8% [upper
95% CL, 4.2%]) (14, 79, 87).
ten Wolde and colleagues (81) performed serial com-
pression ultrasonography in 246 patients who had a non-
diagnostic lung scan, elevated D-dimer levels, and low or
moderate to high clinical probability (81). The observed
failure rate, 2.0% (upper 95% CL, 4.7%), appears some-
what higher than those in other studies that used serial leg
testing (12, 13, 71, 72, 81). However, this may be the
result of chance.
DISCUSSION
This syste atic review of diagnos ic strategies to ex-
clude pulmonary embolism in patients with clinical suspi-
cion of the disease allows several interesting inferences. The
first concerns strategies performed in all referred patients.
Table 4. Outcome of the Diagnostic Strategies after Two Diagnostic Rounds in Patients with Suspected Pulmonary Embolism*
Exclusion Strategy Study, Year (Reference) Included
Patients
VTE
Complications†
Failure Rate
(95% CL)
n %
Normal results on CUS and pulmonary angiography in patients
with elevated D-dimer levels, nondiagnostic lung scans, and
moderate to high clinical probability
Miron et al., 1999 (87) 35 0 0 (10.0)
Perrier et al., 1999 (14) 37 1 2.7 (14.2)
Perrier et al., 2001 (79) 58 0 0 (6.2)
Total 130 1 0.8 (4.2)
Normal results on CUS in patients with elevated D-dimer
levels, low clinical probability, nondiagnostic lung scans
Wells et al., 2001 (78) 41 1 2.4 (12.9)
Normal results on CUS in patients with normal D-dimer levels,
moderate clinical probability, and nondiagnostic lung scans
Wells et al., 2001 (78) 60 0 0 (6.0)
Normal results on serial CUS in patients with elevated D-dimer
levels, low clinical probability or moderate to high clinical
probability, and nondiagnostic lung scans
ten Wolde et al., 2001 (81) 246 5 2.0 (4.7)
Normal results on CUS and pulmonary angiography in patients
with elevated D-dimer levels, low to moderate clinical
probability or high clinical probability, and nondiagnostic
lung scans
Leclercq et al., 2002 (82) 38 0 0 (9.3)
Normal results on CUS and pulmonary angiography in
angiography in patients with nondiagnostic lung scans and
elevated D-dimer levels
de Groot et al., 1999 (77) 40 0 0 (8.8)
* CL � confidence limit; CUS � compression ultrasonography; VTE � venous thromboembolic.
† Symptomatic VTE complications during the 3-month follow-up.
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TABLE 4. Outcome of the Diagnostic Strategies after Two Diagnostic 
Rounds in Patients with Suspected Pulmonary Embolism*
In addition to the accepted methods for excluding pulmo-
nary embolism (that is, normal pulmonary angiogram or
perfusion lung scan), an alternative strategy emerged: nor-
mal D-dimer levels alone or in combination with low clin-
ical probability. A normal D-dimer result as the sole basis
for excluding pulmonary embolism has been evaluated in
only 201 patients and with only one type of assay, but the
upper 95% CL of the failure rate compares favorably with
that of a normal pulmonary angiogram or perfusion lung
scan and is below our arbitrarily chosen upper 95% CL of
3% (7, 14, 15, 73, 75, 77, 85).
The combination of normal D-dimer levels and low
clinical probability, a strategy probably more applicable to
clinical practice, has been evaluated more extensively, with
three types of D-dimer assay. Our analysis indicated that
the combination of low clinical probability and normal
D-dimer levels is accurate regardless of the D-dimer assay
used (78, 81, 83, 84). One moderately sized study evalu-
ated the combination of low to moderate clinical probabil-
ity and normal D-dimer levels (82). Although this strategy
can exclude pulmonary embolism in more patients, its re-
sults require confirmation. The use of a D-dimer test in
combination with clinical probability assessment is obvi-
ously rapid, more convenient for the patient, and probably
cost-effective compared with the current accepted diagnos-
tic methods.
After the initial diagnostic round, we found roughly
two main approaches to continuing the diagnostic process.
The first approach encompassed strategies after initial ab-
normal or nondiagnostic results on lung scintigraphy,
while the second included diagnostic strategies for patients
in whom pulmonary embolism was not excluded by D-
dimer testing combined with clinical probability. Regard-
ing the first approach, we found, as expected, good evi-
dence for the safety of withholding anticoagulant
treatment after a normal pulmonary angiogram (9, 74, 80,
86). Other strategies after a nondiagnostic lung scan eval-
uated serial noninvasive testing of the deep leg veins. Al-
though the data on serial compression ultrasonography ap-
pear especially convincing, they were obtained from only
one large study in 665 patients with low to moderate clin-
ical probability (13). Compression ultrasonography is at-
tractive because it is widely available and easy to perform;
however, it requires patients to make several visits to the
hospital. With respect to the second approach (after D-
dimer testing and clinical probability estimate), a normal
perfusion lung scan is still a useful and safe strategy to
exclude pulmonary embolism (14, 78, 79, 81, 82).
To date, only three studies have evaluated the role of
spiral CT imaging in proper clinical outcome studies. We
found that in one study, which examined patients with low
to moderate clinical probability after a nondiagnostic lung
scan and normal results on compression ultrasonography,
normal results on helical CT were associated with an un-
acceptably high failure rate (76). This is probably because
subsegmental thrombi were not detected. However, in the
second (84) and third (17) studies, the failure rates were
lower (17, 84). The difference between the first and last
two studies can be explained in part by improved resolu-
tion of the more modern CT machines. More data are
needed to study the safety of excluding pulmonary embo-
lism with normal results on spiral CT.
Many strategies have been evaluated for screening after
two diagnostic rounds. However, no conclusions can be
made about which strategy is best because most of the
relevant studies have been modest in size. The results of
these studies are summarized in Table 4.
Most of the patients in studies we examined were out-
patients. One study was performed only in inpatients, six
studies were performed only in outpatients, and the re-
maining studies included both types of patients but pre-
dominantly outpatients. Whether the diagnostic strategies
studied can be used for inpatients with the same results and
failure rates requires further testing.
Our analysis has potential limitations. First, we ac-
cepted the interpretations of the various test outcomes as
reported by the study authors. This may have resulted in
varied failure rates for the same strategy. Nevertheless, the
pooled estimates, particularly those for the strategies exam-
ined in several studies, appear to be robust. A second po-
tential limitation is the risk for spectrum bias. However,
the range of the overall prevalences of pulmonary embo-
lism, an indicator of the case mix of the included studies,
was relatively narrow. Therefore, we do not believe that
spectrum bias influenced our conclusions. Third, the a pri-
ori likelihood of disease in patients with suspected pulmo-
Table 5. Summary Table of the Diagnostic Strategies for
Excluding Pulmonary Embolism with an Upper 95% Confidence
Limit of 3% or Less for 3-Month Thromboembolic Risk*
Variable 3-Month Risk for
VTE Complications
(Upper 95% CL)
Diagnostic strategies for excluding pulmonary
embolism in all referred patients
Normal results on PA 0.8 (2.1)
Normal lung scan 0.9 (2.3)
Normal lung scan and normal leg testing results 0.6 (1.2)
Normal D-dimer level 0.0 (1.8)
Normal D-dimer level and low clinical probability 0.2 (0.8)
Diagnostic strategies for excluding pulmonary
embolism after the first diagnostic round
Abnormal lung scan plus normal results on PA 1.3 (2.8)
Nondiagnostic lung scan plus normal results on
serial IPG
1.7 (2.8)
Nondiagnostic lung scan, normal results on
serial CUS, and low to moderate clinical
probability
0.5 (1.3)
Moderate to high clinical probability or elevated
D-dimer level and low clinical probability plus
normal lung scan
0.0 (1.1)
Moderate to high clinical probability or elevated
D-dimer level and low clinical probability plus
normal results on spiral CT and CUS
0.0 (1.3)
* CL � confidence limit; CT � computed tomography; CUS � compression ul-
trasonography; IPG� impedance plethysmography; PA� pulmonary angiogra-
phy; VTE � venous thromboembolism.
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TABLE 5. Summary Table of the Diagnostic Strategies for Excluding Pulmonary Embolism 
with an Upper 95% Confidence Limit of 3% or Less for 3-Month Thromboembolic Risk*
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DISCUSSION
This systematic review of diagnostic strategies to exclude pulmonary embolism in patients 
with clinical suspicion of the disease allows several interesting inferences. The first concerns 
strategies performed in all referred patients. In addition to the accepted methods for excluding 
pulmonary embolism (that is, normal pulmonary angiogram or perfusion lung scan), an 
alternative strategy emerged: normal D-dimer levels alone or in combination with low clinical 
probability. A normal D-dimer result as the sole basis for excluding pulmonary embolism has 
been evaluated in only 201 patients and with only one type of assay, but the upper 95% 
CL of the failure rate compares favourably with that of a normal pulmonary angiogram or 
perfusion lung scan and is below our arbitrarily chosen upper 95% CL of 3% 7, 14, 15, 73, 75, 77, 85. 
The combination of normal D-dimer levels and low clinical probability, a strategy probably 
more applicable to clinical practice, has been evaluated more extensively, with three types 
of D-dimer assay. Our analysis indicated that the combination of low clinical probability 
and normal D-dimer levels is accurate regardless of the D-dimer assay used 78, 81, 83, 84. One 
moderately sized study evaluated the combination of low to moderate clinical probability 
and normal D-dimer levels 82. Although this strategy can exclude pulmonary embolism in 
more patients, its results require confirmation. The use of a D-dimer test in combination 
with clinical probability assessment is obviously rapid, more convenient for the patient, and 
probably cost-effective compared with the current accepted diagnostic methods.
After the initial diagnostic round, we found roughly two main approaches to continuing 
the diagnostic process. The first approach encompassed strategies after initial abnormal or 
nondiagnostic results on lung scintigraphy while the second included diagnostic strategies for 
patients in whom pulmonary embolism was not excluded by D-dimer testing combined 
with clinical probability. Regarding the first approach, we found, as expected, good 
evidence for the safety of withholding anticoagulant treatment after a normal 
pulmonary angiogram 9, 74, 80, 86. Other strategies after a nondiagnostic lung scan evaluated 
serial noninvasive testing of the deep leg veins. Although the data on serial compression 
ultrasonography appear especially convincing, they were obtained from only one large study 
in 665 patients with low to moderate clinical probability 13. Compression ultrasonography is 
attractive because it is widely available and easy to perform; however, it requires patients to 
make several visits to the hospital. With respect to the second approach (after D-dimer 
testing and clinical probability estimate), a normal perfusion lung scan is still a useful and 
safe strategy to exclude pulmonary embolism 14, 78, 79, 81, 82. 
To date, only three studies have evaluated the role of spiral CT imaging in proper clinical 
outcome studies. We found that in one study, which examined patients with low to moderate 
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clinical probability after a nondiagnostic lung scan and normal results on compression 
ultrasonography, normal results on helical CT were associated with an unacceptably high 
failure rate 76. This is probably because subsegmental thrombi were not detected. However, 
in the second 84 and third 17 studies, the failure rates were lower. The difference between 
the first and last two studies can be explained in part by improved resolution of the more 
modern CT machines. More data are needed to study the safety of excluding pulmonary 
embolism with normal results on spiral CT. Many strategies have been evaluated for screening 
after two diagnostic rounds. However, no conclusions can be made about which strategy 
is best because most of the relevant studies have been modest in size. The results of 
these studies are summarized in Table 4.
Most of the patients in studies we examined were outpatients. One study was performed 
only in inpatients, six studies were performed only in outpatients, and the remaining 
studies included both types of patients but predominantly outpatients. Whether the diagnostic 
strategies studied can be used for inpatients with the same results and failure rates requires 
further testing.
Our analysis has potential limitations. First, we accepted the interpretations of the 
various test outcomes as reported by the study authors. This may have resulted in varied 
failure rates for the same strategy. Nevertheless, the pooled estimates, particularly those for 
the strategies examined in several studies, appear to be robust. A second potential limitation 
is the risk for spectrum bias. However, the range of the overall prevalences of pulmonary 
embolism, an indicator of the case mix of the included studies, was relatively narrow. 
Therefore, we do not believe that spectrum bias influenced our conclusions. Third, the a 
priori likelihood of disease in patients with suspected pulmonary embolism is known to differ 
according to referral pattern and clinical setting, which may vary among hospitals, regions, 
and countries. For that reason, it is wise to advocate a strategy that has been evaluated in 
different settings with similar results. Fourth, our arbitrarily chosen boundaries of 3% for the 
upper 95% CL of the failure rate and 90% for the minimal completeness of follow-up can be 
criticized. However, we defined these criteria a priori to maximize the methodologic quality of 
the included studies. Finally, since the studies we examined did not directly compare different 
diagnostic strategies, inferences about the relative safety of one strategy compared with 
another should be made with caution.
Overall, many diagnostic strategies to exclude pulmonary embolism have been 
prospectively evaluated in consecutive patients. The diagnostic strategies with a failure 
rate of 3% or less (that is, a 3-month thromboembolic risk of 3%) are summarized in 
Table 5. We expect that clinicians will be increasingly interested in working with a simple 
strategy that can be performed quickly in every clinical setting. The first goal of this strategy 
will be to exclude pulmonary embolism safely in as many patients as possible. This can be 
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done by using either normal D-dimer levels in patients who have low clinical probability or a 
normal perfusion lung scan. The next goal will be to develop a reliable, simple method to 
confirm the diagnosis of pulmonary embolism. Our analysis, however, was not designed to 
identify safe methods to confirm the presence of pulmonary emboli. The most accurate 
tests for excluding pulmonary embolism after the first round of diagnostic tests remains a 
normal pulmonary angiogram, a normal perfusion lung scan, or normal results on serial leg 
testing in patients with a nondiagnostic lung scan and low to moderate clinical probability. 
If spiral CT is indeed shown to be an accurate method, the diagnostic approach may be 
further simplified. However, the choice of a diagnostic strategy should depend not only on the 
strategy’s accuracy but also on the local facilities and expertise required for its use.
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ABSTRACT
Background We designed a diagnostic strategy, based on clinical probability and D-dimer 
concentration to select patients who are unlikely to have pulmonary embolism (PE), before 
further diagnostic workup was performed. The utility and safety of this strategy were evaluated 
in a prospective management study.
Methods Consecutive patients with suspected PE had D-dimer testing and clinical probability 
assessment with a clinical decision rule. Patients with a low probability and a normal D-dimer 
concentration (< 500 ng/ml) were considered not to have PE, and further diagnostic testing 
and anticoagulant therapy were withheld. In patients with a low probability and elevated D-
dimer level or with a moderate or high probability, bilateral compression ultrasonography of 
the legs was performed. If deep venous thrombosis was detected, venous thromboembolism 
was diagnosed If compression ultrasonography was normal pulmonary angiography was 
performed. All patients were followed up for 3 months. 
Results Of the 234 consecutive patients, 26% had the combination of a low probability and 
normal D-dimer level. During the follow up period, none of these patients died and 3 patients 
had recurrent complaints of PE. In these 3 patients, PE was excluded by objective testing. 
The 3-month thromboembolic risk was therefore 0% (95% confidence interval, 0-6%). The 
prevalence of PE in the entire population was 22%. 
Conclusions The combination of a low clinical probability and a normal D-dimer concentration 
appears to be a safe method to exclude pulmonary embolism, with a high clinical utility, and 
is readily accepted by clinicians.
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INTRODUCTION
Diagnosing or excluding pulmonary embolism (PE) is difficult because the clinical manifestations 
are nonspecific1. Less than 30% of patients presenting with signs and symptoms suggestive 
of PE actually have the disease confirmed by objective testing2-4. As a result, the diagnostic 
approach has gradually changed from trying to confirm PE to also identifying the large 
proportion of patients who do not have the disease. Several methods have recently been 
advocated for excluding PE.
Clinical assessment has been used to stratify patients with suspected PE into low, 
moderate or high clinical probability categories. Studies have been performed with the use of 
clinical judgement, as well as a structured algorithm, to achieve this stratification. However, 
in 3 to 28% of patients with a low clinical probability, PE was subsequently confirmed to be 
present 2,5-10. These figures are too high to safely exclude PE in symptomatic patients on the 
basis of clinical probability assessment alone.
The finding of a normal plasma concentration of D-dimer, the degradation product of cross-
linked fibrin, was shown to be able to exclude PE accurately in most patients presenting with 
clinical suspicion. The sensitivity and negative predictive value vary depending on the type 
of D-dimer assay, but with the current rapid tests, both are usually high (90-100%, and 94-
100%, respectively) 6,11-17. To safely exclude PE, the sensitivity should approach 100%. This 
is important because for every 2% decrease in sensitivity, 1 per 1000 evaluated patients will 
die of recurrent PE, as a result of inappropriately withholding anticoagulant therapy18. Most 
D-dimer assays do not have a sufficiently high sensitivity to be safely used and accepted by 
clinicians as the only method to exclude PE.
Hence, the combination of clinical assessment and D-dimer concentration may be well 
suited to differentiate between patients who will probably have PE and those who will not have 
this disease. Findings in recent studies in patients with suspected venous thromboembolism 
(VTE) support this assumption 6,7,19. The aim of the present study was to evaluate the utility and 
safety of a novel strategy in excluding PE in patients with a low clinical probability, according 
to a validated clinical decision rule7, and a normal D-dimer concentration. In these patients no 
further diagnostic investigations were performed and anticoagulant therapy was withheld. In 
the remaining patients we used compression ultrasonography (CUS), followed by pulmonary 
angiography if results were normal.
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PATIENTS AND METHODS
Patients
Consecutive inpatients and outpatients older than 16 years, with clinically suspected PE seen 
at St. Elisabeth Hospital, Tilburg, the Netherlands, were prospectively included in the study 
between January 1, 1998, and May 31, 2000. The protocol was approved by the local ethics 
committees, and written informed consent was obtained from all patients.
Study design and diagnostic studies
The clinical decision rule (CDR) was completed and the patients were stratified into low, 
moderate or high clinical probability categories of PE. The CDR consists, as described 
elsewhere7, of risk factors for PE, signs and symptoms from history and physical examination, 
chest radiography, oxygen saturation tests, and electrocardiography, as well as the likelihood 
for an alternative diagnosis for the patient’s symptoms. The CDR was applied by a group of 
at least 10 attending physicians, who all received extensive instructions about how to use the 
rule before to the start of the study. The plasma D-dimer concentration was then measured 
with a quantitative raid enzyme-linked immunosorbent D-dimer assay (Vidas DD; bioMérieux, 
Paris, France). The concentration was expressed in nanograms per milliliter of fibrinogen 
equivalent units. The cut-off value, according to the manufacturer’s instructions, was 500 ng/
mL. All measurements were carried out in duplicate by a technician, who was unaware of the 
outcome of the CDR and the patient’s history.
Patients with a low probability of PE and a normal D-dimer test result (< 500 ng/ml) did not 
undergo further diagnostic procedures and anticoagulant treatment was withheld. They were 
instructed to return to the thrombosis unit immediately when signs or symptoms of PE or deep 
venous thrombosis (DVT) recurred and appropriate objective testing (CUS, lung scanning or 
pulmonary angiography) was performed to confirm or refute the diagnosis. 
In patients with a low probability of PE and elevated D-dimer concentration, or moderate 
or high clinical probability, first bilateral CUS of the legs was performed, within 24 hours. 
The femoral vein was visualised in the supine position in its full length and the popliteal vein 
was investigated in the prone position to the trifurcation. Visualisation of a clot, i.e. not being 
able to compress the vein and lack of flow, was considered as abnormal and to indicate the 
presence of DVT.
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When a DVT was present VTE was diagnosed and treatment with anticoagulants was initiated. 
If CUS was normal, selective pulmonary digital substraction angiography was performed, within 
48 hours after initial presentation. A 7F Swan-Ganz flow-directed pulmonary angiography true-
size catheter was positioned into a main pulmonary artery and selectively in the lobar arteries 
of both lungs. Subselective magnification series were obtained of lower, middle and upper 
portions of both lungs with the catheter in lobar and segmental branches. Anteroposterior 
projections were obtained routinely; different projections and/or selective series were obtained 
if the initial images were not conclusive. Bilateral pulmonary angiography was performed in 
all patients. The following criteria were considered diagnostic of PE: a constant intraluminal 
filling defect or a persistent acute cut-off sign of an arterial pulmonary branch seen on more 
than 1 projection. In case of doubt a second experienced radiologist was asked for his opinion 
and the diagnosis was made by means of consensus; if necessary, additional superselective 
series were performed.
3-month follow-up
All patients were re-evaluated by the study coordinator (M.J.H.A.K.) 1 week and 1 and 3 
months after inclusion at the outpatient clinic or interviewed by phone. Suspected venous 
thrombotic events (PE or DVT) were investigated by appropriate objective diagnostic methods, 
within 48 hours of presentation. When a patient was readmitted to the hospital for any cause, 
the charts were reviewed. Venous thromboembolic events, as well as causes of dead, were 
recorded and adjudicated independently. 
RESULTS
During the investigation period, 251 consecutive patients with clinically suspected PE were 
studied. Seventeen patients (7%) were excluded because of refusal or inability to give consent 
(5 patients), contraindications to pulmonary angiography (2 patients) and absence of D-dimer 
measurements because of logistic problems (10 patients). 
Thus, the study population available for analysis consisted of 234 patients. The mean age 
of this cohort was 51 years (SD, 17 years) and the prevalence of VTE was 22%. Of the total 
population 83% presented as outpatients and 11% had a history of previous VTE (Table). The 
3-month follow-up period was completed in all patients.
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Low clinical probability and normal D-dimer concentration
The Figure summarizes the results of the evaluated diagnostic strategy. The clinical probability 
of PE, according to the CDR, was low in 120 (51%), moderate in 74 patients (32%) and high 
in 40 patients (17%). Of the patients with a low clinical probability, 60 had a normal D-dimer 
concentration, so no further diagnostic procedures were performed and the patients did not 
receive anticoagulant therapy. This subgroup represents 26% of the original study cohort. 
Fifty-six of these presented as outpatients. Thus, in 4 (10%) of the 40 already hospitalised 
patients and in 56 (29%) of the 194 outpatients, PE was excluded by this diagnostic strategy. 
During the 3-month follow-up period none of the patients with a low clinical probability and a 
normal D-dimer concentration died, and 3 returned with new complaints of PE (3, 14 and 16 
days after initial presentation). In all these 3 patients PE was excluded (by normal pulmonary 
angiography in 2 normal perfusion scan results in 1). Hence, the subsequent rate of VTE in 
this patient group during follow up was 0% (95% confidence interval [CI], 0-6%).
Patients with other test outcomes
Of the 174 patients with either a low clinical probability of PE but elevated D-dimer 
concentration or a moderate or high clinical probability, 27 had a DVT detected by bilateral 
CUS. This subgroup with confirmed VTE by CUS represents 12% of the original study cohort. 
In the patients with a normal CUS (n=147) pulmonary angiography was performed. PE was 
present in 25 patients. Thus, a total of 52 patients had documented VTE; hence the overall 
prevalence was 22%. Of the 122 patients with a normal pulmonary angiography, 1 presented 
with suspected PE 10 days after the initial pulmonary angiogram. Pulmonary angiography 
was again performed and showed PE. Hence, the subsequent rate of VTE in patients with 
normal pulmonary angiograms was 0.8% (95% CI, 0.02-4.5%). During the 3-month follow-up 
period of these 122 patients, a total of 4 patients died. The causes of death were cancer in 3 
and progressive chronic obstructive pulmonary disease in 1.
Additional observations
In the present study, only patients with a low clinical probability of PE in combination with a 
normal D-dimer concentration were considered not to have PE. If we had added the patients 
with a moderate clinical probability and a normal D-dimer concentration to this group, a total 
of 85 (36%) of the presenting cohort would have been spared further diagnostic procedures 
and anticoagulant therapy. One of these 85 patients had PE involving the segmental arteries, 
confirmed by pulmonary angiography (failure rate 1.2%; 95% CI, 0.03-6.4%). This patient was 
a 40 year old women, who recently had a neurosurgical operation (9 days before presentation) 
and who presented with complaints of dyspnea of 3 days’ duration. The remaining 149 patients, 
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i.e. with a low or moderate clinical probability and elevated D-dimer concentration or with a 
high clinical probability, would have undergone further diagnostic procedures, which would 
have revealed PE in approximately one third (51 patients).
The D-dimer concentration was measured in all patients. The result was normal in 100 
patients (43%) of the presenting population. One of these 100 patients actually had PE in 
segmental arteries at pulmonary angiography (same patient as described above). The D-
dimer concentration of this patient was 480 ng/ml. The sensitivity of the D-dimer assay was 
98% (95% CI, 90-100%) and the negative predictive value 99% (95% CI, 95-100%).
DISCUSSION
The primary finding of this study is that the combination of a low clinical probability of PE a 
normal D-dimer concentration is able to exclude the disease safely in a substantial proportion 
(26%) of patients presenting with suspected PE. This new strategy was introduced in a large 
teaching hospital that previously used lung scanning and pulmonary angiography and was 
well accepted by the clinicians (physicians, internists, pulmonologists, and surgeons) involved 
in the diagnostic work up of such patients.
Furthermore, the present study confirms that the combination of CUS and pulmonary 
angiography is a feasible, effective, and safe subsequent diagnostic strategy. Performing CUS 
of the deep leg veins in patients with a moderate or high clinical probability or a low clinical 
probability and elevated D-dimer levels (n=174) was worthwhile: 16% had DVT detected by 
ultrasonography and anticoagulant treatment was initiated. Taken together, the use of the 
clinical probability assessment, D-dimer assay and CUS, all non-invasive methods, was able 
to confirm or refute the diagnosis in 37% of the patients of the original study cohort. Pulmonary 
angiography was performed without any complication, confirming earlier observations20, 
although in one patient the initial pulmonary embolism was most likely missed. The outcome 
with respect to subsequent episodes of symptomatic VTE during the 3-month follow up in 
patients with a low clinical probability and a normal D-dimer concentration (failure rate 0%; 
95%CI, 0-6%) compared favourable with that of patients with normal pulmonary angiograms 
(failure rate 0.8%; 95%CI, 0.02-4.5%) and is in agreement with studies using normal perfusion 
scans results or serial ultrasound scan results to exclude VTE 4,6,7,19,21.
Only a limited number of prospective management studies with D-dimer, CDR, or a 
combination of both are available 6,7,19,21. Our observations of the combination of CDR and D-dimer 
are comparable to the findings of these studies. However, de Groot et al19 and Perrier et al6 used 
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the combination only in patients with a nondiagnostic perfusion-ventilation lung scan result, 
whereas in the present study the combination was used as the first step in the diagnostic 
workup. Therefore, a larger proportion of our study cohort, approximately one quarter, was 
spared radiologic or nuclear investigations compared with these studies. 
In a recent study by Perrier and colleagues21, D-dimer measurements were used as the first 
test in the diagnostic work up of 444 outpatients with suspected PE. A total of 159 patients (36%) 
had normal D-dimer concentrations, and this method was used as the sole test to exclude VTE 
(subsequent failure rate was 0%; 95% CI, 0-2.3%). If we had adopted a similar strategy, while 
we used exactly the same D-dimer assay, we would have missed 1 patient with significant PE, 
although our findings are still consisted with the CIs of that study. It should be noted that we 
studied both inpatients and outpatients and that combining clinical assessment and D-dimer 
testing was readily accepted by the specialists who see patients with suspected PE. 
Several studies using CUS and pulmonary angiography in patients with suspected PE 
have been published. An abnormal venous ultrasonogram is found in 5% to 12% of patients 
with a nondiagnostic lung scan result 6,7,22-25. In a meta-analysis by van Rossum et al25, the 
prevalence of DVT in patients with clinically suspected PE was approximately 18%, and 
in patients with proven PE 36% to 45% (range, 10%-93%). Our observations with respect 
to the proportion of patients with abnormal CUS are comparable to the findings in patients 
with a high-probability lung scan result but are higher than the proportion of patients with a 
nondiagnostic lung scan result6,7,22-25. Investigations that assessed the validity and safety of 
pulmonary angiography found that this method may be falsely negative in approximately 1% 
and that the morbidity and mortality rates associated with the test itself are very low (0.4% 
(95% CI, 0.09-1.25%) and 0% (95% CI, 0.0-0.53%), respectively), as was seen in the present 
study 2,20,26.
Some aspects of our study warrant comment. Although we studied a consecutive series 
of patients with suspected PE seen in a large teaching hospital, the total number of patients 
included is moderate. In particular, in the subgroup of patients with a low clinical probability 
of PE and a normal D-dimer concentration, there remains some uncertainty about the safety 
of withholding further diagnostic testing and anticoagulant treatment, since the upper limit 
of the 95% CIl of the 3-month thromboembolic risk was 6%. Similar outcome studies using 
other strategies to exclude VTE usually had an upper limit of 4% 6,21,27-29. However, there is 
a wealth of evidence that D-dimer assays based on enzyme-linked immunosorbent assays 
are effective in excluding significant VTE. Therefore, it seems reasonable to conclude that a 
normal D-dimer concentration combined with a low clinical probability of PE is safe. Further 
studies are required to include patients with a moderate clinical probability.
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We did not include perfusion-ventilation lung scanning in the present strategy. This is 
mainly because of the limited availability of, in particular, ventilation scanning and the often 
nondiagnostic test results. The strategy used in this study eliminates the need for nuclear 
medicine facilities, which may be relevant for those institutes without such services.
We conclude that the combination of a low clinical probability of PE, assessed by a CDR, 
and a normal D-dimer concentration contributes to the increasing body of evidence that this 
is a rapid and cost-effective method to exclude PE safely, and that this strategy is readily 
accepted. The combination of CUS and pulmonary angiography remains a valid and effective 
approach for patients with suspected PE. 
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ABSTRACT
Context Previous studies have evaluated the safety of relatively complex combinations of 
clinical decision rules and diagnostic tests in patients with suspected pulmonary embolism.
Objective To assess the clinical effectiveness of a simplified algorithm using a dichotomized 
clinical decision rule, D-dimer testing, and computed tomography (CT) in patients with 
suspected pulmonary embolism.
Design, Setting, and Patients Prospective cohort study of consecutive patients with clinically 
suspected acute pulmonary embolism, conducted in 12 centers in the Netherlands from 
November 2002 through December 2004. The study population of 3306 patients included 
82% outpatients and 57% women.
Interventions Patients were categorized as “pulmonary embolism unlikely” or “pulmonary 
embolism likely” using a dichotomized version of the Wells clinical decision rule. Patients 
classified as unlikely had D-dimer testing, and pulmonary embolism was considered excluded 
if the D-dimer test result was normal. All other patients underwent CT, and pulmonary embolism 
was considered present or excluded based on the results. Anticoagulants were withheld from 
patients classified as excluded, and all patients were followed up for 3 months.
Main Outcome Measure Symptomatic or fatal venous thromboembolism (VTE) during 3-
month follow-up.
Results Pulmonary embolism was classified as unlikely in 2206 patients (66.7%). The 
combination of pulmonary embolism unlikely and a normal D-dimer test result occurred in 1057 
patients (32.0%), of whom 1028 were not treated with anticoagulants; subsequent nonfatal 
VTE occurred in 5 patients (0.5% [95% confidence interval (CI), 0.2%-1.1 %]). Computed 
tomography showed pulmonary embolism in 674 patients (20.4%). Computed tomography 
excluded pulmonary embolism in 1505 patients, of whom 1436 patients were not treated with 
anticoagulants; in these patients the 3-month incidence of VTE was 1.3% (95% CI, 0.7%-
2.0%). Pulmonary embolism was considered a possible cause of death in 7 patients after a 
negative CT scan (0.5% [95% CI, 0.2%-1.0%]). The algorithm was completed and allowed a 
management decision in 97.9% of patients.
Conclusions A diagnostic management strategy using a simple clinical decision rule, D-
dimer testing, and CT is effective in the evaluation and management of patients with clinically 
suspected pulmonary embolism. Its use is associated with low risk for subsequent fatal and 
nonfatal VTE.
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INTRODUCTION
The main challenge in the diagnostic workup of patients with clinically suspected pulmonary 
embolism is to accurately and rapidly distinguish the approximately 25% of patients who have 
the disease and require anticoagulant treatment from the 75% who do not 1,2. A number of new 
approaches have improved the diagnostic process for pulmonary embolism. The first is the 
combination of a clinical decision rule such as the Wells score,3 which categorizes patients 
as low, intermediate, or high clinical probability of pulmonary embolism, with a D-dimer test. 
Several management studies have shown that pulmonary embolism can be safely ruled out 
without the need for additional imaging in patients with low clinical probability and a normal 
D-dimer test result, occurring in 20% to 40% of patients 3-5. In these studies, 3 categories of 
likelihood were used. However, a retrospective analysis suggested that the clinical utility of the 
Wells score could be further increased by using 2 instead of 3 categories of clinical probability, 
dichotomizing patients as either likely or unlikely to have had a pulmonary embolism,3 but no 
large prospective studies evaluating this dichotomization have been carried out.
Another advancement is computed tomography (CT), which has emerged as a prominent 
imaging technique for the exclusion or confirmation of pulmonary embolism, as well as the 
detection of alternative diagnoses 6-10. However, a critical missing piece of information has 
been whether it is safe to withhold anticoagulation treatment after a CT that is negative for 
pulmonary embolism11,12. In a recent study, 13 recurrent venous thromboembolism (VTE) 
occurred in 1.7% of patients who initially had a low or intermediate probability for pulmonary 
embolism using the Geneva score, 14 an abnormal D-dimer test result, normal bilateral 
compression ultrasound (CUS) of the leg veins, and a normal multidetector-row CT scan. In 
that study, all patients with high probability for pulmonary embolism had to undergo pulmonary 
angiography after normal CT and normal CUS. A more efficient strategy would consist of an 
algorithm with a dichotomized decision rule, D-dimer testing, and CT, in which pulmonary 
embolism is considered excluded in patients with an unlikely clinical probability score and a 
normal D-dimer test result, while CT is used in all other patients as the sole imaging method 
to make management decisions. Therefore, we performed a prospective study in a large 
cohort of consecutive patients with clinically suspected pulmonary embolism to evaluate the 
effectiveness of this novel management strategy.
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METHODS 
Study Design
The Christopher Study was a prospective cohort study evaluating a diagnostic algorithm 
consisting of sequential application of a clinical decision rule, D-dimer testing, and CT within 
24 hours of presentation (figure). All patients were followed up for a period of 3 months after 
presentation to document the occurrence of subsequent symptomatic VTE
FIGURE. Diagnostic Flowchart        3503 Patients With Clinically 
                Suspected Pulmonary 
                Embolism
2206 Pulmonary Embolism 
         Unlikely (Decision Rule 
         Score ≤4)
       1100 Pulmonary Embolism 
                Likely (Decision Rule 
                Score >4) 
       197  Excluded
               184 Met Exclusion Criteria
               13 Did Not Provide Consent
3306 Study Patients
Clinical Decision Rule
D-Dimer Test
       1057 Normal D-Dimer Test Result
                (D-Dimer ≤500 ng/mL)
       1149 Abnormal D-Dimer Test Re-
                sult (D-Dimer >500 ng/mL)
       1057 Pulmonary Embolism 
                 Excluded
       1505 Pulmonary Embolism 
                 Excluded
       674 Pulmonary Embolism 
               Confirmed
       20 Inconclusive        50 Computed Tomography 
             Not Performed
Follow-up at 3 mo
5 Nonfatal Event
4 Pulmonary Embolism
1 Deep Vein Thrombosis 
0 Fatal Pulmonary Embolism 
2 Lost to Follow-up
Follow-up at 3 mo
11 Nonfatal Event
3 Pulmonary Embolism 
8 Deep Vein Thrombosis 
7 Fatal Pulmonary Embolism 
1 Lost to Follow-up
Follow-up at 3 mo
9 Nonfatal Event
3 Pulmonary Embolism
6 Deep Vein Thrombosis 
11 Fatal Pulmonary Embolism 
1 Lost to Follow-up
Follow-up at 3 mo
1 Nonfatal Event
1 Pulmonary Embolism 
0 Deep Vein Thrombosis 
0 Fatal Pulmonary Embolism 
0 Lost to Follow-up
 Follow-up at 3 mo
1 Nonfatal Event
0 Pulmonary Embolism
1 Deep Vein Thrombosis
1 Fatal Pulmonary Embolism 
0 Lost to Follow-up 
       1028 Did Not Receive Treatment*       1436 Did Not Receive Treatment†       674 Received Treatment        18 Did Not Receive Treatment        45 Did Not Receive Treatment
       2249 Computed Tomography 
                 Indicated    
*Excludes 29 patients treated with anticoagulant therapy for reasons other than venous thromboembolism. 
†Excludes 69 patients treated with anticoagulant therapy for reasons other than venous thromboembolism.
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Patients
Consecutive patients with clinically suspected pulmonary embolism, defined as a sudden onset 
of dyspnea, sudden deterioration of existing dyspnea, or sudden onset of pleuritic chest pain 
without another apparent cause, were potentially eligible for the study. Patients presenting 
to the emergency ward (outpatients) and inpatients were eligible. Patients presenting to an 
outpatient office were sent directly to the emergency department for evaluation. Patients were 
recruited between November 2002 and September 2004.
Exclusion criteria were treatment with therapeutic doses of unfractionated or low-
molecular-weight heparin for more than 24 hours, life expectancy less than 3 months, 
pregnancy, geographic inaccessibility precluding follow-up, age younger than 18 years, 
allergy to intravenous contrast agents, renal insufficiency (creatinine clearance <30 mL/ min 
[<0.5 mL/s]), logistic reasons (eg, unavailability of CT, patient too ill to undergo CT scanning), 
or hemodynamic instability. Five academic and 7 general urban hospitals in the Netherlands 
participated. The institutional review boards of all participating hospitals approved the study 
protocol, and written or oral informed consent was obtained from all participants.
TABLE 1. Clinical Decision Rule*
Variable         points
Clinical signs and symptoms of deep vein thrombosis 
(minimum of leg swelling and pain with palpation of the deep veins)   3
Alternative diagnosis less likely than pulmonary embolism    3
Heart rate > 100/min       1.5
Immobilization (> 3 days) or surgery in previous 4 weeks    1.5
Previous pulmonary embolism or deep vein thrombosis    1.5
Hemoptysis        1.0
Malignancy (receiving treatment, treated in the last 6 months or palliative)  1.0
* clinical probability of pulmonary embolism unlikely: 4 or less points; clinical probability of pulmonary 
embolism likely: more than 4 points. Source: Wells et al. 3
Clinical Decision Rule and D-Dimer Assay
Patients with clinically suspected pulmonary embolism were evaluated by an attending 
physician using a validated clinical decision rule (table 1)3 Pulmonary embolism was classified 
as “unlikely” with a clinical decision rule score of 4 or less points, and “likely” with a score of 
more than 4 points. This cut-off was chosen because it has been shown to give an acceptable 
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VTE diagnostic failure rate of 1.7% to 2.2% in combination with a normal D-dimer test result.3 
An estimated 300 attending physicians in the participating hospitals used the clinical decision 
rule with the study participants.
In patients with a clinical decision rule indicating pulmonary embolism unlikely, a D-dimer 
concentration was measured, using either the VIDAS D-dimer assay (Biomerieux, Marcy 
L’Etoile, France) or the Tinaquant assay (Roche Diagnostica, Mannheim, Germany). A D-
dimer concentration of 500 ng/mL or less was defined as nor-mal. In patients with pulmonary 
embolism unlikely and a normal D-dimer test result, the diagnosis of pulmonary embolism was 
considered excluded and anticoagulant treatment was withheld. Those patients who had a 
combination of clinical decision rule indicating pulmonary embolism unlikely with an abnormal 
D-dimer test result, or who had a clinical decision rule indicating pulmonary embolism likely, 
underwent CT.
Radiological Evaluation
Computed tomography was performed using either single-detector row or multidetector-row 
systems. Patients were examined during suspended inspiration. The single-detector row CT 
parameters were 3-mm slice thickness with a 2-mm reconstruction interval at 120 kV/140 
mAs, 120 to 140 mL of nonionic contrast material containing 350 mg of iodine per mL with 
an injection speed of 3.0 mL/s and an injection delay of 16 seconds. Multidetector-row CT 
parameters were 1.25-mm slice thickness with a 1.2-mm reconstruction interval at 120 kV/120 
mAs, 80 to 100 mL of nonionic contrast material containing 350 mg of iodine per mL with an 
injection speed of 4.0 mL/s and bolus tracking in the common pulmonary artery to get optimal 
contrast opacification of the pulmonary arteries.
The pulmonary arteries were evaluated up to and including the subsegmental vessels from 
the level of the aortic arch to the lowest hemidiaphragm. Pulmonary embolism was diagnosed 
if contrast material outlined an intraluminal defect or if a vessel was totally occluded by low-
attenuation material on at least 2 adjacent slices. These patients received low-molecular-
weight heparin or unfractionated heparin, followed by vitamin K antagonists, according 
to local practice. In patients without pulmonary embolism, the presence or absence of an 
alternative diagnosis was recorded and anticoagulant treatment was withheld. The CT was 
considered inconclusive if the images could not be interpreted because of motion artifacts due 
to movements of the patient or the heart or if there was insufficient contrast enhancement of 
the pulmonary arteries. The management of patients in whom the CT could not be performed 
or who had an inconclusive CT scan was left to the discretion of the attending physician.
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The decision of the presence or absence of pulmonary embolism was made by trained 
attending radiologists who were blinded to any specific patient clinical information. By protocol 
design they knew that a patient referred for CT either had a D-dimer level that was above 500 
ng/mL or a clinical decision rule score that was higher than 4 points, but did not know which of 
these items was the reason for performing a CT scan.
Outcome Measures
The primary outcome of the study was the incidence of symptomatic VTE events during 3 months 
of follow-up, defined as fatal pulmonary embolism, nonfatal pulmonary embolism, or deep vein 
thrombosis (DVT). An independent adjudication committee, whose members were unaware of 
the patient’s allocation within the diagnostic algorithm, evaluated all suspected VTE and deaths. 
A diagnosis of pulmonary embolism or DVT was based on a priori defined and generally accepted 
criteria 15. Deaths were classified as caused by pulmonary embolism in case of confirmation 
by autopsy, in case of an objective test positive for pulmonary embolism prior to death, or if 
pulmonary embolism could not be confidently excluded as the cause of death.
Follow-up consisted of a scheduled outpatient visit or telephone interview at 3 months. 
Patients were additionally instructed to contact the study center or their general practitioner im-
mediately in the event of symptoms suggestive of DVT or pulmonary embolism. At each visit, 
information was obtained on complaints suggestive of VTE, including acute onset of dyspnea, 
acute worsening of existing dyspnea, acute onset of chest pain, unilateral leg swelling and 
leg pain, as well as interval initiation of anticoagulants. In case of clinically suspected DVT or 
pulmonary embolism, objective diagnostic tests were required, in- cluding CUS for suspected 
DVT, and ventilation-perfusion scintigraphy or CT for suspected pulmonary embolism. In case 
of death, information was obtained from the general practitioner, from the hospital records, or 
from autopsy.
Statistical Analysis
The 2 primary analyses were incidence of symptomatic VTE during follow-up, confirmed by 
objective testing, in (1) the group of patients in whom anticoagulant treatment was withheld 
based on a classification of pulmonary embolism unlikely by clinical decision rule and a 
normal D-dimer test result, and (2) the group of patients in whom anticoagulant treatment was 
withheld based on a CT scan that excluded pulmonary embolism. Additional analyses were 
performed for fatal pulmonary embolism in these groups, as well as among the patients with 
a normal CT scan and an alternative diagnosis on CT separately.
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Sample size was based on an assumption of a 1% incidence of VTE in both patient groups5,9 
and a goal to keep the upper limit of the 95% confidence interval (CI) below 2.7%, which has 
been reported as the upper limit of the range of recurrent VTE after a normal angiogram 16. We 
calculated that approximately 1000 patients would have to be included in each group, using a 2-
sided type I error of .05 and a type II error of .20. Since we expected that approximately 30% of 
patients would have a classification of pulmonary embolism unlikely by clinical decision rule and a 
normal D-dimer test result,5 a total study population of 3300 patients was needed.
Exact 95% CIs were calculated around the observed incidences using StatXact software, 
version 5 (Cytel Software Corp, Cambridge, Mass). Descriptive parameters were calculated 
using SPSS software, version 11.5 (SPSS Inc, Chicago, Ill). For statistical differences, the 
Fisher exact test was used; statistical significance was set at P < .05.
RESULTS
Study Patients
A total of 3503 consecutive patients with clinically suspected pulmonary embolism were 
screened, of whom 184 (5.3%) were excluded because of predefined exclusion criteria: more 
than 24 hours of low-molecular-weight heparin (n=50), life expectancy less than 3 months (n=47), 
pregnancy (n=26), geographic inaccessibility precluding follow-up (n=20), renal insufficiency 
(n=26), logistic reasons (n=10), age younger than 18 years (n=4), and allergy to intravenous 
contrast agent (n=1). In addition, 13 patients refused consent (Figure). The final study population 
of 3306 participants included 2701 (81.7%) outpatients and 605 (18.3%) inpatients; the baseline 
demographic and clinical characteristics of the 3306 study patients are shown in table 2.
Results of Diagnostic Algorithm
Of the 3306 included patients, 2206 (66.7%) had a clinical decision rule indicating pulmonary 
embolism unlikely and were tested for D-dimer concentrations (Figure). The prevalence of 
pulmonary embolism in these patients was 12.1% (266/2206; 95% CI, 10.7%-13.5%) versus 
37.1% (408/1100; 95% CI, 34.2%-40.0%) in those with a clinical decision rule indicating pul-
monary embolism likely (P<.001). Among the 1149 patients classified as unlikely but with an 
abnormal D-dimer test result, the prevalence of pulmonary embolism was 23.2% (266/ 1149). 
D-dimer test results were normal in 1057 (32.0%) patients, and in these patients, pulmonary 
embolism was considered excluded. Of the 2206 patients undergoing D-dimer testing, 968 (44%) 
had a VIDAS D-dimer test performed; 1238 patients (56%) had a Tinaquant D-dimer test.
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Of the 2249 patients with either abnormal D-dimer concentrations (n=1149) or a clinical 
decision rule indicating pulmonary embolism likely (n=1100), 2199 underwent CT. In the 
other 50 patients a CT was indicated but not performed because of lack of venous access, 
extreme obesity, DVT confirmed by CUS prior to CT, or a deteriorating clinical condition 
prior to CT. Multidetector-row CT was performed in 1939 patients and single-detector row 
CT in 260 patients. Computed tomography excluded pulmonary embolism in 1505 patients 
(45.5% of the study population). In these patients, 702 (21.2% of the study population) had ad-
ditional diagnostic information visualized on CT: pneumonia (n=212), pleural effusion (n=163), 
malignancy (n=50), and other diagnoses (n=277). Pulmonary embolism was confirmed in 
674 patients (20.4% of the study population). Computed tomography was inconclusive in 20 
patients (0.9%). Hence, the diagnostic algorithm could be completed according to the protocol 
in 3256 patients (98.5%) and allowed a management decision in 3236 patients (97.9%).
TABLE 2. Baseline Demographic and Clinical Characteristics of Study Population (n = 3306)*
Characteristic       Value
Age, mean (SD), y       53.0 (18.4)
Female        1897 (57.4)
Outpatients       2701 (81.7)
Duration of complaints, median (IQR), d     2(1-5)
Paralysis        91(2.8)
Immobilization or recent surgery     610 (18.5)
Previous venous thromboembolism      480 (14.5)
COPD with treatment      341 (10.3)
Heart failure with treatment      243 (7.4)
Malignancy       476 (14.4)
Estrogen use, women      438 (23.1)
Clinical symptoms of deep vein thrombosis    190 (5.7)
Heart rate >100/min       867 (26.2)
Hemoptysis       176 (5.3) 
Abbreviations: COPD, chronic obstructive pulmonary disease; IQR, interquartile range.
*Data are presented as number and percentage unless otherwise indicated.
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Patients With Pulmonary Embolism Unlikely  
and Normal D-Dimer Test Result
Of the 1057 patients with the combination of a clinical decision rule indicating pulmonary 
embolism unlikely and a normal D-dimer test result, 29 patients (2.7%) were treated with 
oral anticoagulants during follow-up for various reasons other than VTE. Three of the 1028 
remaining patients returned with symptomatic VTE events (2 nonfatal pulmonary embolism, 
1 DVT) during the 3-month follow-up. In 25 patients, the protocol was violated and a CT or 
a ventilation-perfusion scan was performed while not indicated. Pulmonary embolism was 
diagnosed in 2 of these 25 patients. Therefore, the incidence of VTE was 5 of 1028 (0.5% 
[95% CI, 0.2%- 1.1%]) (Table 3). Two patients were lost to follow-up (0.2%). In a “worst case” 
scenario, in which these 2 patients would have developed VTE, the incidence of VTE would 
have been 7 of 1028 (0.7% [95% CI, 0.3%-1.4%]). There were no fatal pulmonary embolisms. 
Eight (0.8%) of the 1057 patients died of other causes.
Of the study population, 605 were inpatients, and 56 of these had a decision rule indicating 
pulmonary embolism unlikely and a normal D-dimer test result (9.3%). No VTE was observed 
at follow-up in these patients (VTE rate, 0% [95% CI, 0%-6.4%] ). The results for inpatients and 
outpatients were comparable (VTE rate, 0% [95% CI, 0%- 6.4%] vs 0.5% [95% CI, 0.2%-1.2%]). 
There were no significant differences between patients at academic and general hospitals.
The VIDAS D-dimer assay had a true-negative rate of 44.2% (428/968 patients) and the 
Tinaquant D-dimer assay had a true-negative rate of 50.8% (629/1238 patients) (P<.002). The 
negative predictive values for the VIDAS and Tinaquant assays were 100% (95% CI, 99.1%-
100%) and 99.2% (95% CI, 98.1%-99.7%), respectively.
TABLE 3. Venous Thromboembolic Events (VTEs) During 3-Month Follow-up (n = 3138)*
Variable No.
Total VTEs,
No. (%) [95% CI]
Fatal Pulmonary Embolism,
No. (%) [95% CI]
Pulmonary embolism unlikely 
and normal D-dimer test result 1028 5 (0.5) [0.2-1.1] 0 (0) [0.0-0.3]
Pulmonary embolism excluded by CT 1436 18 (1.3) [0.7-2.0] 7 (0.5)[0.2-1.0]
CT normal 764 9 (1.2)[0.5-2.2] 3 (0.4) [0.1-1.1]
CT alternative diagnosis 672 9 (1.3)[0.6-2.5] 4 (0.6) [0.1-1.5]
Pulmonary embolism diagnosed by CT 674 20 (3) [1.8-4.6] 11 (1.6) [0.8-2.9]
Abbreviations: CI, confidence interval; CT, computed tomography. *A total of 168 patients were excluded due to treatment with 
anticoagulation outside of protocol, inconclusive CT, or CT not performed.
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Patients With CT Excluding Pulmonary Embolism
Of the 1505 patients in whom CT excluded pulmonary embolism, 69 (4.6%) received 
anticoagulants during follow-up for various reasons other than VTE. Of the 1436 patients 
who did not receive anticoagulant treatment, 18 experienced VTE events during the 3-month 
follow-up (1.3% [95% CI, 0.7%-2.0%]). Eleven of these patients had nonfatal symptomatic 
thromboembolic events (3 pulmonary embolism and 8 DVT). Fatal pulmonary embolism was 
presumed to have occurred in the other 7 patients (0.5% [95% CI, 0.2%-1.0%]); it was proven 
by autopsy in 2 and attributed as the cause of death in 5 (Table 4). Follow-up was incomplete 
in one of the 1436 patients (0.1%). In a “worst case” scenario in which this patient would have 
developed VTE, the incidence of VTE would have been 19 of 1436 (1.3% [95% CI, 0.8%-2.1%]).
TABLE 4. Deaths Attributed to Pulmonary Embolism
Patient
Sex
Age, 
y
Results of Computed 
Tomography
Anticoagulant 
Therapy
Past Medical 
History
Time of  
Death
After 
Enrollment, d
Circumstances of Death
Male 60 Normal No COPD, alcohol 
abuse
3 Sudden death at home
Female 65 Alternative diagnosis: 
pulmonary metastases
No Colon cancer; 
multiple 
metastases in liver, 
spleen, adrenal 
glands
18 Dehydration due to 
chemotherapy-induced 
diarrhea; morphine for pain 
complaints; sudden death
Male 46 Normal No Multiple myeloma 40 Bedridden due to 
complaints of pain 
associated with myeloma; 
sudden death at home; 
autopsy result: pulmonary 
embolism
Female 69 Alternative diagnosis:
interstitial
pneumonia
No Progressive 
dyspnea in past 
half year due 
to interstitial 
pneumonia
41 Computed tomography at 
day 34 showed pulmonary 
embolism; progressive 
respiratory insufficiency; 
ventilator dependency; 
palliative care; autopsy 
result: pulmonary embolism 
and bilateral pneumonia
Female 60 Alternative diagnosis: 
pericarditis carcinomatosa
No COPD, breast 
cancer
75 Immobilization in electric 
wheelchair in nursing 
home; gradual worsening, 
cardiac failure due to 
pericarditis
Female 77 Alternative diagnosis: 
pneumonia; at review, a 
subsegmental pulmonary 
embolism had been 
missed at inclusion
No Hypertension 86 Collapse on street with 
swollen face
Female 31 Normal No Pulmonary 
embolism in 2002, 
diabetes, renal 
insufficiency,
estrogen use
94 Antibiotics for CAPD 
peritonitis; sudden death
Abbreviations: CAPD, continuous ambulatory peritoneal dialysis; COPD, chronic obstructive pulmonary disease.
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Rates of VTE during follow-up were comparable for inpatients and outpatients (1.4% ([95% 
CI, 0.4%-3.1%]) vs 1.2% [95% CI, 0.7%-2.1%], respectively). Among the patients who did not 
receive anticoagulants, similar incidences of VTE were observed in those with a normal CT 
scan (9/764 [1.2%] {95% CI, 0.5%-2.2%}) and those with additional diagnostic information on 
CT (9/672 [1.3%] {95% CI, 0.6%- 2.5%}) (Table 3). Similar incidences of VTE were observed 
in untreated patients who underwent multidetectorrow CT (14/1266 [1.1%] {95% CI, 0.6%-
1.9%}) vs single-detector row CT (4/170 [2.4%]{95% CI, 0.6%-5.9%}).
Twenty patients returned with symptoms of pulmonary embolism during follow-up. 
Computed tomography was again used as the diagnostic method in 13 of these 20 patients 
and was nor-mal in all. No VTE was demonstrated at later follow-up.
The overall mortality rate in patients in whom CT excluded pulmonary embolism was 8.6% 
(129 patients).
Patients With CT That Was Inconclusive or Not Performed
Of the 20 patients with an inconclusive CT scan, pulmonary embolism was demonstrated by 
ventilation-perfusion lung scan in 2 patients, and they received anticoagulant treatment. Dur-
ing follow-up,1 of the 18 remaining patients had a nonfatal VTE event. Of the 50 patients in 
whom CT was indicated but not performed, 3 had pulmonary embolism demonstrated by ven-
tilation-perfusion lung scan, and 2 patients had DVT demonstrated by CUS; during follow-up, 1 
of the remaining 45 patients had a fatal pulmonary embolism, while DVT occurred in 1 patient. 
The mortality rate for inconclusive CT was 5% (1/20) and for CT not performed, 14% (7/50).
Patients With Pulmonary Embolism Confirmed by CT
Of the 674 patients in whom CT demonstrated pulmonary embolism, 20 patients (3.0%) had 
a recurrent VTE despite anticoagulant treatment. This included 11 fatal pulmonary embolism, 
3 nonfatal pulmonary embolism, and 6 DVT. One patient was lost to follow-up. The overall 
mortality in this group was 7.2% (55 patients).
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DISCUSSION
This large cohort study of 3306 consecutive patients with clinically suspected pulmonary 
embolism demonstrates that the use of a diagnostic algorithm consisting of a dichotomous 
decision rule, D-dimer testing, and CT scan can guide treatment decisions with a low risk for 
subsequent pulmonary embolism. No further diagnostic testing was necessary in the third 
of our patients who had an unlikely clinical probability score in combination with a normal D-
dimer test result, with a 3-month incidence of VTE of 0.5%. Computed tomography effectively 
ruled out pulmonary embolism in all other patients without using other imaging tests (3-month 
incidence of VTE in those with a negative CT of 1.3%). The algorithm was pragmatic in that 
it could be completed in 98.5% of the eligible patients and allowed a management decision 
in 97.9%.
Other management studies have documented the safety of a low clinical probability in 
combination with a normal D-dimer concentration for the exclusion of pulmonary embolism 3-5,17. 
In these studies, the rate of VTE during follow-up ranged from 0% to 1.5%. However, because 
the sample size was limited, upper confidence limits were as high as 6.0% 3-5, 15.
In contrast to our simple algorithm, a recent study 13 used a more complex flowchart 
with sequential testing that included clinical probability assessment, D-dimer assay, CUS, 
CT, as well as pulmonary angiography to exclude pulmonary embolism in patients with high 
likelihood and negative workup. As the authors pointed out, their study was not a true outcome 
study, since CUS was performed in all patients with abnormal D-dimer levels, and patients 
with abnormal CUS and a normal CT scan were treated with anticoagulation. That study 
had a smaller sample size (674 patients) and a higher rate of exclusion (25% vs 5.6% in our 
study).
To improve the simplicity and utility of their decision rule, Wells et al proposed changing 
their model from the original 3 categories (low, moderate, high) to 2 categories (pulmonary 
embolism unlikely and pulmonary embolism likely).3 Our study is the first to prospectively 
validate the safety of the dichotomized score in combination with the D-dimer assay. Com-
pared with a combination using the 3-category classification, this approach has the potential 
to increase the number of patients in whom pulmonary embolism can be excluded by 
approximately 50% 3,17.
Despite concerns that the sensitivity of CT for pulmonary embolism is lower than that of 
pulmonary angiography,18,19 the observed risk of subsequent symptomatic VTE in those pa-
tients in whom pulmonary embolism was excluded by CT was comparable to the risk reported 
after a normal pulmonary angiogram (3-month incidence, 1.3% [95% CI, 0.7%-2.0%] vs 1.7% 
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[95% CI, 1.0%-2.7%],16 respectively). In addition, in our study fatal pulmonary embolism 
occurred in 0.5% (95% CI, 0.2%- 1.0%) of patients in whom CT had excluded pulmonary 
embolism, compared with 0.3% (95% CI, 0.02%- 0.7%) after normal pulmonary angiography 
16. Computed tomography has the potential advantage of providing additional diagnostic 
information for the presenting symptoms in patients without pulmonary embolism.
Several potential limitations in our study require comment. First, the absence of pulmonary 
embolism was not verified by pulmonary angiography. However, the clinical outcome after a 
3-month follow-up is widely accepted as an appropriate alternative to establish the safety of a 
diagnostic strategy, given a near-complete follow-up20. Second, while our cohort study has the 
strength of minimal loss to follow-up (3 patients, 0.1%) and independent blinded adjudication 
of all outcomes, a randomized controlled study design would have allowed a direct comparison 
to other validated strategies. Third, CT was again used to exclude pulmonary embolism in 13 
of 20 patients who returned during follow-up with symptoms after CT had excluded pulmonary 
embolism at baseline. Although these could represent false-negative results, these patients 
were not treated and further follow-up was uneventful, making this unlikely. Fourth, the use 
of multidetectorrow CT has the potential for overdiagnosis by imaging very small periph-
eral subsegmental emboli. Because patients did not undergo confirmatory pulmonary 
angiography, our study design did not permit assessing the false-positive rate of CT scans. 
Only 10% of our patients underwent single-detector row CT, so we could not make a 
meaningful comparison of the impact of each test. However, the overall prevalence of 
pulmonary embolism in our study (20%) is comparable to the prevalence in a previous 
multicenter study performed with single-detector row CT (24%) 9. This does not support a 
concern that multidetector-row CT technology will lead to a high number of false-positive 
results. Finally, a definitive cause of death could not be established for all patients with 
normal test results who died during follow-up. However, pulmonary embolism was assigned 
as the cause of death if it could not be confidently excluded, a conservative assumption that 
strengthens our conclusions about low risk for this strategy.
The generalizability of our findings should be considered. The baseline clinical 
characteristics and the incidence of pulmonary embolism for our study population are 
comparable with those observed in other population-based studies, except for a somewhat 
younger mean age 5,10,12. The low proportion of patients excluded and the enrollment of 
consecutive patients who were referred to both academic and nonacademic hospitals further 
supports broad applicability of these results, as does the similar rates of VTE during follow-up 
between inpatients and outpatients.
In conclusion, a diagnostic management strategy using a simple clinical decision rule, 
D-dimer testing, and CT is as effective as other more complex diagnostic strategies in the 
evaluation and management of patients with clinically suspected pulmonary embolism. Its use 
is associated with low risk for subsequent fatal and nonfatal VTE.
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ABSTRACT
Objectives Diagnostic strategies in patients with suspected pulmonary embolism have been 
extensively studied in outpatients; their value in hospitalized patients has not been well 
established. Our aim was to determine the safety and clinical utility of a simple diagnostic 
strategy in hospitalized patients with suspected pulmonary embolism.
Design Prospective management study
Setting 12 teaching hospitals (5 academic, 7 general hospitals)
Subject 605 hospitalized patients with clinically suspected pulmonary embolism. All patients 
completed the study.
Interventions First the clinical decision rule (CDR)-score was calculated. An unlikely CDR-
score in combination with a normal D-dimer excluded pulmonary embolism. All other patients 
underwent helical CT. CT either diagnosed or excluded pulmonary embolism, in which case 
anticoagulants were started or withheld. All patients were instructed to report symptoms of 
venous thrombosis. Objective tests were performed to confirm venous thromboembolism. The 
primary outcome was the incidence of symptomatic venous thrombosis during three months 
follow-up.
Results  The combination of an unlikely CDR-score and a normal D-dimer excluded pulmonary 
embolism in 60 patients (10% of all patients); no venous thromboembolic event occurred during 
follow-up (0%; 95% CI 0%-6.7%). CT excluded pulmonary embolism in 380 patients; during 
follow-up venous thromboembolism occurred in 5 patients (1.4%; 95% CI 0.4%-3.1%).
Conclusions An unlikely CDR-score in combination with a normal D-dimer appears to 
exclude pulmonary embolism safely in hospitalized patients. Before clinical implementation 
it is important this safety is confirmed by others. CT testing was obviated in only 10% of 
patients. CT can safely exclude pulmonary embolism in hospitalized patients.  
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INTRODUCTION
Hospitalized patients are at high risk for the development of venous thrombosis (deep vein 
thrombosis or pulmonary embolism) and if they do develop thrombosis the morbidity and 
mortality increases compared to hospitalized patients without venous thrombosis 1. Autopsy 
series of hospitalized patients have shown that pulmonary embolism accounts for 5-10% of 
hospital deaths 2, 3 . Therefore, it is important to be able to safely exclude or confirm thrombosis 
in patients with a clinical suspicion of this disease. Even more so because unnecessary 
anticoagulant treatment can lead to morbidity and mortality, i.e. minor (6.2 per 100 patient-
years), major (1.1 per 100 patient-years), or fatal (0.25  per 100 patient-years) bleedings 4.
Several diagnostic strategies for patients with clinically suspected pulmonary embolism 
evaluated in recent years start with the exclusion of the disease by using a low clinical probability 
assessment in combination with a normal D-dimer test 5-8. The results of these studies are 
mainly based on outpatients, sometimes on the combination of in- and outpatients, rarely on 
hospitalized patients alone. There is a debate about the clinical utility of D-dimer testing in 
hospitalized patients because of the low proportion with a normal D-dimer concentration 9-11.
Furthermore, the safety of withholding anticoagulant treatment after a normal helical 
computed tomography (CT) as the only imaging technique is still uncertain, because of the 
limited studies, again mainly in outpatients 7,12-14. 
We recently completed a large outcome study in which the safety of a diagnostic strategy 
using the combination of a clinical decision rule (CDR) and D-dimer concentration followed 
by helical CT was evaluated in patients with clinically suspected pulmonary embolism 15. The 
aim of the present analysis is to evaluate the safety and clinical utility of this strategy in 
hospitalized patients.
MATERIALS AND METHODS
This study was part of a large management study in 12 teaching hospitals (5 academic and 
7 general hospitals) in the Netherlands which evaluated a diagnostic strategy including a 
CDR, D-dimer testing and helical CT 15. Patients were included between November 2002 and 
September 2004. The Institutional Review Board of all participating hospitals approved the 
study protocol.
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Study participants
Hospitalized patients with clinically suspected pulmonary embolism were eligible for inclusion 
in this analysis. The hospitalization was for other reasons than suspected pulmonary embolism. 
Patients were excluded if they had received therapeutic unfractionated or low-molecular-
weight-heparin for more than 24 hours before inclusion, were younger than 18 years of age, 
were pregnant, had a known allergy to intravenous contrast agents, had a life expectancy of 
less than three months or if there was geographic inability for follow-up. 
Diagnostic strategy
The figure shows the diagnostic strategy of the study. A validated clinical decision rule 
(CDR) was used. This rule consists of seven questions including the presence of symptoms 
of deep venous thrombosis (3 points), pulse frequency (> 100 beats per minute is 1.5 
points), immobilization or surgery within the last four weeks (1.5 points), previous venous 
thromboembolism (1.5 points), hemoptysis (1 point), malignancy (1 point) and the possibility 
of an alternative diagnosis (3 points if pulmonary embolism is more likely than an alternative 
diagnosis) 6. Patients were classified into those with a likely CDR-score (> 4) or unlikely CDR-
score (4 or below). 
In case of an unlikely CDR-score, the D-dimer concentration was measured using either 
the Vidas D-Dimer assay (Biomerieux, Marcy Létiole, France) or the Tinaquant assay (Roche 
Diagnostica, Mannheim, Germany). A D-dimer concentration of ≤ 500 ng/ml fibrinogen 
equivalents was defined as normal for both assays. In case of an unlikely CDR-score 
and a normal D-dimer concentration, pulmonary embolism was considered excluded and 
anticoagulant treatment was withheld. Patients with an unlikely CDR-score in combination 
with an abnormal D-dimer concentration or patients with a likely CDR-score, underwent a 
helical CT. If the CT did not demonstrate pulmonary embolism, anticoagulant treatment was 
withheld. If the CT demonstrated pulmonary emboli, anticoagulant treatment was initiated, 
using unfractionated or low-molecular-weight-heparin and vitamin K antagonists, according 
to the local practice.
Helical CT was performed using single- or multi-slice detector systems according to the 
protocol as described 15. The management of the patients in whom helical CT could not be 
performed was left to the discretion of the attending physician.
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Follow-up and outcome
After completing the diagnostic strategy, the patients were instructed to return to the hospital if 
signs and symptoms of deep venous thrombosis or pulmonary embolism occurred during the 
3 months follow-up period. A regular follow-up was scheduled after 3 months and consisted 
of a telephone interview or a hospital visit. Information on signs and symptoms suggestive of 
deep venous thrombosis or pulmonary embolism, the use of anticoagulants and comorbidity 
was obtained. If a patient was clinically suspected of deep venous thrombosis or pulmonary 
embolism, objective tests were performed to confirm or exclude the diagnosis, i.e. compression 
ultrasonography for suspected deep venous thrombosis, ventilation-perfusion lung scanning, 
helical CT, or pulmonary angiography for suspected pulmonary embolism. The results of these 
tests were adjudicated by an independent committee that was not aware of the original test 
results. In case of death, information was obtained by reviewing the hospital charts, the results 
from autopsy or by contacting the general practitioner. All deaths were adjudicated by the 
independent committee and classified as due to pulmonary embolism in case of confirmation 
by autopsy, in case of an objective positive test for pulmonary embolism prior to death or if 
pulmonary embolism could not be confidently excluded as the cause of death. 
The primary outcome of the study was the incidence of symptomatic venous thrombosis 
during three months follow-up, defined as non-fatal or fatal pulmonary embolism or deep 
venous thrombosis.
Statistical analysis
The incidences of symptomatic venous thromboembolism confirmed by objective testing in the 
group of patients in whom anticoagulant treatment was withheld were calculated for the groups 
of patients with 1) an unlikely CDR-score in combination with a normal D-dimer concentration 
or 2) a helical CT scan that excluded pulmonary embolism. Exact 95% confidence intervals 
(CI) were calculated around the observed incidences using StatXact software, version 5 (Cytel 
Software Corp, Cambridge, Mass, USA). Descriptive parameters were calculated using SPSS 
software, version 11.5 (SPSS, Inc., Chicago, Illinois).      
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RESULTS
Study patients
The study population consisted of 605 hospitalized patients. These patients were a part of a 
large management study with 3505 eligible in- and outpatients of whom 197 were excluded 
because of predefined criteria or no informed consent 15. The baseline characteristics of the 
hospitalized patients are presented in Table 1. 
Compared to the 2701 outpatients that were included in the original study, the hospitalized 
patients were older, had higher prevalences of the risk factors such as immobility and recent 
surgery and more patients were known with comorbid conditions such as cancer, heart-failure 
and chronic obstructive pulmonary diseases. Two patients were excluded, because the CDR-
score was not calculated.
TABLE 1. Baseline characteristics of the hospitalized patients
Characteristics     hospitalized patients (n = 605) 
Age, years (standard deviation)   61 (18)
Women, n (%)     344 (57) 
Immobility, n (%)     156 (26) 
Recent surgery, n (%)    113 (19) 
Previous venous thromboembolic events, n (%)  53 (9) 
Duration of complaints, days, median (IQR*)  6.0 (6) 
Cancer, n (%)     156 (26) 
Heart-failure with treatment, n (%)   77 (13) 
COPD** with treatment, n (%)    103 (17) 
Estrogen use, n (%)     27 (5)
* interquartile range 
** chronic obstructive pulmonary disease 
Results of the Clinical Decision Rule and D-dimer concentration.
The results of the CDR are presented in Table 2. In this study the dichotomized CDR-score 
was used. Of the 603 patients 291 (48%) had an unlikely CDR-score (≤ 4). The D-dimer 
test was normal in 60 of these patients (21% of the patients with an unlikely CDR-score and 
10% of all patients). In four patients the protocol was violated and helical CT was performed, 
which did not demonstrate pulmonary emboli, while another three patients received vitamin K 
antagonists for various reasons other than venous thromboembolism, such as atrial fibrillation 
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and valvular heart disease. Therefore, in 53 patients pulmonary embolism was considered 
excluded and anticoagulant treatment was withheld. During follow-up, completed in all 
patients, no venous thromboembolic events and no death attributed to pulmonary embolism 
occurred in these 53 hospitalized patients (failure rate 0%; 95% CI 0%-6.7%) (Table 3, figure). 
This was comparable with the outcome in outpatients (failure rate 0.5%; 95% CI 0.2%-1.2%). 
Two hospitalized patients died of other reasons than venous thromboembolism. The CDR of 
the hospitalized patients revealed more PE-likely CDR-scores (52%), i.e. a CDR-score > 4, as 
compared to the outpatients (29%) (p<0.001).
FIGURE. Flowchart with outcomes at presentation and at 3 months  
for hospitalized patients with suspected pulmonary embolism.
* pulmonary embolism
† without patients receiving anticoagulants for other reasons than pulmonary embolism
‡ venous thromboembolic event
 Clinically suspected 
PE* (n=605) 
        no CDR-score (n=2)  
clinical decision rule (n=603) 
PE unlikely      PE likely  
   (n=291)      (n=312) 
D-dimer normal  D-dimer abnormal  helical computed tomography 
(n=60)   (n=231)    (n=547) 
       (n=4) 
PE excluded PE excluded PE diagnosed inconclusive not performed  
(n=56)  (n=380)  (n=150)  (n=8)  (n=9) 
no treatment no treatment treatment 
(n=53† )  (n=368† )   (n=150) 
follow-up at 3 months , n=603 
VTE‡
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Results of the helical CT.
Both patients with an unlikely CDR-score and elevated D-dimer test (n = 231) as well as 
patients with a likely CDR-score (n = 312) were scheduled for helical CT (figure). 
In 9 patients (2%) the protocol was violated and helical CT was not performed, while in 8 
patients (1%) the results were inconclusive.
Of the patients with an unlikely CDR-score and elevated D-dimer test, pulmonary embolism 
was excluded by helical CT in 179 patients (77% of this group of patients). In total, helical CT 
excluded pulmonary embolism in 380 patients. During follow-up none of these patients were 
lost to follow up. Twelve patients received vitamin K antagonists for various other reasons 
than venous thromboembolism such as atrial fibrillation and valvular heart disease. Five of the 
remaining 368 patients without anticoagulant treatment had a venous thromboembolic event 
during the three months follow-up (failure rate 1.4%; 95% CI 0.4%-3.1%); two patients had a 
deep venous thrombosis, one a non-fatal pulmonary embolism and two patients died in whom 
pulmonary embolism could not be ruled out. Fifty-four patients died during follow-up due to 
other causes than venous thromboembolism.
Helical CT demonstrated pulmonary embolism in 150 patients (25% of the total study 
population). An unlikely CDR-score was present in 43 of these patients with pulmonary 
embolism. Six patients had recurrent venous thrombosis despite anticoagulant treatment (4%; 
95% CI 1.5%-8.5%). This included one deep venous thrombosis, one with non-fatal and four 
with fatal pulmonary embolism.
TABLE 2. Clinical decision rule (CDR)-score in hospitalized patients with suspected pulmonary embolism 
(PE) and the frequency of pulmonary embolism calculated per CDR-score range, for the original CDR and 
for the dichotomized CDR, which was used in the present study.
 original CDR dichotomized CDR
CDR-score n PE, n (%*) CDR n PE, n (%*) CDR n PE, n(%*)
0.0 – 1.0 50 3 (6%) <2 138 15 (11%)
1.5 – 2.0 88 12 (14%) ≤4 291 44(15%)
2.5 – 3.0 121 17 (14%)
3.5 – 4.0 32 12 (38%) 2-6 415 112 (27%)
4.5 – 5.0 134 35 (26%)
5.5 – 6.0 128 48 (38%)
6.5 – 7.0 29 14 (48%) > 4 312 106(34%)
7.5 – 8.0 10 3 (30%) >6 50 23 (46%)
≥8.5 11 6 (55%)
total 603 150 (25%)
* the percentage of patients with pulmonary embolism in the respective CDR-score range 
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TABLE 3. Incidence of venous thromboembolic events (VTE) during three months follow-up (FU) for 
hospitalized patients without anticoagulant treatment.    
       VTE during FU 
      n n (%:95% CI*) 
unlikely CDR**-score and normal d-dimer  53 0 (0:0-6.7)  
pulmonary embolism excluded by CT***:   368  5 (1.4: 0.4-3.1)
- CT normal     152 2 (1.3:0.2-4.7) 
- CT with an alternative diagnosis   216 3 (1.4:0.3-4.0)  
* confidence interval
** clinical decision rule
***computed tomography 
Additional observations.
Helical CT was normal in only 160 of the 547 hospitalized patients who underwent CT-
scanning (29%) and demonstrated an alternative diagnosis in 220 of 547 patients (40%). 
These alternative diagnosis were infiltrate (n = 50), pleural effusion (n = 76), tumor (n = 12), or 
other diagnosis (n = 82). The diagnostic strategy could be completed according to the protocol 
in 596 patients (99%) and allowed a management decision in 588 patients (97%).
DISCUSSION
This large study in consecutive hospitalized patients with clinically suspected pulmonary 
embolism shows that the combination of an unlikely CDR-score and normal D-dimer 
concentration is only present in approximately 10% of patients. Since no venous 
thromboembolism occurred during follow up, this combination appears to be safe, although 
the 95% confidence interval is wide (0%-6.7%). If helical CT was indicated according to the 
diagnostic strategy and did not show pulmonary emboli, pulmonary embolism could be safely 
excluded without the need for additional imaging, such as compression ultrasonography of 
the legs, as has been previously used 7,12. Our fast and simple diagnostic strategy was well 
accepted by the clinicians involved in the diagnostic work-up of hospitalized patients as shown 
by the low percentage of protocol violations (2%) and the high proportion of management 
decisions that could be made with this strategy (97%).  
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Little is known about the value of clinical probability assessment in hospitalized patients with 
clinically suspected pulmonary embolism. Most of the previous studies have been performed 
in outpatients or both in- and outpatients and reported the results for the total patient group 
6,16-20. Miron et al. performed a study in 145 consecutive hospitalized patients with clinically 
suspected pulmonary embolism and assessed the clinical probability empirically. Hospitalized 
patients with a low (33% of the population), intermediate (58%) or high (9%) clinical probability 
according to the physician showed an observed prevalence of pulmonary embolism of 13%, 
44%, and 70%, respectively 9. Ollenberger and Worsley studied the effect of patient location 
on the performance of two clinical models to predict pulmonary embolism. They found that the 
area under a fitted receiver operating characteristic curve for both models tested decreased 
significantly when applied to inpatients in comparison to outpatient 21. The CDR we used 
originally divided patients into 3 groups (CDR-score < 2, 2-6 and > 6) with an observed 
incidence of pulmonary embolism of 3.6%, 30% and 66.7%, respectively 6. In the present study 
the CDR was dichotomized. Fourty-eight percent of the hospitalized patients had an unlikely 
CDR-score with an observed incidence of pulmonary embolism of 15%. This incidence in 
patients with a likely CDR-score was 35%. In addition, in patients diagnosed with pulmonary 
embolism 29% had an unlikely CDR-score and 71% a likely CDR-score. This suggests that 
the dichotomized CDR used in the present study is of diagnostic value, although the CDR with 
3 categories is more capable to identify patients with low or high risk of pulmonary embolism, 
as is shown in table 2. Interestingly, in outpatients the incidence of pulmonary embolism was 
12% in patients with an unlikely CDR-score and 40% in patients with a likely CDR-score, which 
suggests that the ability of the CDR to distinguish between patients with an unlikely or likely 
risk of pulmonary embolism does not differ between hospitalized patients and outpatients. 
Future studies may be necessary to improve the diagnostic accuracy of clinical assessment 
in hospitalized patients.
Several studies have shown that the contribution of a normal D-dimer concentration 
in excluding venous thromboembolism in hospitalized patients is limited due to the low 
prevalence of a normal test result (6-19%) and low specificity [20-46%] 9-11, 22. In our diagnostic 
algorithm D-dimer was normal in one-fifth of patients with an unlikely CDR-score. Most of 
the hospitalized patients with an unlikely CDR-score had elevated D-dimer concentrations, 
which could be attributed in part to the large number of hospitalized patients who had either 
undergone recent surgery or were known to have malignant disease. In spite of this low yield 
of normal D-dimer tests, we believe that in hospitalized patients presenting with suspected 
pulmonary embolism it remains relevant to start the diagnostic work-up by performing two easy 
and inexpensive tests. The advantage is that CT scanning (and radiation) can be avoided. The 
counterpart is that D-dimer testing costs time and the diagnosis can be delayed. However, 
when there is a clinical suspicion of pulmonary embolism anticoagulant treatment can be 
started while awaiting the results of the diagnostic strategy. By calculating the CDR-score 
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(with the variables obtained by the history of the patient and physical examination) in all 605 
hospitalized patients and measuring the D-dimer concentration in 291 hospitalized patients 
with an unlikely CDR-score, a total of 60 patients could be withheld from helical CT testing and 
pulmonary embolism was safely excluded (approximately 10% of all hospitalized patients). 
Many studies have assessed the clinical validity of a negative CT in patients with suspected 
pulmonary embolism, but  the incidence rate of venous thromboembolic events in untreated 
patients with negative CT’s varies 7, 12, 23-25. More recent studies show that CT in combination 
with compression ultrasonography can be used safely to rule out pulmonary embolism (VTE 
incidence 0.7%-1.8%; upper 95% CI 3.3%-3.9%) 7,12,24,25. Our study shows that it is safe to 
withhold anticoagulant treatment in hospitalized patients with a normal CT as the sole imaging 
technique. Another advantage of helical CT is the possibility of finding an explanation for the 
complaints, other than pulmonary embolism, i.e. an alternative diagnosis. In the present study, 
an alternative diagnosis was suggested in 40% of the hospitalized patients who underwent 
CT-scanning, which was more frequent than in outpatients. Recently it has been suggested 
that, especially in patients with a low clinical probability of  pulmonary embolism, the positive 
predictive value of CT might be rather low (58%; 95% CI 40%-73%) 26. This may overestimate 
the incidence of pulmonary embolism in our patients. However, the frequency of pulmonary 
embolism in our cohort was 25%, which is comparable to previous studies using pulmonary 
angiography 5.
Although this is the largest cohort of hospitalized patients with suspected pulmonary 
embolism studied so far, the limited number of hospitalized patients with an unlikely CDR-score 
and normal D-dimer is the major limitation of this study. As a result, in spite of no observed 
venous thromboembolic events during follow-up, the upper limit of the 95% confidence limit of 
this observation is 6.7%, which may be consider too high.
In conclusion, the results of the studied simple and fast diagnostic strategy in hospitalized 
patients show that pulmonary embolism appears to be safely excluded by an unlikely CDR-
score in combination with a normal D-dimer concentration, although not frequently observed. 
By using this diagnostic strategy approximately 10% of the hospitalized patients will not need 
helical CT to exclude pulmonary embolism. Before clinical implementation of this strategy it 
is important to confirm the safety of this combination by further studies. The clinical decision 
rule for pulmonary embolism in hospitalized patients should be improved. If a helical CT 
is performed and does not show pulmonary embolism, it is safe to withhold anticoagulant 
treatment. 
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ABSTRACT 
Background  The diagnostic work-up of patients with suspected pulmonary embolism (PE) 
has been optimized and simplified by the use of clinical decision rules (CDR), D-dimer testing 
and spiral computed tomography (s-CT). Whether this strategy is equally safe and efficient in 
specific subgroups of patients is evaluated in this study. 
Methods  A diagnostic strategy including a CDR, D-dimer test and s-CT was evaluated in 
patients with malignancy, previous venous thromboembolism (VTE), chronic obstructive 
pulmonary disease or heart failure and in older patients. PE was ruled out by either an 
unlikely CDR and a normal D-dimer or a s-CT negative for PE. The safety of these tests 
was assessed by the 3-month incidence rate of symptomatic VTE in those without PE at 
baseline. The efficiency was evaluated by calculating the numbers needed to test for the 
different subgroups. 
Results  The venous thromboembolic incidence rate after the combination of an unlikely 
CDR and a normal D-dimer varied from 0% (95% CI: 0–7.9%) in the 482 patients older than 
75 years of age to 2% (95% CI: 0.05–10.9%) in the 474 patients with a malignancy. For s-CT 
these incidences varied from 0.3% to 1.8%. The number needed to test in order to rule out 
one patient from PE with the studied strategy was highest in cancer patients and in the elderly 
patients (approximately 10). 
Conclusion  It appears to be safe to rule out PE by either the combination of an unlikely CDR 
and a normal D-dimer or by a negative s-CT in various subgroups of patients with suspected 
PE. However, the clinical usefulness of the CDR in combination with the D-dimer as the initial 
step in the diagnostic process varied among these patient groups.
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INTRODUCTION
The main problem in the diagnostic work-up of patients with pulmonary embolism (PE) is the 
low incidence of PE among those who present with a clinical suspicion of this disease 1,2. As a 
consequence of this low incidence, the diagnostic yield of imaging tests is low. Because most 
imaging techniques for PE have a high radiation dose, use contrast materials, require expertise 
to interpret and are costly, it is not desirable that all patients with suspected PE immediately 
undergo imaging. For this purpose a clinical decision rule (CDR) combined with D-dimer testing 
is frequently used as the first-line method to rule out PE. With these tests approximately 30% of 
the suspected population can be safely withheld from further diagnostic work-up 3–5. Although the 
CDR and D-dimer test have been investigated in various algorithms to exclude PE 6, there is a 
continuing debate about the safety and diagnostic efficiency of these tests for specific subgroups, 
such as those with malignancy, previous venous thromboembolism (VTE), chronic obstructive 
pulmonary disease (COPD) or heart failure and older patients 7–10. For example, higher incidence 
of PE in cancer patients and in the elderly can decrease the negative predictive value and thus 
the safety, while comorbidity may reduce the efficiency because of more frequently abnormal 
D-dimer results than in patients without those conditions 11. Spiral computed tomography (s-CT) 
is increasingly used as the imaging technique of choice in patients with suspected PE. Several 
large management studies have shown that s-CT followed by ultrasonography of the legs is safe 
to rule out PE 12–14. Recently it has been suggested that a s-CT negative for PE without the use of 
lower-limb ultrasonography might be safe as well 15. Again, the accuracy and diagnostic yield in the 
various subgroups is not well studied.
We recently completed a large outcome study that evaluated the safety of a diagnostic 
strategy using the combination of a CDR and D-dimer test followed by s-CT in 3306 patients 
referred with clinically suspected PE 16. The aim of this analysis was to evaluate the safety and 
clinical usefulness of this strategy in the different subgroups with malignancy, previous VTE, 
COPD or heart failure, and older age.
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METHODS
This study was part of a large management study in 12 teaching hospitals in the 
Netherlands, evaluating a diagnostic algorithm consisting of a CDR, D-dimer assay and 
s-CT within 24 hours 16.
Patients were included between November 2002 and August 2004. The Institutional Review 
Boards of all participating hospitals approved the study protocol.
Study participants
Consecutive patients with clinically suspected PE and a malignancy, previous VTE, COPD, 
heart failure or an age over 75 years were included in this analysis. Exclusion criteria were: 
treatment with therapeutic doses of unfractionated or low-molecular-weight heparin (LMWH) 
for more than 24 h, life expectancy of less than 3 months, pregnancy, geographic inaccessibility 
precluding follow-up, age below 18 years, allergy to intravenous contrast agents, previous 
participation in the study or hemodynamic instability.
Diagnostic algorithm
Patients with clinically suspected PE were evaluated by an attending physician using a 
validated CDR (Table 1) 3. PE was considered unlikely if the CDR score was ≤  4 points, and 
considered likely if the CDR score > 4 points. In patients with a CDR indicating PE unlikely, 
a D-dimer concentration was measured, using either the Vidas D-dimer assay (Biomerieux, 
Marcy L’Etoile, France) or the Tina-quant assay (Roche Diagnostica, Mannheim, Germany). 
A D-dimer concentration of ≤ 500 ng mL was defined as normal. In patients with an unlikely 
CDR and a normal D-dimer concentration, the diagnosis of PE was considered excluded and 
anticoagulant treatment was withheld. All other patients underwent s-CT.
Spiral-CT was performed using either single-slice or multislice detector systems according 
to the protocol as described in the original study 16. Patients with confirmed PE on s-CT 
received LMWH or unfractionated heparin, followed by vitamin K antagonists, according to 
local practice. In patients without PE, the presence or absence of an alternative diagnosis was 
recorded and anticoagulant treatment was withheld. The management of patients in whom the 
s-CT could not be performed or who had a non-conclusive s-CT scan was left to the discretion 
of the attending physician.
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TABLE 1 Clinical decision rule (CDR) according to Wells et al.3. Score ≤ 4: unlikely probability of 
pulmonary embolism (PE); score > 4: likely probability of PE
Variable         points
Clinical signs and symptoms of deep vein thrombosis 
(minimum of leg swelling and pain with palpation of the deep veins)   3
Alternative diagnosis less likely than pulmonary embolism    3
Heart rate > 100/min       1.5
Immobilization (> 3 days) or surgery in previous 4 weeks    1.5
Previous pulmonary embolism or deep vein thrombosis    1.5
Hemoptysis        1.0
Malignancy (receiving treatment, treated in the last 6 months or palliative)  1.0
Follow-up
Follow-up consisted of a hospital visit or telephone interview at 3 months. In addition, patients 
were instructed to contact the study center or their general practitioner immediately in case of 
complaints suggestive of deep venous thrombosis (DVT) or PE. At each visit information was 
obtained on complaints suggestive for VTE and use of anticoagulants. In case of clinically 
suspected DVT or PE, appropriate objective tests (compression ultrasound for suspected 
DVT, ventilationperfusion scintigraphy or s-CT for suspected PE) were required to confirm or 
refute the diagnosis. In case of death, information was obtained from the general practitioner, 
from the hospital records or from autopsy.
Outcome
The primary outcome of the study was the incidence of symptomatic venous thromboembolic 
events during 3 months follow-up, defined as fatal PE, non-fatal PE or DVT. An independent 
adjudication committee, members of which were unaware of the results of the diagnostic 
algorithm, evaluated all suspected venous thromboembolic events and deaths. A diagnosis of 
PE or DVT was made, based on a priori defined and generally accepted criteria 17. Deaths 
were classified as being because of PE in case of confirmation by autopsy, in case of an 
objective positive test for PE prior to death, and if PE could not be confidently excluded as the 
cause of death.
Statistical analysis
Separate analyses were performed for the patient subgroups with malignancy, with previous 
VTE, COPD, heart failure and patients older than 75 years of age. The incidences of 
symptomatic VTE confirmed by objective testing were calculated for the group of patients 
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in whom anticoagulant treatment was withheld based on (i) a classification of PE unlikely 
by CDR and a normal D-dimer or (ii) a s-CT scan that excluded PE. Exact 95% confidence 
intervals (CI) were calculated around the observed incidences using StatXact software, 
version 5. Descriptive parameters were calculated using SPSS software, version 11.5 (SPSS, 
Inc., Chicago, IL, USA).
To be able to compare the clinical usefulness of the CDR and D-dimer for the different 
subgroups, the proportion of useful test results and the number needed to test (NNT) to rule 
out one PE were calculated. The proportion of useful test results is the number of true negative 
tests divided by all other test results. In order to calculate the NNT for every subgroup the 
inverse of this proportion was used.
RESULTS
Study population
The overall study population consisted of 3306 patients with a mean age of 53 years, 82% of 
whom were outpatients 16. The three subgroups of patients with malignancy, with previous 
VTE, and older than 75 years of age all consisted of approximately 480 patients, while 341 
patients had COPD and 243 patients had heart failure at presentation (Table 2).
The proportion of outpatients was approximately 70% in all subgroups, except for those 
patients with previous VTE where this figure was 89% (Table 2). The incidence of confirmed 
PE varied from 16.5% in those with heart failure to 27.4% in those with cancer.
TABLE 2 Baseline characteristics of the overall study population  
and the different clinical subgroups with suspected PE
symptomatic VTE confirmed by objective testing were calcu-
lated for the group of patients in whom anticoagulant
treatment was withheld based on (i) a classification of PE
unlikely by CDR and a normal DD or (ii) a s-CT scan that
excluded PE. Exact 95% confidence intervals (CI) were
calculated around the observed incidences using StatXact
software, version 5. Descriptive parameters were calculated
using SPSS software, version 11.5 (SPSS, Inc., Chicago, IL,
USA).
To be able to compare the clinical usefulness of the CDR
and DD for the different subgroups, the proportion of useful
tes results and the number needed to test (NNT) to rule out
one PE were calculated. The proportion of useful test results is
the number of true negative tests divided by all other test
results. In order to calculate the NNT for every subgroup the
inverse of this proportion was used.
Results
Study population
The overall study population consisted of 3306 patients with a
mean age of 53 years, 82% of whomwere outpatients [16]. The
three subgroups of patients with malignancy, with previous
VTE, and older than 75 years of age all consisted of
approximately 480 patients, while 341 patients had COPD
and 243 patients had heart failure at presentation (Table 2).
The proportion of outpatients was approximately 70% in all
subgroups, except for those patients with previous VTE where
this figure was 89% (Table 2). The incidence of confirmed PE
varied from 16.5% in those with heart failure to 27.4% in those
with cancer.
Results of the combination of CDR and DD test
The proportion of patients with the combination of an unlikely
CDR score and a normal DD concentration varied in the
different subgroups (Table 3). In patients with a malignancy
and patients older than 75 years of age this figure was
approximately 10%. Hence, the number of patients that
needed to be tested to rule out one PE was around 10, whereas
for the other three subgroups this figure was about half and the
proportion with an unlikely CDR and normal DD was
consequently higher. The incidence of venous thromboembolic
events during the 3 months of follow-up in the various studied
subgroups was similar and comparable to the overall study
population. There was no difference between the two different
DD tests used.
Results of s-CT in the different subgroups
Of the 417 s-CT scans performed in patients with malignancy,
286 (69%) ruled out PE (Table 4). In the remaining 31% of the
performed s-CT scans PE was confirmed, therefore 3.3 scans
Table 2 Baseline characteristics of the overall study population and the different clinical subgroups with suspected PE
Overall study population Malignancy Previous VTE COPD Heart failure Age > 75 years
n (%) 3306 474 (14) 480 (15)* 341 (10) 243 (7) 482 (15)
Female (n) (%) 1896 (57) 250 (53) 157 (61) 171 (50) 134 (55) 274 (57)
Mean age (years) (SD) 53 (18.4) 63 (14.4) 55 (18.4) 65 (14.5) 72 (14.5) 82 (5.4)
Outpatient (n) (%) 2701 (82) 318 (67) 427 (89) 239 (70) 165 (68) 329 (68)
Overall PE incidence 674 (20) 130 (27) 129 (27) 62 (18) 40 (17) 131 (27)
Lost to follow-up (n) 4 0 1 0 0 0
Number of patients receiving
anticoagulants for reasons
other than VTE
98 10 36 16 22 26
*Two hundred and fifty-nine of the 480 patients (54%) with previous venous thromboembolism (VTE) had previous pulmonary embolism (PE).
COPD, chronic obstructive pulmonary disease.
Table 3 Diagnostic performance of an unlikely clinical decision rules (CDR) in combination with a normal D-dimer (DD) in the overall study population
and the different clinical subgroups with suspected PE
Total study
population Malignancy Previous VTE COPD Heart failure Age > 75 years
n (% of total) 3306 474 (14) 480 (14) 341 (10) 243 (7) 482 (15)
CDR unlikely (n) (%) 2206 (67) 241 (51) 185 (39) 213 (63) 159 (65) 278 (58)
D-dimer (DD) normal (n) (%) 1142 (35) 55 (12) 128 (27) 90 (26) 45 (19) 52 (11)
CDR unlikely and normal
DD (n) (%)
1057 (32) 49 (10) 95 (20) 77 (23) 43 (18) 47 (10)
VTE incidence during FU
(n) (%; 95% CI)
5 (0.5; 0.2–1.1) 1 (2.0; 0.05–10.9) 1 (1.1; 0.03–5.7) 1 (1.3; 0.03–7.0) 0 (0; 0–8.2) 0 (0; 0–7.9)
NNT for one negative (95% CI) 3.1 (3.0–3.3) 10 (7.5–12.6) 5.1 (4.2–6.1) 4.4 (3.7–5.4) 5.7 (4.3–7.5) 10.6 (7.9–13.5)
COPD, chronic obstructive pulmonary disease; FU, follow up; NNT, number needed to test; VTE, venous thromboembolism; DD, D-dimer.
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Results of the combination of CDR and DD test
The proportion of patients with the combination of an unlikely CDR score and a normal D-
dimer concentration varied in the different subgroups (Table 3). In patients with a malignancy 
and patients older than 75 years of age this figure was approximately 10%. Hence, the number 
of patients that needed to be tested to rule out one PE was around 10, whereas for the other 
three subgroups this figure was about half and the proportion with an unlikely CDR and normal 
DD was consequently higher. The incidence of venous thromboembolic events during the 
3 months of follow-up in the various studied subgroups was similar and comparable to the 
overall study population. There was no difference between the two different D-dimer tests 
used.
TABLE 3 Diagnostic performance of an unlikely clinical decision rules (CDR) in combination with a normal 
D-dimer (DD) in the overall study population and the different clinical subgroups with suspected PE
symptomatic VTE confirmed by objective testing were calcu-
lated for the group of patients in whom anticoagulant
treatment was withheld based on (i) a classification of PE
unlikely by CDR and a normal DD or (ii) a s-CT scan that
excluded PE. Exact 95% confidence intervals (CI) were
calculated around the observed incidences using StatXact
software, version 5. Descriptive parameters were calculated
using SPSS software, version 11.5 (SPSS, Inc., Chicago, IL,
USA).
To be able to compare the clinical usefulness of the CDR
and DD for the different subgroups, the proportion of useful
test results and the number needed to test (NNT) to rule out
one PE were calculated. The proportion of useful test results is
the number of true negative tests divided by all other test
results. In order to calculate the NNT for every subgroup the
inverse of this proportion was used.
Results
Study population
The overall study population consisted f 3306 patients with a
mean age of 53 years, 82% of whomwere outpatients [16]. The
three subgroups of patients with malignancy, with previous
VTE, and older than 75 years of age all consisted of
approximately 480 patients, while 341 patients had COPD
and 243 patients had heart failure at presentation (Table 2).
The proportion of outpatients was approximately 70% in all
subgroups, except for those patients with previous VTE where
this figure was 89% (Table 2). The incidence of confirmed PE
varied from 16.5% in those with heart failure to 27.4% in those
with cancer.
Results of the combination of CDR and DD test
The proportion of patients with the combination of an unlikely
CDR score and a normal DD concentration varied in the
different subgroups (Table 3). In patients with a malignancy
and patients older than 75 years of age this figure was
approximately 10%. Hence, the number of patients that
needed to be tested to rule out one PE was around 10, whereas
for the other three subgroups this figure was about half and the
proportion with an unlikely CDR and normal DD was
consequently higher. The incidence of venous thromboembolic
events during the 3 months of follow-up in the various studied
subgroups was similar and comparable to the overall study
population. There was no difference between the two different
DD tests used.
Results of s-CT in the different subgroups
Of the 417 s-CT scans performed in patients with malignancy,
286 (69%) ruled out PE (Table 4). In the remaining 31% of the
performed s-CT scans PE was confirmed, therefore 3.3 scans
Table 2 Baseline characteristics of the overall study population and the different clinical subgroups with suspected PE
Overall study population Malignancy Previous VTE COPD Heart failure Age > 75 years
n (%) 3306 474 (14) 480 (15)* 341 (10) 243 (7) 482 (15)
Female (n) (%) 1896 (57) 250 (53) 157 (61) 171 (50) 134 (55) 274 (57)
Mean age (years) (SD) 53 (18.4) 63 (14.4) 55 (18.4) 65 (14.5) 72 (14.5) 82 (5.4)
Outpatient (n) (%) 2701 (82) 318 (67) 427 (89) 239 (70) 165 (68) 329 (68)
Overall PE incidence 674 (20) 130 (27) 129 (27) 62 (18) 40 (17) 131 (27)
Lost to follow-up (n) 4 0 1 0 0 0
Nu ber of patients receiving
anticoagulants for reasons
othe than VTE
98 10 36 16 22 26
*Two hundred and fifty-nine of the 480 patients (54%) with previous venous thromboembolism (VTE) had previous pulmonary embolism (PE).
COPD, chronic obstructive pulmonary disease.
Table 3 Diagnostic performance of n unlikel clinical decisi rules (CDR) in combi ation w th a normal D-dimer (DD) in the overall study population
and the different clinical subgroups with suspected PE
Total study
population Malignancy Previous VTE COPD Heart failure Age > 75 years
n (% of total) 3306 474 (14) 480 (14) 341 (10) 243 (7) 482 (15)
CDR unlikely (n) (%) 2206 (67) 241 (51) 185 (39) 213 (63) 159 (65) 278 (58)
D-dimer (DD) normal (n) (%) 1142 (35) 55 (12) 128 (27) 90 (26) 45 (19) 52 (11)
CDR unlikely and normal
DD (n) (%)
1057 (32) 49 (10) 95 (20) 77 (23) 43 (18) 47 (10)
VTE incidence during FU
(n) (%; 95% CI)
5 (0.5; 0.2–1.1) 1 (2.0; 0.05–10.9) 1 (1.1; 0.03–5.7) 1 (1.3; 0.03–7.0) 0 (0; 0–8.2) 0 (0; 0–7.9)
NNT for one negative (95% CI) 3.1 (3.0–3.3) 10 (7.5–12.6) 5.1 (4.2–6.1) 4.4 (3.7–5.4) 5.7 (4.3–7.5) 10.6 (7.9–13.5)
COPD, chronic obstructive pulmonary disease; FU, follow up; NNT, number needed to test; VTE, venous thromboembolism; DD, D-dimer.
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Results of s-CT in the different subgroups
Of the 417 s-CT scans performed in patients with malignancy, 286 (69%) ruled out PE (Table 
4). In the remaining 31% of the performed s-CT scans PE was confirmed, therefore 3.3 scans 
have to be carried out to detect one PE. Five patients with a s-CT result negative for PE 
returned with symptomatic venous thromboembolic events (one DVT, one non-fatal PE and 
three fatal PE) during the 3 months of follow-up. Two of the patients with fatal PE died suddenly 
during immobilization because of severe pain and weakness on days 18 and 30, respectively, 
while the third patient died 75 days after inclusion. This latter patient was diagnosed with 
a pericarditis carcinomatosa. Hence, the VTE incidence after a s-CT without PE in this 
subgroup was 1.8% (95% CI: 0.6–4.0%). This incidence is comparable to the total study 
population (1.3%; 95% CI: 0.8–2.1%). For the other studied subgroups both the incidences of 
VTE during follow-up and the number of tests needed to find one PE were comparable (Table 
4). Moreover, there was no difference between the patients who underwent single-slice or 
multi-slice s-CT.
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The percentages of alternative diagnoses varied in the different patient groups. The lowest 
proportion of alternative diagnoses was shown in the group with patients who had experienced 
previous VTE (24% of all performed s-CT scans) and the highest percentages were observed in 
patients with malignancy or COPD: 42% and 50%, respectively. The most frequent pulmonary 
abnormalities were consolidation and pleural fluid (data not shown).
TABLE 4 Diagnostic performance of spiral computed tomography (s-CT) in the overall study population 
and in the different clinical subgroups with suspected PE
have to be carried out to detect one PE. Five patients with a
s-CT result negative for PE returned with symptomatic venous
thromboembolic events (one DVT, one non-fatal PE and three
fatal PE) during the 3 months of follow-up. Two of the patients
with fatal PE died suddenly during immobilization because of
severe pain and weakness on days 18 and 30, respectively, while
the third patient died 75 days after inclusion. This latter patient
was diagnosed with a pericarditis carcinomatosa. Hence, the
VTE incidence after a s-CT without PE in this subgroup was
1.8% (95% CI: 0.6–4.0%). This incidence is comparable to the
total study population (1.3%; 95% CI: 0.8–2.1%). For the
other studied subgroups both the incidences of VTE during
follow-up and the number of tests needed to find one PE were
comparable (Table 4). Moreover, there was no difference
between the patients who underwent single-slice or multi-slice
s-CT.
The percentages of alternative diagnoses varied in the
different patient groups. The lowest proportion of alternative
diagnoses was shown in the group with patients who had
experienced previous VTE (24% of all performed s-CT scans)
and the highest percentages were observed in patients with
malignancy or COPD: 42% and 50%, respectively. The most
frequent pulmonary abnormalities were consolidation and
pleural fluid (data not shown).
Discussion
This study demonstrates that the combination of an unlikely
CDR and a normal DD appears to have a similar safety in
excluding PE irrespective of the presence of malignancy,
previous VTE, COPD, heart failure or older age. However, the
proportion of patients with normal results varied and was
lowest in those with malignancy and in older patients
(approximately 10%). In the other studied subgroups these
proportions were approximately twice as high. Consequently,
the number of tests needed to rule out one PEwas highest in the
cancer subgroup and the elderly.
With respect to the negative predictive value of a s-CT
without PE for subsequent VTE in the 3 months of follow-up,
this appeared to be comparable to the overall study population.
The number of s-CT required to have one CT indicating the
presence of PE varied from three to five, with the lowest
diagnostic yield in those with heart failure.
Although both the combination of an unlikely CDR and
normal DD and a s-CT negative for PE appear to be safe in the
various subgroups, as described above, it should be noted
that the 95% CI of the VTE incidences are sometimes wide
owing to the relatively small number of patients in each
subgroup. Therefore, safety data have to be considered with
caution.
What are the clinical interpretations of these findings?
Firstly, the subsequent risk of VTE in those ruled out from PE
with an unlikely CDR and a normal DD concentration
appears to be similar for the various subgroups. Therefore, the
diagnostic yield dominates in the decision of whether or not to
use these tests. For the subgroups of patients with previous
VTE, COPD or heart failure the NNT is close to that in the
overall study population (4.4–5.7 vs. 3.1, respectively), indica-
ting that these tests are clinically useful in managing these
patients. However, for the malignancy subgroup and the
elderly population the numbers needed to test to rule out PE
are higher. Considering the low diagnostic yield of tests in these
groups, two approaches are possible. If the existing diagnostic
strategy includes an upfront CDR and DD assay this seems
useful to do, even in patients with a malignancy, as a CT scan
can be prevented at least in one out of every ten patients tested
and aDD test is convenient, easy and inexpensive. On the other
hand, if the clinical setting is more imaging-oriented and DD
results are not readily available, it might be more efficient to
directly proceed to s-CT. Moreover, the consequence of the
high NNT to rule out one PE with CDR and DD is also
reflected in the small improvement in the diagnostic yield of the
CT. The incidence of PE in the malignancy subgroup was 27%
(Table 2). If s-CT had been performed directly in all these
patients, 3.7 scans would have had to be performed to find one
positive. With the use of CDR and DD the incidence of PE in
the patients who underwent s-CT increased to 31%, leading to
3.3 s-CT scans to be performed for one PE (Table 4). Thus, the
Table 4 Diagnostic performance of spiral computed tomography (s-CT) in the overall study population and in the different clinical subgroups with
suspected PE
Total study
population Malignancy
Previous
VTE COPD
Heart
failure
Age
>75 years
Performed s-CT scans (n) 2199 417 378 258 193 422
PE ruled out by s-CT (n) (%) 1505 (67) 286 (69) 249 (66) 196 (76) 153 (79) 289 (68)
Normal n (%) 803 (37) 109 (26) 157 (42) 80 (31) 78 (40) 135 (32)
Alternative diagnosis (n) (%) 702 (32) 177 (42) 89 (24) 116 (50) 75 (39) 154 (36)
PE confirmed by s-CT (n) (%) 674 (31) 129 (31) 129 (34) 62 (24) 40 (21) 131 (31)
Inconclusive s-CT (n) 20 2 3 0 0 2
VTE incidence during FU after
s-CT ruled out PE
(n) (%; 95% CI)
19 (1.3; 0.8–2.1) 5 (1.8; 0.6–4.0) 2 (0.8; 0.1–2.9) 2 (1.0; 0.1–3.6) 2 (1.3; 0.2–4.6) 1 (0.3; 0.01–1.9)
NNT to find one positive
s-CT (95% CI)
3.2 (3.1–3.5) 3.3 (2.8–3.8) 2.9 (3.3–2.6) 4.2 (3.4–5.2) 4.8 (3.7–6.4) 3.2 (2.8–3.7)
COPD, chronic obstructive pulmonary disease; FU, follow up; NNT, number needed to test; VTE, venous thromboembolism; PE, pulmonary
embolism.
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DISCUSSION
This study demonstrates that the combination of an unlikely CDR and a normal D-dimer 
appears to have a similar saf ty in excludi  PE irrespectiv  of the pres nce of malignancy, 
previous VTE, COPD, heart failure or older age. However, the proportion of patients with normal 
r sults varied and was lowest in th se with malign ncy and in lder patients (a proximately 
10%). In the other studied subgroups these proportions were approximately twice as high. 
Consequently, the number of tests needed to rule out one PE was highest in the cancer 
subgroup and the elderly.
With respect to the negative predictive value of a s-CT without PE for subsequent VTE in 
the 3 months of follow-up, this appeared to be comparable to the overall study population. The 
number of s-CT required to have one CT indicating the presence of PE varied from three to 
five, with the lowest diagnostic yield in those with heart failure.
Although both the combination of an unlikely CDR and normal D-dimer and a s-CT negative 
for PE appear to b  s fe in the v rious subgroups, as des ribed above, it should be noted that 
the 95% CI of the VTE incidences are sometimes wide owing to the relatively small number of 
patients in each subgr up. Therefore, safety data hav  to be considered with cauti n.
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What are the clinical interpretations of these findings? Firstly, the subsequent risk of VTE in 
those ruled out from PE with an unlikely CDR and a normal D-dimer concentration appears 
to be similar for the various subgroups. Therefore, the diagnostic yield dominates in the 
decision of whether or not to use these tests. For the subgroups of patients with previous 
VTE, COPD or heart failure the NNT is close to that in the overall study population (4.4–5.7 vs. 
3.1, respectively), indicating that these tests are clinically useful in managing these patients. 
However, for the malignancy subgroup and the elderly population the numbers needed to 
test to rule out PE are higher. Considering the low diagnostic yield of tests in these groups, 
two approaches are possible. If the existing diagnostic strategy includes an upfront CDR and 
D-dimer assay this seems useful to do, even in patients with a malignancy, as a CT scan can 
be prevented at least in one out of every ten patients tested and a D-dimer test is convenient, 
easy and inexpensive. On the other hand, if the clinical setting is more imaging-oriented and 
D-dimer results are not readily available, it might be more efficient to directly proceed to s-
CT. Moreover, the consequence of the high NNT to rule out one PE with CDR and D-dimer 
is also reflected in the small improvement in the diagnostic yield of the CT. The incidence of 
PE in the malignancy subgroup was 27% (Table 2). If s-CT had been performed directly in all 
these patients, 3.7 scans would have had to be performed to find one positive. With the use 
of CDR and D-dimer the incidence of PE in the patients who underwent s-CT increased to 
31%, leading to 3.3 s-CT scans to be performed for one PE (Table 4). Thus, the increase in 
diagnostic yield if CDR and D-dimer are included in the diagnostic work-up in the malignancy 
subgroup is small. However, it is based on the assumption that the diagnostic yield of s-
CT includes only the confirmation of PE, while the presence or absence of an alternative 
diagnosis might be at least as informative.
In conclusion, ruling out PE by either the combination of an unlikely CDR and a normal 
D-dimer or by a s-CT negative for PE appears safe for subgroups of suspected PE patients 
with malignancy, previous VTE, COPD or heart failure and in elderly patients. Judgement on 
the threshold for clinical usefulness of the CDR in combination with the D-dimer as the initial 
step in the diagnostic process not only depends on the NNT to rule out one PE, but also on 
the clinical setting.
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Assessment of the clinical pretest probability in patients with clinically suspected pulmonary 
embolism (PE), based on clinical judgement alone (further referred to as ‘clinical probability 
estimate’) or a structured prediction model, in order to guide further diagnostic testing has 
aroused new interest. Wells and colleagues derived a clinical model based on information from 
the medical history, physical examination, blood gas analyses, chest X-ray, electrocardiography 
and the likelihood of an alternative diagnosis1. This model was subsequently simplified1,2. 
These models have now successfully been applied in several management studies in patients 
with suspected PE3–5.
However, the diagnostic accuracy of the clinical probability assessment in previous studies 
varied significantly 1–4,6. The reason for this observed heterogeneity in test accuracy is not fully 
explained. An important determinant of test accuracy is its reproducibility, which so far has 
not been studied. We therefore evaluated the interobserver variability of the original clinical 
probability assessment using a previously described structured clinical model. In addition, we 
compared the results of the clinical model with those of the clinical probability estimate in the 
same patient as assessed by the same physician. 
The investigation was performed within the framework of a management study in a large 
teaching hospital, in which the outcome of the clinical probability was used in combination 
with a D-dimer test to guide further diagnostic and therapeutic management4. In consecutive 
in- and outpatients with clinically suspected PE, clinical probability was assessed by two 
independent physicians using an estimate and a structured clinical model as described by 
Wells and colleagues (further referred to as ` extended clinical model’) with the classification of 
low, moderate or high probability of PE1. After completion of the study, the obtained information 
was used to calculate the result (low, moderate or high and unlikely or likely probability) of the 
simplified clinical model, as described by Wells and colleagues2. The primary analysis was 
performed in the patient group with a duplicate assessment of the clinical probability of PE 
using the extended and simplified clinical model. The agreement between distinct observers 
was expressed by a weighted kappa (κ). A weighted κ value of 1 corresponds to perfect 
agreement, 0 to agreement as expected by chance. We also calculated a weighted κ for 
the agreement between the results of the extended clinical model and the clinical probability 
estimate.
In a total of 45 consecutive patients independent, duplicate assessments of the clinical 
pretest probability of PE using the clinical model were available for analyses. Of the 45 patients, 
13 had the diagnosis of PE established according to the studyprotocol, i.e. a prevalence of 
29%. The mean age of the study population was 56 years (range 19–89 years), 66% was 
female and 89% were outpatients.
In 38 of the 45 study patients various items in the extended structured clinical model were 
completed differently. This resulted in a different category of clinical probability in 14 patients. 
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The κ value of the duplicate scores of clinical probability was 0.54 [95% confidence interval 
(CI) 0.28 - 0.80]. The weighted κ value for low and moderate grouped together was 0.48 (95% 
CI 0.03 - 0.93). The discrepancies included a different score for the presence or absence of 
dyspnea or worsening of chronic dyspnea (14 patients), nonpleural chest pain (14 patients), 
likelihood of an alternative diagnosis (12 patients), risk factors for venous thromboembo-
lism (9 patients), pleural chest pain (8 patients), interpretation of chest X-ray (8 patients), 
temperature between 37.8 and 38.6 °C (8 patients), heart rate > 90 min-1 (6 patients), pleural 
rub (5 patients) and leg symptoms suspicious for deep vein thrombosis (4 patients).
Using the simplified model, duplicate assessment in the categories low, moderate and high, 
resulted in a different category in 11 patients with a κ value of 0.6 (95% CI 0.34 - 0.85). These 
differences were mainly due to a different score for the likelihood of an alternative diagnosis (8 
patients). The weighted κ value for low and moderate grouped together was 0.54 (95% CI 0.01 
- 1.07). Of the 45 patients the duplicate assessment in the categories unlikely/likely resulted in 
a different category in six patients, κ value 0.66 (95% CI 0.41 - 0.91). These differences were 
mainly due to a different score with respect to an alternative diagnosis (5 patients).
In 31 unselected patients the attending physicians completed the clinical probability of PE 
as assessed both by the clinical model and by estimating the overall likelihood of PE using the 
same information from medical history and physical examination. The clinical probability was 
scored differently in 18 patients in the extended clinical model compared with the estimate, 
resulting in a κ value of 0.23 (95% CI 0.05 - 0.42).
The present investigation shows that the reproducibility of the clinical probability assessment 
using a structured prediction model is at best moderate in patients with suspected PE. Despite 
the use of a standardized diagnostic algorithm, it is insufficiently objective to allow for a 
reproducible outcome by different physicians. This may in part explain the heterogeneity in the 
reported estimates of test accuracy of the clinical probability in patients with suspected PE.
It is well known that the signs and symptoms associated with PE are seen in many other 
medical conditions and are therefore non-specific for PE. The presumed advantage of the 
clinical models over the clinical probability estimate is that they may have less interobserver 
variability due to the fact that they are based on defined, relatively objective clinical findings. 
However, we found a significant interobserver variability in the clinical model evaluated. Clinical 
disagreement was present on all aspects of the model, i.e. regarding the patients’ history, 
physical examination and interpretation of diagnostic tests. Despite the use of standardized 
case record forms, they were usually completed differently by the two independent physicians. 
Most of the differences were due to interpretation of features in the patients’ history. Some of 
the questions have to be read properly, i.e. the likelihood of an alternative diagnosis, which is 
not objective, is very often conclusive for the outcome of the clinical probability in the model.
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Components of the patients’ history and physical findings which caused most of the differences 
in the extended model are not present in the simplified model. This resulted in a better κ 
value for the simplified model (i.e. 0.60), especially for the simplified model with likely and 
unlikely categories. If the likelihood of an alternative diagnosis had not been incorporated 
in the simplified model, the reproducibility would even have been better. The κ value of the 
simplified model with likely and unlikely categories would then be higher than the κ value of 
0.66 we observed.
Clinical disagreement over patients’ histories is also observed in other studies where 
clinicians agreed about the history in only 75% of cases7,8. It is not less of a problem in the 
physical examination. The usual κ values for most components of clinical findings are about 
0.4–0.6 9,10. Some experts have termed these x values `moderate’ 11. The problem of clinical 
disagreement also extends to the interpretation of diagnostic tests, as is the case for X-rays 
and ECGs. When two cardiologists examined the same ECG from 38 patients, a κ value of 
0.3 was found 12.
The reproducibility of the clinical probability is moderate, but comparable to other clinical 
examinations used in daily medical practice. The question is, given the observed clinical 
disagreement about patients’ history, physical findings and interpretation of diagnostic 
tests, whether it is possible to develop a more objective clinical model. Until this has been 
accomplished, the moderate reproducibility of clinical probability assessment is a limitation 
of its clinical utility and therefore clinicians should be aware of this when they use it for the 
assessment of patients.
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ABSTRACT
Background The Wells rule is a widely applied clinical decision rule, in the diagnostic work-
up of patients with suspected pulmonary embolism (PE). The objective of this study was to 
validate and simplify this rule.
Methods The clinical probability of PE, the odds ratios for the separate variables and the 
areas under the ROC curve for the original and two newly derived simplified Wells rules 
were calculated in 3306 consecutive patients with clinically suspected PE. Furthermore, the 
safety in ruling out PE in combination with a normal D-dimer test was assessed by comparing 
the incidence of venous thromboembolism (VTE) during follow-up and the clinical utility by 
comparing the proportion of patients safely excluded by these combined methods. 
Results The discriminative potential of the prediction rule was comparable to that of the 
original study, although the odds ratios decreased.
The performance of the original and simplified rules was similar with areas under the curve 
ranging from 0.72 to 0.74. 
The VTE incidence at 3 months with the Wells rule (score ≤ 4) and a normal D-dimer was 
0.8%. For the modified rule (1 or 2 points per variable, cut-off ≤ 2) and the simplified rule (1 
point per variable, cut-off ≤ 1) these incidences were 0.6% and 0.5%, respectively. Proportion 
of patients safely excluded for PE was 32%, 31% and 30%, respectively.
Conclusions This study further validates the diagnostic utility of the Wells rule and indicates 
that the scoring system can be simplified to one point for each variable. 
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INTRODUCTION
The diagnostic work-up of patients with clinically suspected pulmonary embolism is challenging 
because of the relatively low prevalence of the disease in this population. In the past, several 
attempts have been made to include clinical information in the diagnostic process in order 
to rule out pulmonary embolism and withhold expensive and time-consuming imaging 
techniques without compromising patient’s safety. However, the majority of these attempts 
have not been clinically successful 1-5. The main concern with these assessments of clinical 
probability involved the use of many variables including subjective elements as well as the 
often complicated scoring methods.
The quantitative clinical decision rule (CDR) published by Wells and colleagues in 2000 
incorporated 7 items from the medical history and physical examination easily obtained in the 
initial diagnostic work-up 6. Because of its relative comprehensiveness and therefore ease 
of use in a clinical setting this rule is now widely accepted in the exclusion of pulmonary 
embolism and has been incorporated in several guidelines 7-12. It was obtained by selecting 
the most predictive variables for the presence or absence of pulmonary embolism from an 
extended 40-item list. These variables were initially tested in a univariate regression analysis 
and those variables that were significant after the stepwise regression analysis were selected 
for the final rule. According to the value of the odds ratios scoring points of 1, 1.5 or 3 were 
assigned (Table 1). 
However, there is evidence that over time prediction rules may loose their discriminatory 
power 13-15. In addition, the different weights given in the Wells rule may make the rule difficult 
to memorize and could lead to summing mistakes in the acute care setting. We speculated 
whether a simplified rule would yield similar results. 
In order to further validate and possibly simplify the clinical decision rule of Wells and 
colleagues we used the data of a large management study in consecutive patients with 
suspected pulmonary embolism 16. In all patients the clinical decision rule was assessed 
while the D-dimer test and spiral CT were obtained when indicated. First, we assessed the 
discriminative power of the rule for the presence of pulmonary embolism and compared this 
with the original study cohort of Wells et al. Subsequently, the relative contribution of the 
different elements of the rule was analysed, and we investigated whether the existing scoring 
system could be simplified. 
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METHODS
Data were derived from a large prospective diagnostic management study that included 
patients with clinically suspected pulmonary embolism enrolled between November 2002 and 
August 2004 in 12 hospitals in the Netherlands 16.
Patients and management
Consecutive in- and outpatients with clinically suspected acute pulmonary embolism were 
eligible. Patients were excluded if they had received (low molecular weight) heparin for more 
than 24 hours, were younger than 18 years of age, were pregnant, had a known hypersensitivity 
for iodinated contrast fluid, had a life expectancy of less than three months or if there was 
geographic inability for follow-up.
At presentation the CDR of Wells and colleagues was performed in all patients 6. With 
a CDR score ≤ 4, pulmonary embolism was considered unlikely and a D-dimer test was 
performed (Tinaquant, Roche Diagnostica, Mannheim, Germany or Vidas D-dimer, Biomerieux, 
Marcy L’Etoile, France) 16. The D-dimer test was defined as normal if the concentration was 
≤ 0.5 mg/l. The combination of pulmonary embolism unlikely and a normal D-dimer result 
was considered to rule out pulmonary embolism and anticoagulant treatment was withheld. 
These patients were followed up for three months, all other patients underwent spiral CT. The 
CT scan was considered positive for pulmonary embolism if intraluminal filling defects were 
present or if a vessel was totally occluded. 
In case of clinically suspected venous thromboembolism (VTE) in the three months follow-
up period, compression ultrasound for suspected DVT and ventilation-perfusion scintigraphy 
or CT for suspected pulmonary embolism were required to confirm or refute the diagnosis. 
Validation of the Wells clinical decision rule 
The original study distinguished three probability categories (low, moderate and high). For 
purpose of comparison the prevalence of pulmonary embolism in these three probability 
categories was calculated in the present study cohort and compared with the derivation and 
validation population of the original study of Wells et al. 6. 
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Development of the simplified clinical decision rules
Subsequently we recalculated the coefficients of the variables of the Wells rule by fitting a 
multivariable logistic regression model in our study group. The estimated coefficients and 
the 95% confidence intervals (CI) were transformed to odds ratios. These odds ratios were 
compared to the original odds ratios reported by Wells et al. 6. 
Rather than using three different sets of points, as in the original Wells rule, we developed 
a modified rule with two sets of points, by assigning two points to the variable with the highest 
odds ratios and one point to the remaining variables in the model. In addition, a simplified 
rule was developed by assigning only unit weights to all variables in the model. 
For all patients in our study, we calculated their score with the modified and the simplified 
rule. With the simplified rule, for example, a patient receives one additional point for each of 
the seven variables that is present. 
To determine the performance of the two novel rules the area under the Receiver Operating 
Characteristic (ROC) curve was calculated and compared to the area under the curve of the 
original Wells rule. ROC curves show the performance of a diagnostic test; the area under the 
curve of an ideal rule would be 1.00 and that of a useless rule 0.50. The significance for the 
ROC curves was tested by the method described by Hanley and McNeil 17. The discriminative 
power of the novel rules for distinguishing into two pulmonary embolism probability groups 
was also analysed, using the method described previously 6. 
Safety and clinical utility of the different scoring options  
of the clinical decision rules combined with D-dimer testing
Since the CDR is never used as the only test to rule out pulmonary embolism, the diagnostic 
safety and utility of the combination of the CDR and the D-dimer test were evaluated. The 
safety of this combination was defined as the observed incidence of symptomatic venous 
thromboembolic events during the three months of follow-up in patients in whom pulmonary 
embolism was considered unlikely based on the CDR with a normal D-dimer test result. 
The clinical utility was assessed by calculating the proportion of patients in whom further 
diagnostic testing could be safely withheld. The safety as well as the clinical utility of these two 
new simplified scores was compared to the classical CDR score with a dichotomized cut-off 
score of ≤ 4 for pulmonary embolism unlikely 16.
The 95 % CI for the three month VTE incidence rate for each possible score of the CDR in 
combination with a normal D-dimer result were calculated. The upper limit of the 95% CI was 
chosen to be acceptable with a VTE incidence rate below 3.0%.
One cut-off score was chosen leading to a dichotomized rule instead of the classically used 
three categories in order to increase simplicity. 
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RESULTS
Baseline characteristics
A total of 3306 consecutive patients with clinically suspected acute pulmonary embolism were 
included in the study of whom 2701 (82%) were outpatients. The mean age of the study cohort 
was 53 years (range 18 to 110 years). The CDR was available in 3298 patients (99.8%). 
The variable most frequently observed in the study patients was ‘pulmonary embolism is 
more likely than an alternative diagnosis’ (n=2032, 62%). The two variables with the lowest 
frequency were ‘clinical signs and symptoms of DVT’ (n=190, 6%) and ‘hemoptysis’ (n=176, 
5%), whereas the other variables varied from 11% (malignancy) to 26% (tachycardia). The 
prevalence of proven pulmonary embolism in the entire study cohort was 20%.
Of the 2199 patients with an unlikely CDR score according to Wells et al. the D-dimer test 
result was available in 98%. The D-dimer was positive in 1105 patients.
Figure 1: Prevalence of pulmonary embolism in the low, moderate and high probability groups in
the original study [6] (derivation and validation set), as well as in the present study.
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Validation of the Wells clinical decision rule
A comparison of the prevalence of pulmonary embolism among the three probability categories 
between our study population and the derivation and validation population of Wells et al. is 
shown in Figure 1. The discriminative power of the rule is comparable in the three study 
populations, although a tendency of the expected regression to the mean is shown.
Development of the simplified clinical decision rules
The second column of Table 1 shows the odds ratios of the CDR variables, generated by 
multivariable regression analysis, in our dataset as well as the original odds ratios of the study 
of Wells et al. in the first column. The odds ratios of all included variables are slightly lower in 
our population compared to the population of Wells et al. 
Table 2 details the two new scoring options. In the modified rule two points are assigned to 
‘clinical signs and symptoms of DVT’ and to ‘pulmonary embolism is more likely than an alternative 
diagnosis’, whereas in the simplified rule all variables are given one point if present. 
TABLE 1: Odds ratios for the variables of the Wells clinical decision rule and those observed in the 
present study. 
Odds Ratio with 95%CI 
Variable Wells et al. [6] Present study
1. Clinical signs & symptoms DVT 5.8 4.3 (3.1-5.9)
2. Tachycardia (>100/min) 3.0 1.8 (1.5-2.2)
3. Immobilization or surgery in the previous four weeks 2.5 2.1 (1.7-2.6)
4. Previous DVT/PE 2.4 1.8 (1.4-2.3)
5. Hemoptysis 2.4 1.9 (1.3-2.6)
6. Malignancy 2.3 1.4 (1.1-1.8)
7. An alternative diagnosis is less likely than PE 4.6 3.6 (2.9-4.5)
DVT, deep venous thrombosis; PE, pulmonary embolism
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TABLE 2: Scoring of the various variables in the original, the modified and simplified Wells rule. 
Original Modified Simplified
1. Clinical signs & symptoms DVT 3 2 1 
2. Tachycardia (>100/min) 1.5 1 1 
3.
Immobilization or surgery in the  
previous four weeks
1.5 1 1 
4. Previous DVT/PE 1.5 1 1 
5. Hemoptysis 1 1 1 
6. Malignancy 1 1 1 
7. An alternative diagnosis is less likely than PE 3 2 1 
Cut-off for PE unlikely ≤ 4 ≤ 2 ≤ 1
DVT, deep venous thrombosis; PE, pulmonary embolism 
FIGURE 2: ROC curves of the original, the modified and simplified Wells scoring method
2a: Original scoring method                 2b: Modified scoring method                       2c: Simplified scoring method
In Figure 2 the ROC curves of the original scoring method of Wells et al. and the two 
novel scoring options are depicted. The areas under the curve of the three different 
scoring methods varied from 0.72 to 0.74 with overlapping 95% confidence intervals. The 
discriminative power for the three scores is shown in figure 3 and is very similar. 
Safety and clinical utility of the different scoring options of the 
clinical  decision rules combined with D-dimer testing
The 3 month incidence of VTE for the dichotomized cut-offs with the two new CDRs in 
combination with a normal D-dimer test result, were calculated (Table 3). For comparison 
the results with the original dichotomized Wells score combined with D-dimer, as used in our 
study, are also shown. 
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Both the modified rule with a cut off score of ≤ 2 and the simplified rule with a cut-off score of 
≤ 1 in combination with a normal D-dimer had similar incidence rates of VTE during follow-up. 
The efficiency to reliably exclude patients for pulmonary embolism was around 30% for all 
three scoring options, in combination with a normal D-dimer test. 
If the cut-off score of the modified rule was increased to ≤ 3, the 3 month incidence of VTE 
would have increased to 1.0% (95% CI 0.5% to 1.8%). However, the additional patient group 
with a score of 3 points consisted of 109 patients of whom 5 patients had VTE (4.6%; 95% CI 
2.0% to 10.3%).
Similarly increasing the cut-off to ≤ 2 in the simplified rule, 6 of 135 patients with a score of 2 
points would have had VTE (4.4%; 95% CI: 1.7% to 9.4%). 
TABLE 3: Safety and clinical utility of the different scoring options of the clinical decision  
rules combined with D-dimer testing 
Incidence of VTE during 3 
months follow-up
Proportion of patients in whom 
spiral CT can be withheld
Wells ≤ 4 and 
normal D-dimer
0.8% (95% CI 0.3-1.5%) 32% (95% CI 30-33%)
Modified ≤ 2 and normal 
D-dimer
0.6% (95% CI 0.3-1.3%) 31% (95% CI 29-32%)
Simplified ≤1 
and normal D-dimer
0.5% (95% CI 0.2-1.2%) 30% (95% CI 28-31%)
VTE, venous thrombo-embolic event; CT, computed tomography
Figure 3: Prevalence of pulmonary embolism depicted for the original, the modified and the
simplified Wells rule, using pulmonary embolism likely and unlikely categories.
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DISCUSSION
Although the literature indicates that shrinkage and regression to the mean is often seen in the 
life span of prediction rules 18,19, the present analysis shows that the discriminative power of the 
Wells CDR compares favourably with the original derivation and validation set. The prevalence 
of thrombosis of 7.1% in the low probability group appears to be slightly higher as compared 
to the 3.6% and 2.0% in the derivation and validation set respectively, whereas the observed 
prevalence of 58% in the high probability group is similar to that in the two other sets. Our 
findings indicate that in general the odds ratios for the seven variables were moderately lower 
than observed by Wells et al6. However, this occurred without affecting the validity of the rule. 
Moreover, the two most informative variables remained the same i.e. ‘alternative diagnosis 
less likely than pulmonary embolism’ and ‘clinical signs & symptoms of DVT’. 
In the original rule three different weights were assigned to the various variables based on 
their odds ratios in order to produce a user friendly CDR (Tables 1 and 2). When we simplified 
this by giving two different weights to the variables, i.e. two points for the two variables with 
the highest odds ratios and one point to the other variables, little diagnostic information was 
lost. Most interestingly, when using unit weights, i.e. one point for each variable, in what we 
call the simplified rule the diagnostic accuracy remained unchanged (Fig. 2a, b and c). The 
simplified Wells rule indicates diagnostic testing is required if any of the variables is present 
or if the D-dimer test is positive. If no variables are present and the D-dimer test is negative 
very low rates of VTE during follow-up (0.5%: 95%CI 0.2 to 1.2%) can be expected. With this 
combination of tests approximately 30% of patients with suspected pulmonary embolism can 
be safely withheld from further diagnostic imaging techniques, a similar proportion to that 
observed with the original Wells rule. It should be noted that the cut-off value is the critical 
factor. If the cut-off in the modified and in the simplified rule was increased by one point, 
the incidence of VTE during follow-up would be 5% in the added patient group, which is 
unacceptably high. 
As is noted above the present findings indicate that giving different weights to the variables 
does not improve the diagnostic efficiency of the clinical decision rule. This could be caused by the 
slight regression to the mean of the odds ratios. Theoretically, the explanations for regression to 
the mean are diverse. It could be caused by the influence of interobserver variability, differences in 
interrater reliability and variation in referral pattern 10. A variable with an overestimated regression 
coefficient is more likely to be selected for the specific decision rule than an underestimated one. 
Consequently the selected variables are likely to have too large coefficients 19. Furthermore, a 
prediction rule is often validated in the same clinical setting, or even in the same patient group 
in which the derivation was done. If this group is not representative for the patient population 
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at large, it may reflect changes in morbidity over time.  It is temptative to speculate, why the 
Wells rule has been widely accepted while previous attempts with sometimes similar variables 
have failed 1-5, 20. This could partly be due to the fact that the variables in these rules were too 
numerous and were complicated by the need for additional tests such as blood gas analysis, 
electrocardiography or chest X-ray. The strategy of neural networks which are computerized 
clinical decision rules, popular in the early nineties, was also quickly forgotten, most likely 
because the networks were perceived to be too complicated 21, 22. More recently the application 
of multivariable logistic regression techniques gave more insight into the predictive strength 
and independency of the signs and symptoms for pulmonary embolism, and therefore reliable 
diagnostic models could be created which became more appealing to clinicians 3.  The wide 
acceptance of the Wells rule is possibly due to the inclusion of only seven relevant variables 
which are simple to obtain at the bedside 23. The addition of the clinical opinion of the clinician 
in the subjective variables ‘clinical signs and symptoms of DVT’ and ‘alternative diagnosis less 
likely than pulmonary embolism’ probably further contributed to its popularity. 
Several aspects of our study require comment. This study has a retrospective design which 
implicates that the novel simplified rule has to be validated in a prospective study. However, 
we included a large cohort of consecutive patients and believe that selection bias is very 
unlikely, and therefore we expect that a validation study will confirm the present observation. 
The safety of excluding pulmonary embolism was determined by the subsequent incidence 
of VTE during the three month follow-up. Using follow-up has increasingly been accepted 
as an appropriate reference standard for clinical outcome, if some basic methodological 
principles are adhered to, such as withholding anticoagulant treatment, complete follow-up 
and appropriate diagnostic work-up in case of suspected recurrence of VTE 24. We used the 
combination of an unlikely clinical probability and a normal D-dimer test to rule out pulmonary 
embolism. It should be noted, that the addition of D-dimer testing is mainly responsible for the 
low subsequent incidence of VTE during follow-up. 
In conclusion we validated the Wells rule and although the odds ratios did diminish slightly, 
the performance of the rule remained adequate. Simplification of the rule by assigning only 
one point to each of the seven variables had a similar diagnostic accuracy and clinical utility. 
This simplified rule requires validation. 
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ABSTRACT
Introduction If patients with suspected pulmonary embolism have a normal D-dimer 
concentration, this diagnosis becomes unlikely. Many D-dimer assays are available with 
differences in specificity and sensitivity. The aim of the present study is to compare the 
diagnostic accuracy of a fast and easy to perform D-dimer assay (AutoDimer) with an 
established D-dimer assay (Vidas). 
Materials and Methods In 401 patients with clinically suspected pulmonary embolism D-
dimer was measured using both assays. 
Results Pulmonary embolism was diagnosed in 92 patients (23%). At a cut-off value of 110 
ng/ml, AutoDimer was as accurate as Vidas D-dimer with a sensitivity of 97% (95% CI; 90-
99%), negative predictive value of 97% (95% CI; 91-99%), specificity of 32% (95% CI; 27-
38%) and positive predictive value of 35% (95% CI; 30-42%). In combination with an unlikely 
clinical decision rule-score, no venous thrombosis occurred during follow up (failure rate 0%: 
95% CI; 0%-5.7%). However, the combination of an unlikely clinical decision rule-score and 
AutoDimer D-dimer ≤ 110 ng/ml was only present in 20% of the patients.
Conclusion At a cut-off value of 110 ng/ml the AutoDimer is as safe as Vidas D-dimer in 
excluding pulmonary embolism in symptomatic patients with an unlikely clinical decision rule-
score, although less efficient. These results should be validated in a prospective management 
study. 
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INTRODUCTION
For diagnosing or excluding pulmonary embolism a diversity of diagnostic tools are available, 
including validated clinical decision rules (CDR), spiral computed tomography (CT) and D-
dimer testing 1-4. D-dimers, degradation products of cross-linked fibrin, are an indicator of 
fibrin turnover. If a patient with clinically suspected pulmonary embolism has a normal D-dimer 
concentration, the diagnosis of pulmonary embolism becomes very unlikely 5,6. Nowadays 
most diagnostic strategies use the combination of an unlikely clinical probability assessment 
and a normal D-dimer concentration to exclude pulmonary embolism in a simple and fast way 
with a high accuracy 4,7-9. For this central role the D-dimer assay has to be accurate with a 
high sensitivity and negative predictive value (NPV). Especially in outpatients the test results 
should be available to the clinician within a short time frame.
There are many D-dimer assays available, all with their own characteristics and 
methodology. As a consequence, the test results and cut-off values of the various assays 
are not interchangeable 5,6,10. A new D-dimer test, the Biopool AutoDimer is a rapid 
immunoturbidimetric assay. It has recently been evaluated in patients with suspected deep 
vein thrombosis (DVT) and found to be accurate in the exclusion of DVT 11. The accuracy of 
the AutoDimer in excluding pulmonary embolism has not been established yet.
In this study the diagnostic performances of the AutoDimer was analyzed in comparison to 
an established D-dimer ELISA method in patients with suspected pulmonary embolism.
MATERIALS AND METHODS
Data were collected as part of a large diagnostic management study that was carried out in 
12 teaching hospitals in the Netherlands, evaluating a diagnostic strategy including CDR, D-
dimer and spiral CT 4. Patients were included between November 2002 and August 2004 in 
our hospital, a large tertiary university referral center. The study protocol was approved by the 
local medical ethical committee.
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Patients
Consecutive patients with clinically suspected pulmonary embolism presenting in the Erasmus 
University Medical Center, Rotterdam, were eligible for inclusion in this analysis. Patients were 
excluded if they had received therapeutic unfractionated or low-molecular-weight-heparin for 
more than 24 hours before inclusion, they were younger than 18 years of age, they were 
pregnant, they had a known allergy to intravenous contrast agents, they had a life expectancy 
of less than three months, if a CT scan could not be performed because of overweight, or 
there was geographic inability for follow-up.
Diagnostic work-up
Using a validated CDR, patients with clinically suspected pulmonary embolism were categorized 
as pulmonary embolism unlikely (≤ 4 points) or likely (>4 points) 4,12. In case of an unlikely CDR-
score, the D-dimer concentration was measured, using the Vidas D-dimer assay. In case of an 
unlikely CDR-score and a normal D-dimer concentration, pulmonary embolism was considered 
excluded and anticoagulant treatment was withheld. Patients with an unlikely CDR-score in 
combination with elevated D-dimers or patients with a likely CDR-score underwent spiral CT. 
If spiral CT did not demonstrate pulmonary embolism, anticoagulant treatment was withheld. 
If the spiral CT demonstrated pulmonary emboli, anticoagulant treatment was initiated. Spiral 
CT was performed using multi-slice detector systems, as described previously 4. 
After completing the diagnostic strategy, patients were instructed to return to the hospital 
if signs and symptoms of DVT or pulmonary embolism occurred. All patients were followed 
for 3 months, during which adverse events were recorded and adjucated. If there was a 
clinical suspicion of DVT or pulmonary embolism, objective tests were performed to confirm 
or exclude the diagnosis. 
D-dimer assays
Before anticoagulant therapy was initiated, blood was collected in 0.105 M sodium citrate. 
The samples were centrifuged at 2000 g for 10 minutes at 4°C. D-dimer was immediately 
measured with a quantitative automated ELISA D-dimer assay (Vidas D-Dimer, Biomerieux, 
Marcy L’étiole, France) with a variation coefficient of 5.8% in the linear range of 45-10.000 
ng/ml fibrinogen equivalent units. The cut-off value for a positive test result is 500 ng/ml 4. 
The measurements were carried out by technicians, who were unaware of the outcome of the 
CDR or the spiral CT. Plasma aliquots were stored at -80°C. Samples were thawed at 37°C 
for measurements of the D-dimer levels with the Biopool Autodimer (Trinity Biotech, Kordia), 
an immunoturbidimetric assay on a Sysmex coagulation CA-1500 analyzer (Dade-Behring) 
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with a variation coefficient of 5.4% in the linear range 40-2400 ng/ml D-dimer units. A possible 
influence of storage on the results was studied by measurement of the D-dimer concentrations 
in the same randomly selected samples before and after storage. 
The AutoDimer was evaluated using two cut-off values; 1) the cut-off value of 189 ng/
ml calculated by Gardiner and coworkers in outpatients with suspected DVT 11 and 2) the 
calculated cut-off value which achieved a NPV similar to Vidas D-dimer in the present study 
using a receiver-operator characteristic (ROC) curve analysis. 
Statistical Analysis
The accuracy parameters (sensitivity, NPV, specificity and positive predictive value (PPV)) of 
the Vidas D-dimer and of two cut-off values of the AutoDimer were calculated on the basis of 
the results of the diagnostic strategy. The area under a ROC curve was optimized to obtain 
the best discrimination between patients who did and did not have a thromboembolic event. 
ROC curves depict the trade-off in true-positive versus false positive rates as the cut point for 
defining ‘positive’ and ‘negative’ is shifted along the full spectrum of D-dimer values, where 
an area under the curve of 1.0 would indicate a perfect test. A value of 0.5 would represent 
a non-informative test. The analysis was performed using SPSS version, 11.5 (SPSS Inc. 
Illinois, USA). 
The exclusion efficacy, i.e. the percentage of patients in whom pulmonary embolism was 
excluded, was calculated for two situations. First, the exclusion efficacy if pulmonary embolism 
was excluded by a normal D-dimer concentration as the only test and secondly, the exclusion 
efficacy if pulmonary embolism was excluded by the combination of an unlikely CDR-score 
and normal D-dimer concentration.  
RESULTS
Eight of the 409 consecutively screened patients with suspected pulmonary embolism were 
excluded due to lack of stored blood samples. The clinical characteristics are shown in table 
1. In 91 patients pulmonary embolism was diagnosed by spiral CT. Pulmonary embolism 
was excluded in the other 310 patients by either the combination of an unlikely CDR-score 
and a normal Vidas D-dimer concentration (n = 102, 25%), or by helical CT (n = 205, 34%). 
In three patients CT was inconclusive and pulmonary embolism was excluded by perfusion 
scintigraphy. During the 3 month follow-up period one patient developed a DVT after a normal 
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CT (Vidas D-dimer at presentation 7800 ng/ml). In the present analysis this patient was 
considered as having pulmonary embolism at the time of the study, hence 92 patients (23%) 
had pulmonary embolism.
ROC analysis showed comparable results for both tests with estimated AUC of 0.820 for the 
AutoDimer and 0.821 for the Vidas D-dimer assay (figure 1).
The accuracy parameters of both assays for excluding pulmonary embolism are shown 
in table 2. The Vidas D-dimer assay had a high NPV and sensitivity. However, two of the 150 
patients with pulmonary embolism on spiral CT had a normal D-dimer concentration (≤ 500 
ng/ml). The AutoDimer had a NPV of 96% using the cut-off value of 189 ng/ml. Seven of the 
150 patients with pulmonary embolism on spiral CT had a D-dimer concentration ≤ 189 ng/
ml. Using ROC analysis the calculated cut-off value at which a accuracy similar to Vidas D-
dimer was reached with AutoDimer was 110 ng/ml.Three of the 150 patients with pulmonary 
embolism on spiral CT had a AutoDimer D-dimer concentration ≤ 110 ng/ml.
TABLE 1. Clinical characteristics of the 401 patients with clinically suspected pulmonary embolism.
Characteristic      value
Mean age, years (SD)     52 (18)
Women, n (%)      210 (52)
Outpatients, n (%)      250 (62)
Recent surgery, n (%)     28 (7)
Previous VTE, n (%)     61 (15)
Malignancy, n (%)      74 (18)
SD, standard deviation; VTE, venous thromboembolic events
TABLE 2. Accuracy parameters of two D-dimer assays and the exclusion efficacy in 401 patients
     Vidas  AutoDimer
Parameter    ≤ 500 ng/ml ≤ 189 ng/ml ≤ 110 ng/ml
sensitivity % (95% CI)   98 (92-99) 92 (84-97) 97 (90-99)
specificity % (95% CI)   41 (36-47) 52 (46-58)  32 (27-38)
NPV % (95% CI)    98 (94-99) 96 (91-98) 97 (91-99)
PPV % (95% CI)    33 (28-39) 36 (30-43) 35 (30-42)
Exclusion efficacy:
normal D-dimer (%)    32  42  26
unlikely CDR-score + normal D-dimer (%) 25  33  20
NPV, negative predictive value; PPV, positive predictive value; exclusion efficacy is the percentage of patients with the test result 
mentioned in the table; CDR, clinical decision rule.
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FIGURE 1 Receiver operating characteristics curves for the AutoDimer and Vidas. 
AUC , Area under the curve
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The performance of the AutoDimer with the two cut-off values (189 ng/ml and 110 ng/ml) in 
combination with the CDR was evaluated (table 2). If we had used the AutoDimer with a cut-
off level of 189 ng/ml in the diagnostic strategy of the original study, 132 patients would have 
had the combination of an unlikely CDR-score and normal D-dimer concentration, hence an 
exclusion efficacy 33%. Three patients with pulmonary embolism would have been missed, 
resulting in a failure rate of 2.3% (95% CI; 0.6-7.0%). Eighty patients had the combination 
of an unlikely CDR-score and a D-dimer concentration of ≤ 110 ng/ml, hence an exclusion 
efficacy of only 20%. Pulmonary embolism, however would not have been missed, resulting in 
a failure rate of 0% (95% CI; 0-5.7%).
Comparison of the Vidas and AutoDimer results showed a good correlation (r2 = 0.85). A 
possible influence of storage on the results was studied by measurement of D-dimer levels 
in the same samples before and after storage. There was no difference between the results 
before and after storage (Vidas (n = 40): slope 0.97 (± 0.02), Y-intercept 0.06 (± 0.05), Sy|x 
0.23; AutoDimer (n = 20): slope 1.02 (± 0.01), Y-intercept -0.11 (± 0.05), Sy|x 0.17 ).
DISCUSSION
In patients with clinically suspected pulmonary embolism, D-dimer measurement has gained a 
definitive role in the diagnostic strategy. For this central role in excluding pulmonary embolism 
accuracy and a fast test result are two essential characteristics. The Vidas D-dimer assay has 
been shown to be a test with a high sensitivity and NPV for excluding pulmonary embolism 6,13. 
The performance of the AutoDimer in excluding pulmonary embolism has not been established 
yet. Recently, the use of AutoDimer was evaluated in patients with suspected DVT. A cut-off 
value of 189 ng/ml for excluding DVT in outpatients was assessed as optimal 11. Our study 
shows that the optimal cut-off value of the AutoDimer with a high sensitivity and NPV for 
excluding pulmonary embolism is 110 ng/ml. This difference may in part be explained by a 
possible difference in duration of symptoms before the D-dimer concentration was measured, 
since higher D-dimer levels have been reported in acute DVT compared to patients presenting 
after longer time 14. 
The present study shows that the performance of the AutoDimer strongly depends on 
the cut-off value used. Using ROC analysis the performance of the AutoDimer is similar to 
results of the Vidas D-dimer assay when the cut-off value was 110 ng/ml. In combination 
with an unlikely CDR-score, both assays excluded pulmonary embolism safely as no venous 
thromboembolism occurred during the 3 month follow up period. 
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As anticipated, by lowering the cut-off value of the AutoDimer from 189 to 110 ng/ml, 
the exclusion efficacy of the D-dimer assay as the only test to exclude pulmonary embolism 
decreased from 42% to 26%. This value is still as efficient as the Vidas D-dimer or other 
established D-dimer tests 6,13. The exclusion efficacy of the combination of an unlikely CDR-
score and AutoDimer D-dimer concentration of  ≤ 110 ng/ml was 20%. This combination is less 
efficient than the Vidas D-dimer assay in combination with an unlikely CDR-score (exclusion 
efficacy 25%) 12 4,9.
With respect to speed, the Vidas D-dimer assay is known to take at least 40 minutes. The 
results of the AutoDimer can be available within 10 minutes. This gain of time can be important 
especially in the outpatient setting, where most patients with clinically suspected pulmonary 
embolism present. Another advantage apart from its speed, is that the AutoDimer can be 
performed on a coagulation analyzer present in many laboratories.
A major limitation of this analysis is that it is performed in retrospect. Although the population 
is comparable to other management studies in patients with suspected pulmonary embolism, 
the results should be validated in a prospective management study. Another limitation might 
be that the D-dimer levels were measured with the AutoDimer assay in defrosted samples. 
However, we did not find a difference of D-dimer levels in samples before and after storage 
using both assays. This indicates that the storage procedure did not influence our results, as 
has been previously reported 15.
In conclusion, the combination of an unlikely CDR-score and a normal D-dimer 
concentration is a safe strategy to exclude pulmonary embolism. Our results confirm that for 
every D-dimer assay the optimal cut-off value has to be established. Although it has to be 
validated in a prospective management study, an unlikely CDR-score in combination with a 
D-dimer concentration of ≤ 110 ng/ml measured with the AutoDimer D-dimer assay seems to 
be accurate in excluding pulmonary embolism. 
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ABSTRACT
Background A clinical decision rule (CDR) combined with a D-dimer test is commonly used to 
rule out suspected pulmonary embolism. However, still 70% of the patients need to undergo 
further imaging tests. C-reactive protein (CRP) has been shown to be related to the presence 
or absence of pulmonary embolism.
Objective To evaluate the safety and usefulness of a highly sensitive CRP assay in the 
diagnostic work-up of patients with suspected pulmonary embolism, either alone or combined 
with the CDR and D-dimer.
Methods A diagnostic strategy using CDR, D-dimer and spiral computed tomography was 
used to confirm or rule out pulmonary embolism. Test characteristics of CRP at a cut-off 
concentration of 3 mg/l were calculated based on the outcome of this strategy and three 
months of follow-up. CRP was combined and compared to the CDR and D-dimer test. 
Results  For the 790 included patients the sensitivity and the negative predictive value of 
CRP at a cut-off concentration of 3 mg/l were both 99% (95%CI: 96-100%). The specificity 
was 27%. The exclusion efficiency of the combination of an unlikely CDR and a low CRP was 
lower than an unlikely CDR combined with a normal D-dimer, 19% versus 32% respectively. A 
diagnostic algorithm using all three tests increased the percentage of patients ruled out from 
pulmonary embolism from 32% to 40%, with a 3-month incidence of venous thromboembolism 
of 1.3% (95% CI: 0.3% to 3.2%)
Conclusions The safety of CRP is comparable to D-dimer to rule out pulmonary embolism, 
but the usefulness of CRP in addition to CDR and D-dimer is marginal.
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INTRODUCTION
Rapid confirmation of the presence of pulmonary embolism is important due to the high mortality 
rate associated with missed disease 1. However, only 20% of patients presenting with suspected 
pulmonary embolism actually have emboli confirmed by objective testing 2-4. Therefore, 
inexpensive and quick but highly sensitive tests to rule out the diagnosis are desirable in the 
early phase of the diagnostic work-up of these patients. Several diagnostic methods have 
become available in recent years, which appear promising for this goal.
A clinical decision rule (CDR) and a highly sensitive D-dimer assay are now commonly 
used tools to safely exclude pulmonary embolism. Because of the low specificity of these tests, 
pulmonary embolism can only be ruled out in approximately 30% of patients presenting with 
suspected pulmonary embolism 5. This implies that 70% still needs to undergo further imaging 
tests, such as ventilation/perfusion scintigraphy (V/Q scan) or spiral computed tomography 
(CT). 
Low levels of C-reactive protein (CRP), which is measured by an easy to perform, 
inexpensive and readily available blood test, have also been shown to be related to the absence 
of venous thromboembolism 6-11. Sensitivities of CRP for detecting venous thromboembolism 
varied from 60% to 100% with CRP cut-off values between 5 mg/l and 10 mg/l, although 
most studies had a small sample size and lacked an appropriate reference method for the 
presence or absence of pulmonary embolism. One study determined whether the CRP test 
in combination with clinical probability assessment in patients with suspected pulmonary 
embolism could be an alternative to D-dimer testing11. Diagnostic performance of the CRP 
test in the low clinical probability group at a 5 mg/l cut-off value was not equivalent to a rapid 
D-dimer assay, mainly due to a lower sensitivity of the CRP test11.  Recently more sensitive 
CRP assays have become available. 
The aim of the present study was to evaluate a CRP assay with a detection limit of 3 mg/l in 
the diagnostic work up of suspected pulmonary embolism, either alone or in combination with 
the clinical decision rule and the D-dimer test. In addition, we evaluated whether the accuracy 
could result in a decrease of the number of patients that have to undergo further imaging. 
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METHODS
Data were collected in a large diagnostic management study in 12 teaching hospitals in the 
Netherlands, which evaluated a diagnostic strategy including CDR, D-dimer and spiral CT 12. 
Patients were included between November 2002 and August 2004. The study protocol was 
approved by the Institutional Review Boards.
Patients
Consecutive in- and outpatients with clinically suspected acute pulmonary embolism were 
eligible for inclusion. Patients were excluded if they had received (low molecular weight) 
heparin for more than 24 hours, were younger than 18 years of age, were pregnant, had a 
known hypersensitivity for iodinated contrast, had a life expectancy of less than three months 
or if there was geographic inability for follow-up. For the analysis reported here, data from two 
hospitals were used (Academic Medical Center, Amsterdam and Erasmus Medical Center, 
Rotterdam). 
Diagnostic strategy
Upon referral, the simplified clinical decision rule (CDR) of Wells et al.13 was completed by the 
attending physician. This rule consists of seven questions including the presence of symptoms 
of deep venous thrombosis, pulse frequency, immobilization or surgery within the last four 
weeks, previous venous thromboembolism, hemoptysis, malignancy and the possibility of an 
alternative diagnosis. Patients were classified into those with a likely CDR-score (above 4) or 
unlikely CDR-score (4 or below). 
Blood was obtained from all patients for the measurement of D-dimer concentration 
(Tinaquant D-dimer, Roche Diagnostica, Mannheim, Germany) and of CRP (Tinaquant CRP 
test, Roche Diagnostica). The lowest detection limit of CRP for the test was set at 3 mg/l. The 
CRP concentration did not influence the management decisions.
In patients with an unlikely CDR score and a D-dimer concentration equal or below 0.5 
mg/l no further imaging was performed and no anticoagulant treatment was initiated. Patients 
with a likely CDR score or a D-dimer concentration above 0.5 mg/l underwent spiral CT to 
confirm or rule out pulmonary embolism. Spiral CT was performed with a thin collimation, multi-
detector row spiral CT scanner and 1.25 mm coupes were made. Spiral CT was performed 
using 100 ml of iodinated contrast (Visipaque 320® Nycomed, Oslo, Norway) administered at 
a rate of 4 ml/sec using a bolus tracking protocol. Central intraluminal filling defects or totally 
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occluded vessels were considered as positive for pulmonary embolism. A negative spiral CT 
ruled out pulmonary embolism. 
Patients were instructed to contact the hospital if signs or symptoms of pulmonary embolism 
or deep venous thrombosis occurred during these three months of follow-up. All included 
patients were contacted by phone or seen at the outpatient department after three months. To 
confirm the suspicion of venous thromboembolic events objective testing was needed and the 
results were adjudicated by a blinded committee. In addition all deaths were adjudicated. 
Analysis
A multiple reference standard was used to evaluate the diagnostic accuracy of CRP. Patients 
were classified as having pulmonary embolism in case of a positive helical CT or in case 
of positive testing for venous thromboembolism during follow-up. All other patients were 
classified as not having pulmonary embolism. 
A receiver operating curve (ROC) for the CRP test was composed to evaluate the 
discriminative power to distinguish patients with and without pulmonary embolism.  The 
concentration of 3 mg/l was used to calculate the test characteristics of the CRP test. 
Sensitivity, specificity, positive predictive value and negative predictive value were calculated 
for the total study population. Test characteristics were also calculated for the combination 
of CRP with the CDR, and they were compared to the combination of D-dimer assay and 
the CDR. The McNemar test statistic was used to test the difference. We also evaluated the 
exclusion efficiency of both combinations; i.e. the percentage of patients in whom further 
testing could be safely withheld. Finally, the combination of all three tests, CDR, D-dimer 
and CRP, was explored to see whether adding CRP to the currently established diagnostic 
algorithm with CDR and D-dimer increased the exclusion efficiency.
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RESULTS
Patients characteristics
In 790 non selected patients data on CRP, D-dimer, and the CDR score at presentation were 
available (Figure 1). Baseline characteristics of the study population are detailed in Table 1. 
The mean age was 53 years, 422 (54%) were female and 556 (70%) were outpatients. 
In total 254 (32%) patients had both an unlikely CDR score and a normal D-dimer. These 
patients were considered not to have pulmonary embolism and anticoagulant therapy was 
withheld. During a three-month follow-up two of these patients experienced objectively 
confirmed venous thromboembolism. 
The remaining 536 patients with a likely CDR and/or a high D-dimer concentration underwent 
spiral CT of which 162 (30%) had confirmed PE, 196 (37%) had a completely normal CT and 
172 (32%) had no pulmonary embolism but an alternative diagnosis. During follow-up of the 
368 patients with a CT negative for pulmonary embolism and consequently no anticoagulant 
therapy, four patients experienced objectively confirmed venous thromboembolism. 
In total 162 patients had pulmonary embolism (prevalence 21%).
TABLE 1: Baseline characteristics of 790 study patients
Characteristic Number (%) 
Mean age (range) 53 (19-97)
Female sex 422 (54)
Outpatients 556 (70)
Median duration of symptoms in days (range) 2 (1 to 90)
Paralysis, paresis or 
plaster leg < 4 weeks
24 (3)
Immobilization 124 (16)
Surgery 64 (8)
Previous deep venous thrombosis 42 (5)
Previous pulmonary embolism 57 (7)
Heart failure 90 (11)
Chronic obstructive pulmonary disease 96 (12)
Malignancy 122 (15)
Hormone therapy 80 (10)
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FIGURE 1 Flow chart of diagnostic management strategy
PE, pulmonary embolism; CDR, clinical decision rule; CT, computed tomography; VTE, venous thromboembolic event
CRP analysis
The median CRP value for the patients with pulmonary embolism was 52.0 mg/l (IQR: 17.5 to 
127.0 mg/l) compared to 15.0 mg/l (IQR: 3.0 to 63.3 mg/l) for the patients without pulmonary 
embolism (p<0.001). 
At the set level of CRP measurement of 3 mg/l, the sensitivity was 99% (95% CI: 96 to 
100%). The negative predictive value at this cut-off was 99% (95%CI: 96 to 100%), while the 
specificity was 27% (95% CI: 24 to 31%).  Figure 1 shows the discriminative power of CRP 
when used as the sole test in the diagnostic work-up of suspected pulmonary embolism. The 
979 eligible patients with 
suspected PE 
CDR, D-dimer or CRP not 
performed (n= 189) 
790 included patients 
No PE 
n= 254 
CT negative for PE 
n= 368 
CT positive for PE 
n= 162 
6 patients had confirmed VTE 
during follow up 
CDR >4 or D-dimer > 0.5 mg/l; 
n=536 
CDR ≤ 4 and D-dimer <=0.5 
mg/l; n= 254 
6 protocol 
violations 
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area under the curve for CRP was 0.70 (95% CI: 0.66 to 0.74). Increasing the CRP cut-off 
concentration from 3 to 4 or 5 mg/l would result in a minor increase of the specificity, but in an 
associated decrease in sensitivity (Figure 2). At a cut-off concentration of 5 mg/l, the sensitivity 
would have been 95%, with a negative predictive value of 96% and a specificity of 32%.
The diagnostic performance of CRP at the cut-off concentration of 3 mg/l when combined 
with the CDR is shown in Table 2. The negative predictive value of CRP in the unlikely clinical 
risk category was 99% (95% CI: 96 to 100%). In the likely CDR category the negative predictive 
value was 96%, but due to the smaller group size (280 patients) the 95% confidence interval 
was wider (80 to 100%). The specificities in the two CDR categories were 33% (95%CI: 29 
to 37%) and 14% (95%CI: 9 to 19%), respectively. Therefore, the combination of an unlikely 
CDR score with a CRP concentration of 3 mg/l or lower was present in 149(19%) from the 
initial cohort of patients with suspected pulmonary embolism.
CRP in combination with the CDR was compared to the combination of the D-dimer test 
and the CDR. The negative predictive value of the D-dimer in the unlikely clinical risk category 
was 99% (95%CI: 97 to 100%) and the specificity was 56% (95%CI: 52 to 67%); compared to 
a specificity of 33% for CRP; (p-value <0.001). 
The combination of a normal D-dimer and an unlikely CDR score would have ruled out 
pulmonary embolism without further imaging in 254 patients (32%). This is a higher exclusion 
efficiency than CRP combined with an unlikely CDR score (32% versus 19%, respectively 
(p-value <0.001). 
Finally, adding CRP to the currently used algorithm of CDR and D-dimer to rule out 
pulmonary embolism resulted in the following two options. First, the use of CRP only in 
the unlikely CDR category of patients with an abnormal D-dimer. An unlikely CDR score in 
combination with a normal D-dimer result was present in 254 patients (32% of the study 
population), whereas 259 patients within the unlikely CDR patient category had an abnormal 
D-dimer result. Of these 259 patients 31(12%) had a low CRP concentration. This addition 
of CRP to the strategy of an unlikely CDR and normal D-dimer was, during three months of 
follow-up, associated with a VTE incidence of 1.1% (3 patients; 95% CI: 0.2% to 3.0%). 
Secondly, a low CRP concentration could also be used to rule out pulmonary embolism 
in the likely CDR category as well. As above, 254 patients (32%) had an unlikely CDR score 
and a normal D-dimer result. Of the remaining 536 patients 59 had a low CRP concentration, 
which is 10%. Therefore, the use of this diagnostic algorithm would have ruled out pulmonary 
embolism in 313 patients (i.e. 40% of the initial cohort with suspected pulmonary embolism). 
Four patients with pulmonary embolism would have been missed (3-month VTE incidence 
1.3%; 95%CI: 0.3% to 3.2%).
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FIGURE 2 ROC curve for CRP with the sensitivity and specificity of three different CRP cut-off 
concentrations (mg/l) detailed. (AUC, area under the curve)
TABLE 2 Test characteristics (including 95% confidence interval) of CRP at a cut-off concentration of 3 mg/l
All patients 
n= 790 
CDR unlikely*
n= 510
CDR likely*
n= 280
PE prevalence n(%) 164   (21%) 61  (12%) 103  (37%)
CRP
Sensitivity 99%   (96%-100%) 98%   (91%-100%) 99%   (95%-100%)
Specificity 28%   (24%-31%) 33%   (29%-37%) 14%   (9%-19%)
Negative predictive value 99%   (96%-100%) 99%   (96%-100%) 96%   (80%-100%)
Positive predictive value 26%   (23%-30%) 17%   (13%-21%) 67%   (59%-74%)
PE, pulmonary embolism; CDR, clinical decision rule
*CDR unlikely = 4 or less points; CDR likely = more than 4 points
AUC 0.70 (95%CI: 0.66-0.74)
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DISCUSSION
 This study shows that CRP at a cut-off concentration of 3 mg/l is as sensitive and has a 
comparable negative predictive value as D-dimer, implying that it can be safely used in the 
diagnostic work-up of patients with suspected pulmonary embolism. Because of the lower 
specificity, the efficacy to exclude pulmonary embolism is lower for CRP than for D-dimer.
Several other studies with CRP have been performed in patients with suspected pulmonary 
embolism providing varying sensitivities and specificities 6-8 9;10 11. Only one study had an 
appropriate reference standard for pulmonary embolism and was carried out in a sufficient 
number of patients 11. In that study, the sensitivity and negative predictive value of CRP were 
considerably lower compared to our study. This could be due to the use of a different CRP 
test and a cut-off concentration of 5 mg/l. Using a cut-off of 5 mg/l in our study would have 
produced a sensitivity and negative predictive value that exceed those reported by Aujesky 
et al. Another reason may be the lower prevalence of pulmonary embolism in our study (21% 
versus 30%). 
What could be the potential contribution of CRP in the diagnostic work-up of patients with 
suspected pulmonary embolism? Our analysis showed that low CRP values were observed 
in 12% of the patients with an abnormal D-dimer result in the unlikely CDR category, implying 
that in this specific subgroup 8 CRP tests would have to be performed to rule out one patient 
from having pulmonary embolism. In clinical practice, the D-dimer and CRP will usually be 
measured at the same time, thus in all patients with an unlikely CDR score. The number of 
CRP tests to rule out one patient from pulmonary embolism would then increase to 17, which 
appears to be a marginal diagnostic yield.
An interesting observation in this study was the high sensitivity and negative predictive 
value of CRP in the likely CDR category. It could therefore be argued to use CRP as the first 
and only test to rule out pulmonary embolism, followed by the currently used combination of 
an unlikely CDR score with a normal D-dimer result. With this diagnostic algorithm, 40% of the 
patients would be excluded from having pulmonary embolism, an increase of 8% as compared 
to the strategy without CRP. This might be clinical relevant, in particular since CRP is an easy 
to perform and widely available test that is already regularly measured in patients with chest-
symptoms. Two aspects of this assumption require comment. First, although the negative 
predictive value in the likely CDR score group is high (96%), the 95% confidence interval in that 
group is wide, precluding a definitive conclusion on the safety of CRP in this patient category. 
This should therefore be confirmed in future studies. Moreover, as with the D-dimer assay, 
clinicians feel uncomfortable in relying on a single laboratory test to rule out a potentially fatal 
137
Clinical utility of C-reactive protein in ruling out pulmonary embolism
disease in patients with a high clinical probability. Therefore, this strategy might not be widely 
accepted even if proven safe in a prospective study.
Some aspects of this study require comment. Data on the combination of CRP test, D-
dimer test and CDR score at presentation were available for 81%, which could have resulted 
in selection bias. However, the baseline characteristics as well as the prevalence of pulmonary 
embolism were not different for the patients from the entire cohort. The analyses of CRP in this 
study were performed retrospectively and although the CRP test characteristics were good 
and our population is comparable to other diagnostic management studies in patients with 
suspected pulmonary embolism, these have to be confirmed prospectively. 
In conclusion, the sensitivity and negative predictive value of the CRP test at a cut-off value 
of 3 mg/l were high and comparable to a rapid ELISA D-dimer test. The negative predictive 
value was also high in the subgroup of patients with a likely clinical probability. However, the 
specificity of CRP was too low to substitute D-dimer testing. Addition of CRP to the currently 
used diagnostic algorithm would have increased the exclusion efficiency only marginally. 
Therefore, additional studies are required to evaluate whether varying the cut-off values of 
CRP, D-dimer and CDR might improve the exclusion efficiency.
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The main objective of this thesis was to improve the diagnostic strategies for patients 
presenting with clinically suspected pulmonary embolism. Therefore several studies were 
initiated focusing on different aspects of the currently available as well as newly developed 
diagnostic tools for this patient population. 
A large proportion of patients with clinically suspected pulmonary embolism do not have 
the disease. The first aim of a diagnostic strategy is to safely exclude pulmonary embolism. 
A systematic overview of the effectiveness of the available diagnostic tests and combined 
strategies to exclude pulmonary embolism is presented in Chapter 2. Several invasive and 
non-invasive tests for excluding pulmonary embolism are safe. The combination of a clinical 
probability assessment together with D-dimer testing is an elegant, efficient and patient friendly 
approach to exclude pulmonary embolism.
A clinical management study evaluated a diagnostic strategy consisting of an extended 
clinical decision rule, D-dimer testing, compression ultrasonography and pulmonary 
angiography (Chapter 3). The clinical decision rule divided patients into three categories with a 
low, moderate or high clinical probability of pulmonary embolism. In patients with a low clinical 
probability and a normal D-dimer concentration, pulmonary embolism was considered to be 
excluded and anticoagulant treatment was withheld. All other patients underwent compression 
ultrasonography and, if normal, subsequently also pulmonary angiography. Among all 234 
consecutive patients with clinically suspected pulmonary embolism, 60 had the combination 
of a low clinical probability and normal D-dimer concentration. In these patients pulmonary 
embolism was considered excluded (i.e. 26% of the study population). During 3 months of 
follow up no venous thromboembolic events occurred (failure rate 0%; 95% CI 0-6%). In the 
other 174 patients (74%) a compression ultrasonography was performed, which revealed 
deep venous thrombosis in 27 patients and anticoagulant treatment was started. Pulmonary 
angiography was performed in the remaining 147 patients, and confirmed the presence of 
pulmonary embolism in 25 patients. Thus, the incidence of pulmonary embolism was 22% of 
the total study population. Although the study showed that it was safe to exclude pulmonary 
embolism and withhold anticoagulant treatment in patients with a low clinical probability and 
normal D-dimer concentration (failure rate 0%), it should be noted that the upper limit of 
the confidence interval of this point estimate is still high (6%). This study also confirms that 
pulmonary angiography is a safe technique to assess the presence or absence of pulmonary 
embolism, with a rate of angiography associated complications of 0.4% (95% CI: 0.09-1.25%). 
However, in many hospitals pulmonary angiography is not readily available. This would argue 
for using other noninvasive imaging techniques, such as spiral CT, that is more widely applied 
and is gaining popularity.
In Chapter 4 a diagnostic strategy using spiral computerized tomography as the sole 
imaging technique was evaluated in a large management study. The study enrolled 3306 
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patients with clinically suspected pulmonary embolism. This so called Christopher study 
was performed in 12 general and academic hospitals in The Netherlands. The diagnostic 
strategy consisted of a dichotomized clinical decision rule, i.e. a clinical decision rule-score 
indicating pulmonary embolism unlikely or likely, D-dimer testing and spiral computerized 
tomography (single or multi slice). Pulmonary embolism was excluded in 1057 patients with 
an unlikely CDR-score in combination with a normal D-dimer concentration (32% of the entire 
study population). During 3 months of follow up 5 patients returned with documented venous 
thromboembolism (failure rate 0.5%; 95% CI: 0.2-1.1%). This validates our strategy described 
in Chapter 3. In all other patients (n=2249) a subsequent spiral computerized tomography 
scan was performed which was negative for pulmonary embolism in 1505 patients. Venous 
thromboembolic events became apparent in 11 patients during follow up (failure rate 1.3%; 
95% CI: 0.7-2.0%). Pulmonary embolism was documented by spiral computerized tomography 
in 674 patients (20% of the study population). These results allowed us to conclude that this 
relatively simple and fast strategy can safely exclude or confirm pulmonary embolism. The 
compliance as regards the application of the strategy was high. The diagnostic strategy was 
completed according to the protocol in 98.5% of the patients and allowed a management 
decision in 97.9% of them, which makes it suitable for daily practice in both academic and 
general hospital settings. 
It has been debated whether this diagnostic strategy can be generally applied to all patients, 
including those of older age, those with cancer and hospitalized patients. In these patients 
clinical probability assessment is in most instances high and D-dimer concentrations may be 
nonspecifically elevated due to the presence of concomitant disease. To address this question 
we analyzed the effectiveness of the diagnostic strategy in hospitalized patients (Chapter 5). 
In 605 hospitalized patients with clinically suspected pulmonary embolism, the disease was 
excluded by the combination of an unlikely clinical decision rule-score and normal D-dimer in 
60 patients (10% of the study population). Venous thrombosis did not appear during follow up 
(failure rate 0%; 95% CI: 0-6.7%). Pulmonary embolism was excluded by spiral computerized 
tomography in 380 of these patients with a 3 month failure rate of 1.4% (95% CI: 0.4-3.1%). 
An alternative diagnosis for the symptoms was documented in 216 patients. 
In Chapter 6, this diagnostic strategy was studied in other subgroups including elderly 
patients, patients with chronic obstructive pulmonary disease, heart failure or cancer in whom 
pulmonary embolism was clinically suspected.  As expected, the proportion of patients that 
actually had the combination of an unlikely clinical decision rule-score and a normal D-dimer 
concentration was low in this selected population in comparison to the original study cohort, 
especially in elderly patients and patients with cancer. The results from these studies indicate 
that the diagnostic algorithm using a clinical decision rule, D-dimer and spiral computerized 
tomography overall furnishes a reliable and simple strategy in these particular and selected 
subgroups of patients.
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Presently, the diagnostic strategy in patients with clinically suspected pulmonary embolism 
starts with a clinical probability assessment using a clinical decision rule. This assessment 
is in part based on subjective criteria and the reproducibility is moderate. In Chapter 7 we 
show that the reproducibility can be improved by dichotomizing the short clinical decision rule 
compared to the originally used extended clinical decision rule. The most optimal result, albeit 
with still a moderate reproducibility, was obtained by this dichotomized short clinical decision 
rule (kappa value 0.66; 95% CI: 0.41-0.91). An explanation for the limited reproducibility was 
that a standardized clinical decision rule comprises in part subjective items, as for instance the 
absence of an alternative diagnosis. 
As is shown in Table, the dichotomized clinical decision rule contains 7 variables with 1, 
1.5 or 3 points assigned per variable. Can this clinical decision rule can be further simplified 
using for instance only 1 or 2 points or 1 point for all variables? This question was addressed 
in Chapter 8. There were no differences in safety or clinical utility using the simplified clinical 
decision rules as compared to the original clinical decision rule presented by Wells and 
colleagues. This simplified clinical decision rule should be validated and its reproducibility 
assessed in a prospective management study. 
The safety of the diagnostic strategy is also strongly dependent upon the test 
characteristics of the D-dimer assay used. Several assays, including ELISA, latex-based 
and semi-quantitative assays have been developed. In the Christopher study two of these 
assays, that had previously been shown to be reliable, were used to determine the D-dimer 
concentration. In the Erasmus Medical Center in Rotterdam, the Vidas D-dimer assay was 
used. Most patients with clinically suspected pulmonary embolism were initially seen at the 
emergency department. It is important that after assessing an clinical decision rule-score 
indicating pulmonary embolism unlikely, the D-dimer results become available immediately. 
One of the disadvantages of the Vidas D-dimer assay is that it takes at least 40 to 60 minutes 
to obtain a test result. In addition, the Vidas D-dimer test can only be performed on a special 
analyzer. We assessed the accuracy and exclusion efficacy of a fast D-dimer latex immuno 
assay (AutoDimer) on a routine analyzer in a study described in Chapter 9. At a cut-off value 
of 110 ng/ml, the test had a negative predictive value of 97% (95% CI: 91-99%), which is 
as accurate as the Vidas D-dimer assay. However, the exclusion efficacy of this assay in 
combination with an unlikely clinical decision rule-score was only 20% compared to 25% 
with the Vidas D-dimer assay. Whether the AutoDimer in combination with an unlikely clinical 
decision rule-score can be used to safely exclude pulmonary embolism with an acceptable 
exclusion efficacy remains to be evaluated. 
Although the combination of an unlikely clinical decision rule-score and normal D-dimer 
concentration can safely exclude pulmonary embolism in 25 to 35% of the patients, a large 
proportion of patients needs further diagnostic imaging. C-reactive protein concentration 
correlates with the presence or absence of pulmonary embolism. In Chapter 10 the safety and 
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clinical utility of a high sensitivity C-reactive protein assay in the diagnostic strategy of patients 
with suspected pulmonary embolism was assessed. The exclusion efficacy increased from 
32% using clinical decision rule-score and D-dimer concentration to 40% when C-reactive 
protein was also included in the diagnostic strategy, with a 3 months failure rate of 1.3% (95% 
CI: 0.3-3.2%). Therefore, the use of C-reactive protein in addition to D-dimer and clinical 
decision rule allows for some improvement of the exclusion efficacy.
Future perspectives 
Excluding or diagnosing pulmonary embolism remains a challenge for the physician who 
is confronted with a patient with signs and symptoms suggestive of  pulmonary embolism. 
During the past years the diagnostic strategy has evolved from a complex and time-consuming 
strategy based on invasive techniques to a simple and fast algorithm, based on mostly non-
invasive techniques, including a dichotomized clinical decision rule, D-dimer testing and if 
necessary spiral computerized tomography. One of the main advantages of this strategy 
is that it can be applied in most academic and non-academic hospitals. Furthermore this 
strategy gives an early answer allowing a management decision in nearly all patients within a 
few hours or even less. 
Obviously, this simple strategy should be optimized further. Future challenges are amongst 
others to develop a simple and fast strategy for patients with recurrent pulmonary embolism 
and pregnant patients. In addition, future studies should be focused on further simplification 
of clinical decision rules and reducing their dependence on subjective variables. Furthermore, 
faster or bed-side accurate D-dimer assays are needed. New biomarkers including markers of 
cardiac dysfunction (e.g. brain natriuretic peptide or heart–type fatty acid binding protein) may 
improve the diagnostic strategy. Finally, improvement of diagnostic imaging techniques with 
advanced spiral computerized tomography or magnetic resonance pulmonary angiography 
will be of major importance to optimize the diagnosis of pulmonary embolism. 
TABLE. Clinical decision rule according to Wells
Variable         points
Clinical signs and symptoms of deep vein thrombosis 
(minimum of leg swelling and pain with palpation of the deep veins)   3
Alternative diagnosis less likely than pulmonary embolism    3
Heart rate > 100/min       1.5
Immobilization (> 3 days) or surgery in previous 4 weeks    1.5
Previous pulmonary embolism or deep vein thrombosis    1.5
Hemoptysis        1.0
Malignancy (receiving treatment, treated in the last 6 months or palliative)  1.0
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Bij patiënten met een klinische verdenking op een longembolie zijn diverse diagnostische 
strategieën mogelijk. Het doel van dit proefschrift was het verbeteren van deze strategieën.
Een groot deel van de patiënten met verdenking longembolie blijkt de ziekte niet te hebben. 
Het eerste doel van een diagnostische strategie is dan ook het veilig uitsluiten van longembolie. 
Een overzicht van de diagnostische waarde van de verschillende testen en strategieën wordt 
gegeven in hoofdstuk 2. Meerdere invasieve en niet-invasieve testen voor het uitsluiten van 
longembolie zijn veilig en betrouwbaar. De combinatie van een klinische kansschatting op 
het hebben van longembolie en een D-dimeer test is een efficiënte en patiëntvriendelijke 
manier om longembolie uit te sluiten, echter de betrouwbaarheid dient met verder onderzoek 
te worden aangetoond.
In een klinische management studie werd een diagnostische strategie geëvalueerd, 
bestaande uit een uitgebreide klinische beslisregel, een D-dimeer test, compressie-echografie 
van de benen en longangiografie (hoofdstuk 3). De klinische beslisregel verdeelde de 
patiënten in drie categorieën met respectievelijk een lage, matige of hoge waarschijnlijkheid 
op het hebben van longembolie. Bij patiënten met een lage  waarschijnlijkheid en een normale 
D-dimeer concentratie werd de diagnose longembolie verworpen. Alle overige patiënten 
ondergingen een compressie-echografie van de beenvenen en, indien de echo geen 
trombose toonde, een longangiografie. Van de 234 achtereenvolgende patiënten met een 
verdenking longembolie hadden 60 (26%) de combinatie lage waarschijnlijkheid en normale 
D-dimeer concentratie. De diagnose longembolie werd verworpen. Tijdens de 3 maanden 
daarop volgend zijn er geen veneuze trombo-embolische complicaties waargenomen (0%; 
95% betrouwbaarheidsinterval (BI): 0-6%). Alle overige patiënten (n=174) ondergingen een 
compressie-echografie van de beenvenen. Zevenentwintig patiënten hadden een diepe 
veneuze trombose en antistolling werd gestart. Longangiografie werd uitgevoerd bij 147 
patiënten en bij 25 werden longembolieën aangetoond. De incidentie van longembolie was 
22% voor de totale populatie. Alhoewel de studie toonde dat het veilig is longembolie uit te 
sluiten in patiënten met een lage waarschijnlijkheid en een normale D-dimeer concentratie 
dient opgemerkt te worden dat de bovengrens van het betrouwbaarheidsinterval hoog is (6%). 
Deze studie laat ook zien dat longangiografie een veilige techniek is om longembolie aan te 
tonen of uit te sluiten met een complicatie percentage van slechts 0.4% (95% BI 0.09-1.25%). 
Echter, in veel ziekenhuizen kan een longangiografie niet meer worden uitgevoerd. Spiraal 
computer tomografie daarentegen, is in vrijwel alle ziekenhuizen aanwezig.
In hoofdstuk 4 wordt een grote management studie geëvalueerd waarin spiraal computer 
tomografie de enige beeldvormende techniek is. In deze studie werden 3306 patiënten met 
verdenking longembolie geïncludeerd. Deze (Christopher) studie werd uitgevoerd in 12 
algemene en academische ziekenhuizen in Nederland. De diagnostische strategie startte met 
een klinische beslisregel, waarbij de kans op het hebben van longembolie werd onderverdeeld 
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in waarschijnlijk en onwaarschijnlijk, en een D-dimeer test. Longembolie werd in 1057 patiënten 
(32 %) met een onwaarschijnlijke kans op het hebben van longembolie en een normale D-
dimeer concentratie uitgesloten. Tijdens de daaropvolgende drie maanden keerden slechts 
5 patiënten terug met veneuze trombo-embolische complicaties (0.5%; 95% BI: 0.2-1.1%). 
Dit ondersteunt de eerder beschreven bevindingen uit hoofdstuk 3, namelijk dat de strategie 
veilig is. Alle overige patiënten (n=2249) ondergingen een spiraal computer tomografie. Deze 
toonde geen longembolie bij 1505 patiënten. Elf patiënten keerden terug met veneuze trombo-
embolische complicaties binnen 3 maanden na inclusie (1.3%; 95% BI: 0.7-2.0%). Bij 674 
patiënten werd de diagnose longembolie gesteld (20% van de populatie). Deze eenvoudige 
en snelle strategie maakte het mogelijk met voldoende zekerheid longembolie aan te tonen of 
uit te sluiten. De strategie werd gevolgd bij 98.5% van de patiënten en maakte een beslissing 
over wel of niet behandelen mogelijk bij 97.9% van de patiënten. Deze strategie is daarom 
bruikbaar in zowel algemene als academische ziekenhuizen.
Of deze diagnostische strategie bruikbaar is voor alle patiënten, waaronder ouderen, 
patiënten die zijn opgenomen in een ziekenhuis of patiënten met kanker, is onderwerp van 
discussie. In deze groepen zal de klinische kansschatting meestal een waarschijnlijke kans 
opleveren en de D-dimeer concentratie zal vaak verhoogd zijn door de aanwezigheid van 
andere ziekten. In hoofdstuk 5 is een subanalyse van de Christopher-studie uitgevoerd 
om de betrouwbaarheid van de diagnostische strategie te onderzoeken bij 605 patiënten 
opgenomen in het ziekenhuis. De diagnose werd bij 60 patiënten (10% van de populatie) 
verworpen, omdat de kans op het hebben van longembolie onwaarschijnlijk was en de D-
dimeer concentratie normaal. In de drie opvolgende maanden zijn er geen veneuze trombo-
embolische complicaties opgetreden (0%; 95% BI: 0-6.7%). Longembolie werd uitgesloten met 
spiraal computer tomografie bij 380 patiënten, waarvan bij 1.4% tijdens de drie opvolgende 
maanden veneuze trombo-embolische complicaties werden vastgesteld (95% BI: 0.4-3.1%). 
Bij 216 patiënten werd op basis van het computer tomografisch onderzoek een alternatieve 
diagnose gesteld.
In hoofdstuk 6 wordt de diagnostische strategie onderzocht in andere groepen patiënten, 
waaronder ouderen, patiënten met chronische obstructief longlijden, hartfalen en kanker. Zoals 
verwacht had slecht een klein deel van deze patiënten de combinatie van een onwaarschijnlijke 
kans op het hebben van longembolie en een normale D-dimeer concentratie. Toch toonde 
deze analyse aan dat een strategie bestaande uit een klinische beslisregel, D-dimeer test 
en spiraal computer tomografie ook een betrouwbare en eenvoudige strategie is voor deze 
specifieke groepen patiënten.
De diagnostische strategie voor patiënten met verdenking longembolie begint vaak met 
een klinische kansschattig met behulp van een klinische beslisregel. Deze beslisregel is deels 
gebaseerd op subjectieve criteria en de reproduceerbaarheid is matig. In hoofdstuk 7 wordt 
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getoond dat de reproduceerbaarheid verbeterd kan worden door de beslisregel te verkorten 
en de patiënten onder te verdelen in niet 3 maar 2 categorieën. Dit leverde het meest optimale 
resultaat met nog steeds een matige reproduceerbaarheid (kappa waarde 0.66; 95% BI: 0.41-
0.91). Een verklaring voor de beperkte reproduceerbaarheid is dat de beslisregel voor een 
deel bestaat uit subjectieve variabelen. De belangrijkste subjectieve variabele is de inschatting 
van een arts of longembolie waarschijnlijker is dan een alternatieve diagnose.
De verkorte klinische beslisregel bestaat uit 7 variabelen waaraan 1, 1.5 of 3 punten 
worden toegekend (tabel). Kan deze beslisregel verder worden vereenvoudigd door 
bijvoorbeeld alleen 1 of 2 punten toe te kennen of aan alle factoren 1 punt? Deze vraag 
wordt behandeld in hoofdstuk 8. Er waren geen verschillen in veiligheid en bruikbaarheid 
tussen de oorspronkelijke en de twee bestudeerde puntenverdelingen. Deze vereenvoudigde 
puntenverdeling moet nog gevalideerd worden in een prospectieve management studie.
De veiligheid van de diagnostische strategie is onder andere afhankelijk van de 
karakteristieken van de D-dimeer test. Er zijn verschillende testen ontwikkeld, waaronder 
ELISA, latex en semi-kwantitatieve testen. In de Christopher studie zijn 2 soorten testen 
gebruikt om de D-dimeer concentratie te meten. In het Erasmus Universitair Medisch Centrum 
in Rotterdam werd gebruik gemaakt van de Vidas D-dimeer test. Het merendeel van de 
patiënten met klachten passend bij longembolie presenteert zich op de spoedeisende hulp. 
Vandaar dat het belangrijk is dat na het bepalen van de waarschijnlijkheid op het hebben van 
longembolie de D-dimeer concentratie snel bekend is. Een nadeel van de Vidas D-dimeer test 
is dat het 40 tot 60 minuten duurt voordat het resultaat bekend is. Daarnaast kan de Vidas D-
dimeer test alleen uitgevoerd worden op een speciaal daarvoor aan te schaffen apparaat. De 
accuraatheid en exclusie efficiëntie van een snelle D-dimeer latex immuno test (AutoDimer) 
op een routine apparaat werd bestudeerd in hoofdstuk 9. Bij een grenswaarde van 110 ng/ml 
had deze test een negatief voorspellende waarde van 97% (95% BI: 91-99%), overeenkomstig 
met die van de Vidas D-dimeer test. Echter, de combinatie van een onwaarschijnlijke kans 
op het hebben van longembolie met een D-dimeer concentratie onder of gelijk aan 110 ng/ml 
was slechts aanwezig in 20% van de patiënten, in tegenstelling tot 25% van de patiënten bij 
de Vidas D-dimeer test. Of de Autodimer in combinatie met een onwaarschijnlijke kans veilig 
gebruikt kan worden om longembolie uit te sluiten met een acceptabele exclusie efficiëntie zal 
nog prospectief geëvalueerd moeten worden.
 Hoewel de combinatie van een onwaarschijnlijke kans op het hebben van longembolie 
en een normale D-dimeer concentratie longembolie veilig uitsluit in 25 tot 35% van de 
patiënten, heeft nog steeds een groot deel van de patiënten aanvullende diagnostische testen 
nodig. C-reactief proteïne (CRP) concentratie is gecorreleerd met de aan- of afwezigheid 
van longembolie. In hoofdstuk 10 wordt de veiligheid en bruikbaarheid onderzocht van een 
sensitieve CRP test in de diagnostische strategie van patiënten met verdenking longembolie. 
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De strategie bestond uit een klinische beslisregel, een D-dimeer concentratie en de hoogte 
van CRP. De exclusie efficiëntie steeg van 32% , indien alleen van een klinische beslisregel 
en D-dimeer concentratie werd gebruikt, naar 40% wanneer daaraan meting van CRP werd 
toegevoegd. Tijdens de 3 maanden opvolging waren er 1.3% veneuze trombo-embolische 
complicaties (95% BI: 0.3-3.2%). Het inzetten van CRP naast een klinische beslisregel en D-
dimeer concentratie geeft dus enige verbetering van de exclusie efficiëntie.
Toekomst perspectieven
Het aantonen of uitsluiten van longembolie zal een uitdaging blijven van de arts die 
geconfronteerd wordt met een patiënt met klachten en symptomen die zouden kunnen 
passen bij longembolie. In de afgelopen jaren is de diagnostische strategie veranderd van 
een complexe en langdurige strategie op basis van invasieve technieken naar een eenvoudig 
en snel algoritme bestaand uit een klinische beslisregel, een D-dimeer test en indien nodig 
een spiraal computer tomografie. Eén van de voordelen van deze strategie is dat deze kan 
worden toegepast in zowel de meeste academische als algemene ziekenhuizen. Daarnaast 
kan meestal al binnen een paar uur de diagnose longembolie worden bevestigd of verworpen. 
Dit komt een goede behandeling van de patiënt ten goede.
Deze strategie kan uiteraard nog verbeterd worden. Uitdagingen voor in de toekomst 
zijn onder andere het ontwikkelen van een eenvoudige en snelle strategie voor patiënten 
met verdenking recidief longembolie en zwangeren met klachten verdacht voor longembolie. 
Daarnaast zullen toekomstige studies zich richten op een verdere vereenvoudiging van de 
klinische beslisregel met minder subjectieve variabelen. Ook zullen er snellere D-dimeer 
testen ontwikkeld worden. Nieuwe biomarkers zoals markers voor hartfalen (bijvoorbeeld brain 
natriuretic peptide of heart-type fatty acid binding protein) kunnen een vooruitgang betekenen. 
Tenslotte zullen ook verbeterde beeldvormende technieken een grote bijdrage gaan leveren 
aan het optimaliseren van het diagnostisch traject.
TABEL. Klinische beslisregel volgens Wells
variabele         punten
Klinische tekenen en symptomen van diep veneuze trombose 
(minimaal zwelling van been en pijn bij palpatie diepe venen)    3
Alternatieve diagnose minder waarschijnlijk dan longembolie    3
Hartfrequentie > 100/min       1.5
Immobilisatie (> 3 dagen) of operatie in afgelopen 4 weken    1.5
Longembolie of diep veneuze trombose in voorgeschiedenis    1.5
Haemoptoë        1.0
Maligniteit (waarvoor behandeling in afgelopen 6 maanden of tijdens palliatie)  1.0
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LIST OF ABBREVIATIONS
CDR  clinical decision rule
COPD  chronic obstructive pulmonary disease
CRP  C-reactive protein
CT  computed tomography
CUS  compression ultrasonography
DD  D-dimer
DVT  deep vein thrombosis
IPG  impedance plethysmography
PA  pulmonary angiography
PE  pulmonary embolism
s-CT  spiral computed tomography
VTE  venous thromboembolic event


